{"id": "AIMed.d95.s802_AIMed.d95.s802.p0", "text": "Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex.", "text_with_entity_marker": "Mechanism of CDK activation revealed by the structure of a [E1]cyclinA[/E1]-[E2]CDK2[/E2] complex.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclinA", "entity_1_idx": [[59, 66]], "entity_1_idx_in_text_with_entity_marker": [63, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK2", "entity_2_idx": [[67, 71]], "entity_2_idx_in_text_with_entity_marker": [80, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d95.s803_AIMed.d95.s803.p0", "text": "The crystal structure of the human cyclinA-cyclin-dependent kinase2 (CDK2)-ATP complex has been determined at 2.3 A resolution.", "text_with_entity_marker": "The crystal structure of the human [E1]cyclinA[/E1]-[E2]cyclin-dependent kinase2[/E2] (CDK2)-ATP complex has been determined at 2.3 A resolution.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclinA", "entity_1_idx": [[35, 42]], "entity_1_idx_in_text_with_entity_marker": [39, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin-dependent kinase2", "entity_2_idx": [[43, 67]], "entity_2_idx_in_text_with_entity_marker": [56, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d95.s803_AIMed.d95.s803.p1", "text": "The crystal structure of the human cyclinA-cyclin-dependent kinase2 (CDK2)-ATP complex has been determined at 2.3 A resolution.", "text_with_entity_marker": "The crystal structure of the human [E1]cyclinA[/E1]-cyclin-dependent kinase2 ([E2]CDK2[/E2])-ATP complex has been determined at 2.3 A resolution.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cyclinA", "entity_1_idx": [[35, 42]], "entity_1_idx_in_text_with_entity_marker": [39, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK2", "entity_2_idx": [[69, 73]], "entity_2_idx_in_text_with_entity_marker": [82, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d95.s803_AIMed.d95.s803.p2", "text": "The crystal structure of the human cyclinA-cyclin-dependent kinase2 (CDK2)-ATP complex has been determined at 2.3 A resolution.", "text_with_entity_marker": "The crystal structure of the human cyclinA-[E1]cyclin-dependent kinase2[/E1] ([E2]CDK2[/E2])-ATP complex has been determined at 2.3 A resolution.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin-dependent kinase2", "entity_1_idx": [[43, 67]], "entity_1_idx_in_text_with_entity_marker": [47, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK2", "entity_2_idx": [[69, 73]], "entity_2_idx_in_text_with_entity_marker": [82, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p0", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human [E1]interferon-gamma[/E1] ([E2]IFN-gamma[/E2] SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon-gamma", "entity_1_idx": [[23, 39]], "entity_1_idx_in_text_with_entity_marker": [27, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[41, 50]], "entity_2_idx_in_text_with_entity_marker": [54, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p1", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human [E1]interferon-gamma[/E1] ([E2]IFN-gamma SC1[/E2]) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon-gamma", "entity_1_idx": [[23, 39]], "entity_1_idx_in_text_with_entity_marker": [27, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma SC1", "entity_2_idx": [[41, 54]], "entity_2_idx_in_text_with_entity_marker": [54, 67], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p2", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human [E1]interferon-gamma[/E1] (IFN-gamma SC1) that binds one [E2]IFN-gamma[/E2] receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon-gamma", "entity_1_idx": [[23, 39]], "entity_1_idx_in_text_with_entity_marker": [27, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[71, 80]], "entity_2_idx_in_text_with_entity_marker": [84, 93], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p3", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human [E1]interferon-gamma[/E1] (IFN-gamma SC1) that binds one [E2]IFN-gamma receptor[/E2] alpha chain (IFN-gamma R alpha) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon-gamma", "entity_1_idx": [[23, 39]], "entity_1_idx_in_text_with_entity_marker": [27, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma receptor", "entity_2_idx": [[71, 89]], "entity_2_idx_in_text_with_entity_marker": [84, 102], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p4", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human [E1]interferon-gamma[/E1] (IFN-gamma SC1) that binds one [E2]IFN-gamma receptor alpha chain[/E2] (IFN-gamma R alpha) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon-gamma", "entity_1_idx": [[23, 39]], "entity_1_idx_in_text_with_entity_marker": [27, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma receptor alpha chain", "entity_2_idx": [[71, 101]], "entity_2_idx_in_text_with_entity_marker": [84, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p5", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human [E1]interferon-gamma[/E1] (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain ([E2]IFN-gamma[/E2] R alpha) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon-gamma", "entity_1_idx": [[23, 39]], "entity_1_idx_in_text_with_entity_marker": [27, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[103, 112]], "entity_2_idx_in_text_with_entity_marker": [116, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p6", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human [E1]interferon-gamma[/E1] (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain ([E2]IFN-gamma R alpha[/E2]) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interferon-gamma", "entity_1_idx": [[23, 39]], "entity_1_idx_in_text_with_entity_marker": [27, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma R alpha", "entity_2_idx": [[103, 120]], "entity_2_idx_in_text_with_entity_marker": [116, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p7", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma ([E1-E2]IFN-gamma[/E1] SC1[/E2]) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[41, 50]], "entity_1_idx_in_text_with_entity_marker": [48, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma[/E1] SC1", "entity_2_idx": [[41, 54]], "entity_2_idx_in_text_with_entity_marker": [48, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p8", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma ([E1]IFN-gamma[/E1] SC1) that binds one [E2]IFN-gamma[/E2] receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[41, 50]], "entity_1_idx_in_text_with_entity_marker": [45, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[71, 80]], "entity_2_idx_in_text_with_entity_marker": [84, 93], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p9", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma ([E1]IFN-gamma[/E1] SC1) that binds one [E2]IFN-gamma receptor[/E2] alpha chain (IFN-gamma R alpha) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[41, 50]], "entity_1_idx_in_text_with_entity_marker": [45, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma receptor", "entity_2_idx": [[71, 89]], "entity_2_idx_in_text_with_entity_marker": [84, 102], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p10", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma ([E1]IFN-gamma[/E1] SC1) that binds one [E2]IFN-gamma receptor alpha chain[/E2] (IFN-gamma R alpha) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[41, 50]], "entity_1_idx_in_text_with_entity_marker": [45, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma receptor alpha chain", "entity_2_idx": [[71, 101]], "entity_2_idx_in_text_with_entity_marker": [84, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p11", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma ([E1]IFN-gamma[/E1] SC1) that binds one IFN-gamma receptor alpha chain ([E2]IFN-gamma[/E2] R alpha) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[41, 50]], "entity_1_idx_in_text_with_entity_marker": [45, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[103, 112]], "entity_2_idx_in_text_with_entity_marker": [116, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p12", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma ([E1]IFN-gamma[/E1] SC1) that binds one IFN-gamma receptor alpha chain ([E2]IFN-gamma R alpha[/E2]) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[41, 50]], "entity_1_idx_in_text_with_entity_marker": [45, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma R alpha", "entity_2_idx": [[103, 120]], "entity_2_idx_in_text_with_entity_marker": [116, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p13", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma ([E1]IFN-gamma SC1[/E1]) that binds one [E2]IFN-gamma[/E2] receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma SC1", "entity_1_idx": [[41, 54]], "entity_1_idx_in_text_with_entity_marker": [45, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[71, 80]], "entity_2_idx_in_text_with_entity_marker": [84, 93], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p14", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma ([E1]IFN-gamma SC1[/E1]) that binds one [E2]IFN-gamma receptor[/E2] alpha chain (IFN-gamma R alpha) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma SC1", "entity_1_idx": [[41, 54]], "entity_1_idx_in_text_with_entity_marker": [45, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma receptor", "entity_2_idx": [[71, 89]], "entity_2_idx_in_text_with_entity_marker": [84, 102], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p15", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma ([E1]IFN-gamma SC1[/E1]) that binds one [E2]IFN-gamma receptor alpha chain[/E2] (IFN-gamma R alpha) has been designed and characterized.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IFN-gamma SC1", "entity_1_idx": [[41, 54]], "entity_1_idx_in_text_with_entity_marker": [45, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma receptor alpha chain", "entity_2_idx": [[71, 101]], "entity_2_idx_in_text_with_entity_marker": [84, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p16", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma ([E1]IFN-gamma SC1[/E1]) that binds one IFN-gamma receptor alpha chain ([E2]IFN-gamma[/E2] R alpha) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma SC1", "entity_1_idx": [[41, 54]], "entity_1_idx_in_text_with_entity_marker": [45, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[103, 112]], "entity_2_idx_in_text_with_entity_marker": [116, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p17", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma ([E1]IFN-gamma SC1[/E1]) that binds one IFN-gamma receptor alpha chain ([E2]IFN-gamma R alpha[/E2]) has been designed and characterized.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IFN-gamma SC1", "entity_1_idx": [[41, 54]], "entity_1_idx_in_text_with_entity_marker": [45, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma R alpha", "entity_2_idx": [[103, 120]], "entity_2_idx_in_text_with_entity_marker": [116, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p18", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one [E1-E2]IFN-gamma[/E1] receptor[/E2] alpha chain (IFN-gamma R alpha) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[71, 80]], "entity_1_idx_in_text_with_entity_marker": [78, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma[/E1] receptor", "entity_2_idx": [[71, 89]], "entity_2_idx_in_text_with_entity_marker": [78, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p19", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one [E1-E2]IFN-gamma[/E1] receptor alpha chain[/E2] (IFN-gamma R alpha) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[71, 80]], "entity_1_idx_in_text_with_entity_marker": [78, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma[/E1] receptor alpha chain", "entity_2_idx": [[71, 101]], "entity_2_idx_in_text_with_entity_marker": [78, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p20", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one [E1]IFN-gamma[/E1] receptor alpha chain ([E2]IFN-gamma[/E2] R alpha) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[71, 80]], "entity_1_idx_in_text_with_entity_marker": [75, 84], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[103, 112]], "entity_2_idx_in_text_with_entity_marker": [116, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p21", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one [E1]IFN-gamma[/E1] receptor alpha chain ([E2]IFN-gamma R alpha[/E2]) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[71, 80]], "entity_1_idx_in_text_with_entity_marker": [75, 84], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma R alpha", "entity_2_idx": [[103, 120]], "entity_2_idx_in_text_with_entity_marker": [116, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p22", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one [E1-E2]IFN-gamma receptor[/E1] alpha chain[/E2] (IFN-gamma R alpha) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma receptor", "entity_1_idx": [[71, 89]], "entity_1_idx_in_text_with_entity_marker": [78, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma receptor[/E1] alpha chain", "entity_2_idx": [[71, 101]], "entity_2_idx_in_text_with_entity_marker": [78, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p23", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one [E1]IFN-gamma receptor[/E1] alpha chain ([E2]IFN-gamma[/E2] R alpha) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma receptor", "entity_1_idx": [[71, 89]], "entity_1_idx_in_text_with_entity_marker": [75, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[103, 112]], "entity_2_idx_in_text_with_entity_marker": [116, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p24", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one [E1]IFN-gamma receptor[/E1] alpha chain ([E2]IFN-gamma R alpha[/E2]) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma receptor", "entity_1_idx": [[71, 89]], "entity_1_idx_in_text_with_entity_marker": [75, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma R alpha", "entity_2_idx": [[103, 120]], "entity_2_idx_in_text_with_entity_marker": [116, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p25", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one [E1]IFN-gamma receptor alpha chain[/E1] ([E2]IFN-gamma[/E2] R alpha) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma receptor alpha chain", "entity_1_idx": [[71, 101]], "entity_1_idx_in_text_with_entity_marker": [75, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[103, 112]], "entity_2_idx_in_text_with_entity_marker": [116, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p26", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one [E1]IFN-gamma receptor alpha chain[/E1] ([E2]IFN-gamma R alpha[/E2]) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma receptor alpha chain", "entity_1_idx": [[71, 101]], "entity_1_idx_in_text_with_entity_marker": [75, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma R alpha", "entity_2_idx": [[103, 120]], "entity_2_idx_in_text_with_entity_marker": [116, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s390_AIMed.d45.s390.p27", "text": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.", "text_with_entity_marker": "A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain ([E1-E2]IFN-gamma[/E1] R alpha[/E2]) has been designed and characterized.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[103, 112]], "entity_1_idx_in_text_with_entity_marker": [110, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma[/E1] R alpha", "entity_2_idx": [[103, 120]], "entity_2_idx_in_text_with_entity_marker": [110, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s391_AIMed.d45.s391.p0", "text": "IFN-gamma SC1 was derived by linking the two peptide chains of the IFN-gamma dimer by a seven-residue linker and changing His111 in the first chain to an aspartic acid residue.", "text_with_entity_marker": "[E1-E2]IFN-gamma[/E1] SC1[/E2] was derived by linking the two peptide chains of the IFN-gamma dimer by a seven-residue linker and changing His111 in the first chain to an aspartic acid residue.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[0, 9]], "entity_1_idx_in_text_with_entity_marker": [7, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma[/E1] SC1", "entity_2_idx": [[0, 13]], "entity_2_idx_in_text_with_entity_marker": [7, 25], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s391_AIMed.d45.s391.p1", "text": "IFN-gamma SC1 was derived by linking the two peptide chains of the IFN-gamma dimer by a seven-residue linker and changing His111 in the first chain to an aspartic acid residue.", "text_with_entity_marker": "[E1]IFN-gamma[/E1] SC1 was derived by linking the two peptide chains of the [E2]IFN-gamma[/E2] dimer by a seven-residue linker and changing His111 in the first chain to an aspartic acid residue.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[0, 9]], "entity_1_idx_in_text_with_entity_marker": [4, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[67, 76]], "entity_2_idx_in_text_with_entity_marker": [80, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s391_AIMed.d45.s391.p2", "text": "IFN-gamma SC1 was derived by linking the two peptide chains of the IFN-gamma dimer by a seven-residue linker and changing His111 in the first chain to an aspartic acid residue.", "text_with_entity_marker": "[E1]IFN-gamma SC1[/E1] was derived by linking the two peptide chains of the [E2]IFN-gamma[/E2] dimer by a seven-residue linker and changing His111 in the first chain to an aspartic acid residue.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma SC1", "entity_1_idx": [[0, 13]], "entity_1_idx_in_text_with_entity_marker": [4, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[67, 76]], "entity_2_idx_in_text_with_entity_marker": [80, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s392_AIMed.d45.s392.p0", "text": "Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM.", "text_with_entity_marker": "Isothermal titration calorimetry shows that [E1-E2]IFN-gamma[/E1] SC1[/E2] forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[44, 53]], "entity_1_idx_in_text_with_entity_marker": [51, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma[/E1] SC1", "entity_2_idx": [[44, 57]], "entity_2_idx_in_text_with_entity_marker": [51, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s392_AIMed.d45.s392.p1", "text": "Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM.", "text_with_entity_marker": "Isothermal titration calorimetry shows that [E1]IFN-gamma[/E1] SC1 forms a 1:1 complex with its high-affinity receptor ([E2]IFN-gamma[/E2] R alpha) with an affinity of 27(+/- 9) nM.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[44, 53]], "entity_1_idx_in_text_with_entity_marker": [48, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[111, 120]], "entity_2_idx_in_text_with_entity_marker": [124, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s392_AIMed.d45.s392.p2", "text": "Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM.", "text_with_entity_marker": "Isothermal titration calorimetry shows that [E1]IFN-gamma[/E1] SC1 forms a 1:1 complex with its high-affinity receptor ([E2]IFN-gamma R alpha[/E2]) with an affinity of 27(+/- 9) nM.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[44, 53]], "entity_1_idx_in_text_with_entity_marker": [48, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma R alpha", "entity_2_idx": [[111, 128]], "entity_2_idx_in_text_with_entity_marker": [124, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s392_AIMed.d45.s392.p3", "text": "Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM.", "text_with_entity_marker": "Isothermal titration calorimetry shows that [E1]IFN-gamma SC1[/E1] forms a 1:1 complex with its high-affinity receptor ([E2]IFN-gamma[/E2] R alpha) with an affinity of 27(+/- 9) nM.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma SC1", "entity_1_idx": [[44, 57]], "entity_1_idx_in_text_with_entity_marker": [48, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[111, 120]], "entity_2_idx_in_text_with_entity_marker": [124, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s392_AIMed.d45.s392.p4", "text": "Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM.", "text_with_entity_marker": "Isothermal titration calorimetry shows that [E1]IFN-gamma SC1[/E1] forms a 1:1 complex with its high-affinity receptor ([E2]IFN-gamma R alpha[/E2]) with an affinity of 27(+/- 9) nM.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IFN-gamma SC1", "entity_1_idx": [[44, 57]], "entity_1_idx_in_text_with_entity_marker": [48, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma R alpha", "entity_2_idx": [[111, 128]], "entity_2_idx_in_text_with_entity_marker": [124, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s392_AIMed.d45.s392.p5", "text": "Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM.", "text_with_entity_marker": "Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor ([E1-E2]IFN-gamma[/E1] R alpha[/E2]) with an affinity of 27(+/- 9) nM.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[111, 120]], "entity_1_idx_in_text_with_entity_marker": [118, 127], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma[/E1] R alpha", "entity_2_idx": [[111, 128]], "entity_2_idx_in_text_with_entity_marker": [118, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s393_AIMed.d45.s393.p0", "text": "The crystal structure of IFN-gamma SC1 has been determined at 2.9 A resolution from crystals grown in 1.4 M citrate solutions at pH 7.6.", "text_with_entity_marker": "The crystal structure of [E1-E2]IFN-gamma[/E1] SC1[/E2] has been determined at 2.9 A resolution from crystals grown in 1.4 M citrate solutions at pH 7.6.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[25, 34]], "entity_1_idx_in_text_with_entity_marker": [32, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma[/E1] SC1", "entity_2_idx": [[25, 38]], "entity_2_idx_in_text_with_entity_marker": [32, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s394_AIMed.d45.s394.p0", "text": "Comparison of the wild-type receptor-binding domain and the Asp111-containing domain of IFN-gamma SC1 show that they are structurally equivalent but have very different electrostatic surface potentials.", "text_with_entity_marker": "Comparison of the wild-type receptor-binding domain and the Asp111-containing domain of [E1-E2]IFN-gamma[/E1] SC1[/E2] show that they are structurally equivalent but have very different electrostatic surface potentials.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[88, 97]], "entity_1_idx_in_text_with_entity_marker": [95, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma[/E1] SC1", "entity_2_idx": [[88, 101]], "entity_2_idx_in_text_with_entity_marker": [95, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s396_AIMed.d45.s396.p0", "text": "The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.", "text_with_entity_marker": "The AB loops of [E1]IFN-gamma SC1[/E1] adopt conformations similar to the ordered loops of [E2]IFN-gamma[/E2] observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma SC1", "entity_1_idx": [[16, 29]], "entity_1_idx_in_text_with_entity_marker": [20, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[82, 91]], "entity_2_idx_in_text_with_entity_marker": [95, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s396_AIMed.d45.s396.p1", "text": "The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.", "text_with_entity_marker": "The AB loops of [E1]IFN-gamma SC1[/E1] adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the [E2]IFN-gamma[/E2]/IFN-gamma R alpha complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma SC1", "entity_1_idx": [[16, 29]], "entity_1_idx_in_text_with_entity_marker": [20, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[133, 142]], "entity_2_idx_in_text_with_entity_marker": [146, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s396_AIMed.d45.s396.p2", "text": "The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.", "text_with_entity_marker": "The AB loops of [E1]IFN-gamma SC1[/E1] adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/[E2]IFN-gamma[/E2] R alpha complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma SC1", "entity_1_idx": [[16, 29]], "entity_1_idx_in_text_with_entity_marker": [20, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[143, 152]], "entity_2_idx_in_text_with_entity_marker": [156, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s396_AIMed.d45.s396.p3", "text": "The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.", "text_with_entity_marker": "The AB loops of [E1]IFN-gamma SC1[/E1] adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/[E2]IFN-gamma R alpha[/E2] complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma SC1", "entity_1_idx": [[16, 29]], "entity_1_idx_in_text_with_entity_marker": [20, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma R alpha", "entity_2_idx": [[143, 160]], "entity_2_idx_in_text_with_entity_marker": [156, 173], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s396_AIMed.d45.s396.p4", "text": "The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.", "text_with_entity_marker": "The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of [E1]IFN-gamma[/E1] observed in the crystal structure of the [E2]IFN-gamma[/E2]/IFN-gamma R alpha complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[82, 91]], "entity_1_idx_in_text_with_entity_marker": [86, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[133, 142]], "entity_2_idx_in_text_with_entity_marker": [146, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s396_AIMed.d45.s396.p5", "text": "The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.", "text_with_entity_marker": "The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of [E1]IFN-gamma[/E1] observed in the crystal structure of the IFN-gamma/[E2]IFN-gamma[/E2] R alpha complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[82, 91]], "entity_1_idx_in_text_with_entity_marker": [86, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[143, 152]], "entity_2_idx_in_text_with_entity_marker": [156, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s396_AIMed.d45.s396.p6", "text": "The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.", "text_with_entity_marker": "The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of [E1]IFN-gamma[/E1] observed in the crystal structure of the IFN-gamma/[E2]IFN-gamma R alpha[/E2] complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[82, 91]], "entity_1_idx_in_text_with_entity_marker": [86, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma R alpha", "entity_2_idx": [[143, 160]], "entity_2_idx_in_text_with_entity_marker": [156, 173], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s396_AIMed.d45.s396.p7", "text": "The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.", "text_with_entity_marker": "The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the [E1]IFN-gamma[/E1]/[E2]IFN-gamma[/E2] R alpha complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[133, 142]], "entity_1_idx_in_text_with_entity_marker": [137, 146], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[143, 152]], "entity_2_idx_in_text_with_entity_marker": [156, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s396_AIMed.d45.s396.p8", "text": "The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.", "text_with_entity_marker": "The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the [E1]IFN-gamma[/E1]/[E2]IFN-gamma R alpha[/E2] complex.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IFN-gamma", "entity_1_idx": [[133, 142]], "entity_1_idx_in_text_with_entity_marker": [137, 146], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma R alpha", "entity_2_idx": [[143, 160]], "entity_2_idx_in_text_with_entity_marker": [156, 173], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s396_AIMed.d45.s396.p9", "text": "The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.", "text_with_entity_marker": "The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/[E1-E2]IFN-gamma[/E1] R alpha[/E2] complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[143, 152]], "entity_1_idx_in_text_with_entity_marker": [150, 159], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma[/E1] R alpha", "entity_2_idx": [[143, 160]], "entity_2_idx_in_text_with_entity_marker": [150, 172], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s397_AIMed.d45.s397.p0", "text": "Thus, IFN-gamma R alpha binding does not result in a large conformational change in the AB loop as previously suggested.", "text_with_entity_marker": "Thus, [E1-E2]IFN-gamma[/E1] R alpha[/E2] binding does not result in a large conformational change in the AB loop as previously suggested.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[6, 15]], "entity_1_idx_in_text_with_entity_marker": [13, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma[/E1] R alpha", "entity_2_idx": [[6, 23]], "entity_2_idx_in_text_with_entity_marker": [13, 35], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s398_AIMed.d45.s398.p0", "text": "The structure also reveals the final six C-terminal amino acid residues of IFN-gamma SC1 (residues 253-258) that have not been observed in any other reported IFN-gamma structures.", "text_with_entity_marker": "The structure also reveals the final six C-terminal amino acid residues of [E1-E2]IFN-gamma[/E1] SC1[/E2] (residues 253-258) that have not been observed in any other reported IFN-gamma structures.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[75, 84]], "entity_1_idx_in_text_with_entity_marker": [82, 91], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma[/E1] SC1", "entity_2_idx": [[75, 88]], "entity_2_idx_in_text_with_entity_marker": [82, 100], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s398_AIMed.d45.s398.p1", "text": "The structure also reveals the final six C-terminal amino acid residues of IFN-gamma SC1 (residues 253-258) that have not been observed in any other reported IFN-gamma structures.", "text_with_entity_marker": "The structure also reveals the final six C-terminal amino acid residues of [E1]IFN-gamma[/E1] SC1 (residues 253-258) that have not been observed in any other reported [E2]IFN-gamma[/E2] structures.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[75, 84]], "entity_1_idx_in_text_with_entity_marker": [79, 88], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[158, 167]], "entity_2_idx_in_text_with_entity_marker": [171, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s398_AIMed.d45.s398.p2", "text": "The structure also reveals the final six C-terminal amino acid residues of IFN-gamma SC1 (residues 253-258) that have not been observed in any other reported IFN-gamma structures.", "text_with_entity_marker": "The structure also reveals the final six C-terminal amino acid residues of [E1]IFN-gamma SC1[/E1] (residues 253-258) that have not been observed in any other reported [E2]IFN-gamma[/E2] structures.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma SC1", "entity_1_idx": [[75, 88]], "entity_1_idx_in_text_with_entity_marker": [79, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[158, 167]], "entity_2_idx_in_text_with_entity_marker": [171, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s399_AIMed.d45.s399.p0", "text": "Despite binding to only one IFN-gamma R alpha, IFN-gamma SC1 is biologically active in cell proliferation, MHC class I induction, and anti-viral assays.", "text_with_entity_marker": "Despite binding to only one [E1-E2]IFN-gamma[/E1] R alpha[/E2], IFN-gamma SC1 is biologically active in cell proliferation, MHC class I induction, and anti-viral assays.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[28, 37]], "entity_1_idx_in_text_with_entity_marker": [35, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma[/E1] R alpha", "entity_2_idx": [[28, 45]], "entity_2_idx_in_text_with_entity_marker": [35, 57], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s399_AIMed.d45.s399.p1", "text": "Despite binding to only one IFN-gamma R alpha, IFN-gamma SC1 is biologically active in cell proliferation, MHC class I induction, and anti-viral assays.", "text_with_entity_marker": "Despite binding to only one [E1]IFN-gamma[/E1] R alpha, [E2]IFN-gamma SC1[/E2] is biologically active in cell proliferation, MHC class I induction, and anti-viral assays.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[28, 37]], "entity_1_idx_in_text_with_entity_marker": [32, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma SC1", "entity_2_idx": [[47, 60]], "entity_2_idx_in_text_with_entity_marker": [60, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s399_AIMed.d45.s399.p2", "text": "Despite binding to only one IFN-gamma R alpha, IFN-gamma SC1 is biologically active in cell proliferation, MHC class I induction, and anti-viral assays.", "text_with_entity_marker": "Despite binding to only one [E1]IFN-gamma R alpha[/E1], [E2]IFN-gamma SC1[/E2] is biologically active in cell proliferation, MHC class I induction, and anti-viral assays.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IFN-gamma R alpha", "entity_1_idx": [[28, 45]], "entity_1_idx_in_text_with_entity_marker": [32, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma SC1", "entity_2_idx": [[47, 60]], "entity_2_idx_in_text_with_entity_marker": [60, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s400_AIMed.d45.s400.p0", "text": "This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.", "text_with_entity_marker": "This suggests that one domain of [E1]IFN-gamma[/E1] is sufficient to recruit [E2]IFN-gamma[/E2] R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[33, 42]], "entity_1_idx_in_text_with_entity_marker": [37, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[68, 77]], "entity_2_idx_in_text_with_entity_marker": [81, 90], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s400_AIMed.d45.s400.p1", "text": "This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.", "text_with_entity_marker": "This suggests that one domain of [E1]IFN-gamma[/E1] is sufficient to recruit [E2]IFN-gamma R alpha[/E2] and IFN-gamma R beta into a complex competent for eliciting biological activity.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IFN-gamma", "entity_1_idx": [[33, 42]], "entity_1_idx_in_text_with_entity_marker": [37, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma R alpha", "entity_2_idx": [[68, 85]], "entity_2_idx_in_text_with_entity_marker": [81, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s400_AIMed.d45.s400.p2", "text": "This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.", "text_with_entity_marker": "This suggests that one domain of [E1]IFN-gamma[/E1] is sufficient to recruit IFN-gamma R alpha and [E2]IFN-gamma[/E2] R beta into a complex competent for eliciting biological activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[33, 42]], "entity_1_idx_in_text_with_entity_marker": [37, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[90, 99]], "entity_2_idx_in_text_with_entity_marker": [103, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s400_AIMed.d45.s400.p3", "text": "This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.", "text_with_entity_marker": "This suggests that one domain of [E1]IFN-gamma[/E1] is sufficient to recruit IFN-gamma R alpha and [E2]IFN-gamma R beta[/E2] into a complex competent for eliciting biological activity.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IFN-gamma", "entity_1_idx": [[33, 42]], "entity_1_idx_in_text_with_entity_marker": [37, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma R beta", "entity_2_idx": [[90, 106]], "entity_2_idx_in_text_with_entity_marker": [103, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s400_AIMed.d45.s400.p4", "text": "This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.", "text_with_entity_marker": "This suggests that one domain of IFN-gamma is sufficient to recruit [E1-E2]IFN-gamma[/E1] R alpha[/E2] and IFN-gamma R beta into a complex competent for eliciting biological activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[68, 77]], "entity_1_idx_in_text_with_entity_marker": [75, 84], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma[/E1] R alpha", "entity_2_idx": [[68, 85]], "entity_2_idx_in_text_with_entity_marker": [75, 97], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s400_AIMed.d45.s400.p5", "text": "This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.", "text_with_entity_marker": "This suggests that one domain of IFN-gamma is sufficient to recruit [E1]IFN-gamma[/E1] R alpha and [E2]IFN-gamma[/E2] R beta into a complex competent for eliciting biological activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[68, 77]], "entity_1_idx_in_text_with_entity_marker": [72, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[90, 99]], "entity_2_idx_in_text_with_entity_marker": [103, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s400_AIMed.d45.s400.p6", "text": "This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.", "text_with_entity_marker": "This suggests that one domain of IFN-gamma is sufficient to recruit [E1]IFN-gamma[/E1] R alpha and [E2]IFN-gamma R beta[/E2] into a complex competent for eliciting biological activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[68, 77]], "entity_1_idx_in_text_with_entity_marker": [72, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma R beta", "entity_2_idx": [[90, 106]], "entity_2_idx_in_text_with_entity_marker": [103, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s400_AIMed.d45.s400.p7", "text": "This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.", "text_with_entity_marker": "This suggests that one domain of IFN-gamma is sufficient to recruit [E1]IFN-gamma R alpha[/E1] and [E2]IFN-gamma[/E2] R beta into a complex competent for eliciting biological activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma R alpha", "entity_1_idx": [[68, 85]], "entity_1_idx_in_text_with_entity_marker": [72, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[90, 99]], "entity_2_idx_in_text_with_entity_marker": [103, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s400_AIMed.d45.s400.p8", "text": "This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.", "text_with_entity_marker": "This suggests that one domain of IFN-gamma is sufficient to recruit [E1]IFN-gamma R alpha[/E1] and [E2]IFN-gamma R beta[/E2] into a complex competent for eliciting biological activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma R alpha", "entity_1_idx": [[68, 85]], "entity_1_idx_in_text_with_entity_marker": [72, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma R beta", "entity_2_idx": [[90, 106]], "entity_2_idx_in_text_with_entity_marker": [103, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s400_AIMed.d45.s400.p9", "text": "This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.", "text_with_entity_marker": "This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and [E1-E2]IFN-gamma[/E1] R beta[/E2] into a complex competent for eliciting biological activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[90, 99]], "entity_1_idx_in_text_with_entity_marker": [97, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma[/E1] R beta", "entity_2_idx": [[90, 106]], "entity_2_idx_in_text_with_entity_marker": [97, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d45.s401_AIMed.d45.s401.p0", "text": "The current data are consistent with the main role of the IFN-gamma dimer being to decrease the dissociation constant of IFN-gamma for its cellular receptors.", "text_with_entity_marker": "The current data are consistent with the main role of the [E1]IFN-gamma[/E1] dimer being to decrease the dissociation constant of [E2]IFN-gamma[/E2] for its cellular receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[58, 67]], "entity_1_idx_in_text_with_entity_marker": [62, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[121, 130]], "entity_2_idx_in_text_with_entity_marker": [134, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1806_AIMed.d209.s1806.p0", "text": "Human RIN1 was first characterized as a RAS binding protein based on the properties of its carboxyl-terminal domain.", "text_with_entity_marker": "Human [E1]RIN1[/E1] was first characterized as a [E2]RAS[/E2] binding protein based on the properties of its carboxyl-terminal domain.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RIN1", "entity_1_idx": [[6, 10]], "entity_1_idx_in_text_with_entity_marker": [10, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[40, 43]], "entity_2_idx_in_text_with_entity_marker": [53, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1806_AIMed.d209.s1806.p1", "text": "Human RIN1 was first characterized as a RAS binding protein based on the properties of its carboxyl-terminal domain.", "text_with_entity_marker": "Human [E1]RIN1[/E1] was first characterized as a [E2]RAS binding protein[/E2] based on the properties of its carboxyl-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIN1", "entity_1_idx": [[6, 10]], "entity_1_idx_in_text_with_entity_marker": [10, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS binding protein", "entity_2_idx": [[40, 59]], "entity_2_idx_in_text_with_entity_marker": [53, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1806_AIMed.d209.s1806.p2", "text": "Human RIN1 was first characterized as a RAS binding protein based on the properties of its carboxyl-terminal domain.", "text_with_entity_marker": "Human RIN1 was first characterized as a [E1-E2]RAS[/E1] binding protein[/E2] based on the properties of its carboxyl-terminal domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAS", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [47, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS[/E1] binding protein", "entity_2_idx": [[40, 59]], "entity_2_idx_in_text_with_entity_marker": [47, 71], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1807_AIMed.d209.s1807.p0", "text": "We now show that full-length RIN1 interacts with activated RAS in mammalian cells and defines a minimum region of 434 aa required for efficient RAS binding.", "text_with_entity_marker": "We now show that full-length [E1]RIN1[/E1] interacts with activated [E2]RAS[/E2] in mammalian cells and defines a minimum region of 434 aa required for efficient RAS binding.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RIN1", "entity_1_idx": [[29, 33]], "entity_1_idx_in_text_with_entity_marker": [33, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[59, 62]], "entity_2_idx_in_text_with_entity_marker": [72, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1807_AIMed.d209.s1807.p1", "text": "We now show that full-length RIN1 interacts with activated RAS in mammalian cells and defines a minimum region of 434 aa required for efficient RAS binding.", "text_with_entity_marker": "We now show that full-length [E1]RIN1[/E1] interacts with activated RAS in mammalian cells and defines a minimum region of 434 aa required for efficient [E2]RAS[/E2] binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIN1", "entity_1_idx": [[29, 33]], "entity_1_idx_in_text_with_entity_marker": [33, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[144, 147]], "entity_2_idx_in_text_with_entity_marker": [157, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1807_AIMed.d209.s1807.p2", "text": "We now show that full-length RIN1 interacts with activated RAS in mammalian cells and defines a minimum region of 434 aa required for efficient RAS binding.", "text_with_entity_marker": "We now show that full-length RIN1 interacts with activated [E1]RAS[/E1] in mammalian cells and defines a minimum region of 434 aa required for efficient [E2]RAS[/E2] binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAS", "entity_1_idx": [[59, 62]], "entity_1_idx_in_text_with_entity_marker": [63, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[144, 147]], "entity_2_idx_in_text_with_entity_marker": [157, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1808_AIMed.d209.s1808.p0", "text": "RIN1 interacts with the \"effector domain\" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.", "text_with_entity_marker": "[E1]RIN1[/E1] interacts with the \"effector domain\" of [E2]RAS[/E2] and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RIN1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[45, 48]], "entity_2_idx_in_text_with_entity_marker": [58, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1808_AIMed.d209.s1808.p1", "text": "RIN1 interacts with the \"effector domain\" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.", "text_with_entity_marker": "[E1]RIN1[/E1] interacts with the \"effector domain\" of RAS and employs some [E2]RAS[/E2] determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIN1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[66, 69]], "entity_2_idx_in_text_with_entity_marker": [79, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1808_AIMed.d209.s1808.p2", "text": "RIN1 interacts with the \"effector domain\" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.", "text_with_entity_marker": "[E1]RIN1[/E1] interacts with the \"effector domain\" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of [E2]RAF1[/E2], a known RAS effector.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIN1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAF1", "entity_2_idx": [[172, 176]], "entity_2_idx_in_text_with_entity_marker": [185, 189], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1808_AIMed.d209.s1808.p3", "text": "RIN1 interacts with the \"effector domain\" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.", "text_with_entity_marker": "[E1]RIN1[/E1] interacts with the \"effector domain\" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known [E2]RAS[/E2] effector.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIN1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[186, 189]], "entity_2_idx_in_text_with_entity_marker": [199, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1808_AIMed.d209.s1808.p4", "text": "RIN1 interacts with the \"effector domain\" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.", "text_with_entity_marker": "RIN1 interacts with the \"effector domain\" of [E1]RAS[/E1] and employs some [E2]RAS[/E2] determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAS", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[66, 69]], "entity_2_idx_in_text_with_entity_marker": [79, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1808_AIMed.d209.s1808.p5", "text": "RIN1 interacts with the \"effector domain\" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.", "text_with_entity_marker": "RIN1 interacts with the \"effector domain\" of [E1]RAS[/E1] and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of [E2]RAF1[/E2], a known RAS effector.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAS", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAF1", "entity_2_idx": [[172, 176]], "entity_2_idx_in_text_with_entity_marker": [185, 189], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1808_AIMed.d209.s1808.p6", "text": "RIN1 interacts with the \"effector domain\" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.", "text_with_entity_marker": "RIN1 interacts with the \"effector domain\" of [E1]RAS[/E1] and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known [E2]RAS[/E2] effector.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAS", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[186, 189]], "entity_2_idx_in_text_with_entity_marker": [199, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1808_AIMed.d209.s1808.p7", "text": "RIN1 interacts with the \"effector domain\" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.", "text_with_entity_marker": "RIN1 interacts with the \"effector domain\" of RAS and employs some [E1]RAS[/E1] determinants that are common to, and others that are distinct from, those required for the binding of [E2]RAF1[/E2], a known RAS effector.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAS", "entity_1_idx": [[66, 69]], "entity_1_idx_in_text_with_entity_marker": [70, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAF1", "entity_2_idx": [[172, 176]], "entity_2_idx_in_text_with_entity_marker": [185, 189], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1808_AIMed.d209.s1808.p8", "text": "RIN1 interacts with the \"effector domain\" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.", "text_with_entity_marker": "RIN1 interacts with the \"effector domain\" of RAS and employs some [E1]RAS[/E1] determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known [E2]RAS[/E2] effector.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAS", "entity_1_idx": [[66, 69]], "entity_1_idx_in_text_with_entity_marker": [70, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[186, 189]], "entity_2_idx_in_text_with_entity_marker": [199, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1808_AIMed.d209.s1808.p9", "text": "RIN1 interacts with the \"effector domain\" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.", "text_with_entity_marker": "RIN1 interacts with the \"effector domain\" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of [E1]RAF1[/E1], a known [E2]RAS[/E2] effector.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RAF1", "entity_1_idx": [[172, 176]], "entity_1_idx_in_text_with_entity_marker": [176, 180], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[186, 189]], "entity_2_idx_in_text_with_entity_marker": [199, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1809_AIMed.d209.s1809.p0", "text": "The same domain of RIN1 that binds RAS also interacts with 14-3-3 proteins, extending the similarity between RIN1 and other RAS effectors.", "text_with_entity_marker": "The same domain of [E1]RIN1[/E1] that binds [E2]RAS[/E2] also interacts with 14-3-3 proteins, extending the similarity between RIN1 and other RAS effectors.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RIN1", "entity_1_idx": [[19, 23]], "entity_1_idx_in_text_with_entity_marker": [23, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[35, 38]], "entity_2_idx_in_text_with_entity_marker": [48, 51], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1809_AIMed.d209.s1809.p1", "text": "The same domain of RIN1 that binds RAS also interacts with 14-3-3 proteins, extending the similarity between RIN1 and other RAS effectors.", "text_with_entity_marker": "The same domain of [E1]RIN1[/E1] that binds RAS also interacts with 14-3-3 proteins, extending the similarity between [E2]RIN1[/E2] and other RAS effectors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIN1", "entity_1_idx": [[19, 23]], "entity_1_idx_in_text_with_entity_marker": [23, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RIN1", "entity_2_idx": [[109, 113]], "entity_2_idx_in_text_with_entity_marker": [122, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1809_AIMed.d209.s1809.p2", "text": "The same domain of RIN1 that binds RAS also interacts with 14-3-3 proteins, extending the similarity between RIN1 and other RAS effectors.", "text_with_entity_marker": "The same domain of [E1]RIN1[/E1] that binds RAS also interacts with 14-3-3 proteins, extending the similarity between RIN1 and other [E2]RAS[/E2] effectors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIN1", "entity_1_idx": [[19, 23]], "entity_1_idx_in_text_with_entity_marker": [23, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[124, 127]], "entity_2_idx_in_text_with_entity_marker": [137, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1809_AIMed.d209.s1809.p3", "text": "The same domain of RIN1 that binds RAS also interacts with 14-3-3 proteins, extending the similarity between RIN1 and other RAS effectors.", "text_with_entity_marker": "The same domain of RIN1 that binds [E1]RAS[/E1] also interacts with 14-3-3 proteins, extending the similarity between [E2]RIN1[/E2] and other RAS effectors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAS", "entity_1_idx": [[35, 38]], "entity_1_idx_in_text_with_entity_marker": [39, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RIN1", "entity_2_idx": [[109, 113]], "entity_2_idx_in_text_with_entity_marker": [122, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1809_AIMed.d209.s1809.p4", "text": "The same domain of RIN1 that binds RAS also interacts with 14-3-3 proteins, extending the similarity between RIN1 and other RAS effectors.", "text_with_entity_marker": "The same domain of RIN1 that binds [E1]RAS[/E1] also interacts with 14-3-3 proteins, extending the similarity between RIN1 and other [E2]RAS[/E2] effectors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAS", "entity_1_idx": [[35, 38]], "entity_1_idx_in_text_with_entity_marker": [39, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[124, 127]], "entity_2_idx_in_text_with_entity_marker": [137, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1809_AIMed.d209.s1809.p5", "text": "The same domain of RIN1 that binds RAS also interacts with 14-3-3 proteins, extending the similarity between RIN1 and other RAS effectors.", "text_with_entity_marker": "The same domain of RIN1 that binds RAS also interacts with 14-3-3 proteins, extending the similarity between [E1]RIN1[/E1] and other [E2]RAS[/E2] effectors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RIN1", "entity_1_idx": [[109, 113]], "entity_1_idx_in_text_with_entity_marker": [113, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[124, 127]], "entity_2_idx_in_text_with_entity_marker": [137, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1810_AIMed.d209.s1810.p0", "text": "When expressed in mammalian cells, the RAS binding domain of RIN1 can act as a dominant negative signal transduction blocker.", "text_with_entity_marker": "When expressed in mammalian cells, the [E1]RAS[/E1] binding domain of [E2]RIN1[/E2] can act as a dominant negative signal transduction blocker.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RAS", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RIN1", "entity_2_idx": [[61, 65]], "entity_2_idx_in_text_with_entity_marker": [74, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1812_AIMed.d209.s1812.p0", "text": "This RIN1 sequence shows preferential binding to the ABL-SH3 domain in vitro.", "text_with_entity_marker": "This [E1]RIN1[/E1] sequence shows preferential binding to the [E2]ABL-SH3[/E2] domain in vitro.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RIN1", "entity_1_idx": [[5, 9]], "entity_1_idx_in_text_with_entity_marker": [9, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ABL-SH3", "entity_2_idx": [[53, 60]], "entity_2_idx_in_text_with_entity_marker": [66, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1813_AIMed.d209.s1813.p0", "text": "Moreover, the amino-terminal domain of RIN1 directly associates with, and is tyrosine phosphorylated by, c-ABL.", "text_with_entity_marker": "Moreover, the amino-terminal domain of [E1]RIN1[/E1] directly associates with, and is tyrosine phosphorylated by, [E2]c-ABL[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RIN1", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-ABL", "entity_2_idx": [[105, 110]], "entity_2_idx_in_text_with_entity_marker": [118, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d26.s214_AIMed.d26.s214.p0", "text": "Differential expression of granulysin and perforin by NK cells in cancer patients and correlation of impaired granulysin expression withprogression of cancer.", "text_with_entity_marker": "Differential expression of [E1]granulysin[/E1] and [E2]perforin[/E2] by NK cells in cancer patients and correlation of impaired granulysin expression withprogression of cancer.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "granulysin", "entity_1_idx": [[27, 37]], "entity_1_idx_in_text_with_entity_marker": [31, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "perforin", "entity_2_idx": [[42, 50]], "entity_2_idx_in_text_with_entity_marker": [55, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d26.s214_AIMed.d26.s214.p1", "text": "Differential expression of granulysin and perforin by NK cells in cancer patients and correlation of impaired granulysin expression withprogression of cancer.", "text_with_entity_marker": "Differential expression of [E1]granulysin[/E1] and perforin by NK cells in cancer patients and correlation of impaired [E2]granulysin[/E2] expression withprogression of cancer.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "granulysin", "entity_1_idx": [[27, 37]], "entity_1_idx_in_text_with_entity_marker": [31, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "granulysin", "entity_2_idx": [[110, 120]], "entity_2_idx_in_text_with_entity_marker": [123, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d26.s214_AIMed.d26.s214.p2", "text": "Differential expression of granulysin and perforin by NK cells in cancer patients and correlation of impaired granulysin expression withprogression of cancer.", "text_with_entity_marker": "Differential expression of granulysin and [E1]perforin[/E1] by NK cells in cancer patients and correlation of impaired [E2]granulysin[/E2] expression withprogression of cancer.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "perforin", "entity_1_idx": [[42, 50]], "entity_1_idx_in_text_with_entity_marker": [46, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "granulysin", "entity_2_idx": [[110, 120]], "entity_2_idx_in_text_with_entity_marker": [123, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d26.s215_AIMed.d26.s215.p0", "text": "Granulysin has been identified as an effector molecule co-localized with perforin in the cytotoxic granules of cytotoxic T lymphocytes and natural killer (NK) cells, and has been reported to kill intracellular pathogens in infected cells in the presence of perforin and to induce a cytotoxic effect against tumor cells.", "text_with_entity_marker": "[E1]Granulysin[/E1] has been identified as an effector molecule co-localized with [E2]perforin[/E2] in the cytotoxic granules of cytotoxic T lymphocytes and natural killer (NK) cells, and has been reported to kill intracellular pathogens in infected cells in the presence of perforin and to induce a cytotoxic effect against tumor cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Granulysin", "entity_1_idx": [[0, 10]], "entity_1_idx_in_text_with_entity_marker": [4, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "perforin", "entity_2_idx": [[73, 81]], "entity_2_idx_in_text_with_entity_marker": [86, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d26.s215_AIMed.d26.s215.p1", "text": "Granulysin has been identified as an effector molecule co-localized with perforin in the cytotoxic granules of cytotoxic T lymphocytes and natural killer (NK) cells, and has been reported to kill intracellular pathogens in infected cells in the presence of perforin and to induce a cytotoxic effect against tumor cells.", "text_with_entity_marker": "[E1]Granulysin[/E1] has been identified as an effector molecule co-localized with perforin in the cytotoxic granules of cytotoxic T lymphocytes and natural killer (NK) cells, and has been reported to kill intracellular pathogens in infected cells in the presence of [E2]perforin[/E2] and to induce a cytotoxic effect against tumor cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Granulysin", "entity_1_idx": [[0, 10]], "entity_1_idx_in_text_with_entity_marker": [4, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "perforin", "entity_2_idx": [[257, 265]], "entity_2_idx_in_text_with_entity_marker": [270, 278], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d26.s215_AIMed.d26.s215.p2", "text": "Granulysin has been identified as an effector molecule co-localized with perforin in the cytotoxic granules of cytotoxic T lymphocytes and natural killer (NK) cells, and has been reported to kill intracellular pathogens in infected cells in the presence of perforin and to induce a cytotoxic effect against tumor cells.", "text_with_entity_marker": "Granulysin has been identified as an effector molecule co-localized with [E1]perforin[/E1] in the cytotoxic granules of cytotoxic T lymphocytes and natural killer (NK) cells, and has been reported to kill intracellular pathogens in infected cells in the presence of [E2]perforin[/E2] and to induce a cytotoxic effect against tumor cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "perforin", "entity_1_idx": [[73, 81]], "entity_1_idx_in_text_with_entity_marker": [77, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "perforin", "entity_2_idx": [[257, 265]], "entity_2_idx_in_text_with_entity_marker": [270, 278], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d26.s216_AIMed.d26.s216.p0", "text": "The aim of the present study was to elucidate whether intracellular expression of granulysin and perforin by NK cells might be associated with progression of cancer.", "text_with_entity_marker": "The aim of the present study was to elucidate whether intracellular expression of [E1]granulysin[/E1] and [E2]perforin[/E2] by NK cells might be associated with progression of cancer.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "granulysin", "entity_1_idx": [[82, 92]], "entity_1_idx_in_text_with_entity_marker": [86, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "perforin", "entity_2_idx": [[97, 105]], "entity_2_idx_in_text_with_entity_marker": [110, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d26.s217_AIMed.d26.s217.p0", "text": "Flow cytometric analysis demonstrated high levels of perforin and granulysin expression by CD3(-) CD16(+) cells in healthy controls.", "text_with_entity_marker": "Flow cytometric analysis demonstrated high levels of [E1]perforin[/E1] and [E2]granulysin[/E2] expression by CD3(-) CD16(+) cells in healthy controls.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "perforin", "entity_1_idx": [[53, 61]], "entity_1_idx_in_text_with_entity_marker": [57, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "granulysin", "entity_2_idx": [[66, 76]], "entity_2_idx_in_text_with_entity_marker": [79, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d26.s217_AIMed.d26.s217.p1", "text": "Flow cytometric analysis demonstrated high levels of perforin and granulysin expression by CD3(-) CD16(+) cells in healthy controls.", "text_with_entity_marker": "Flow cytometric analysis demonstrated high levels of [E1]perforin[/E1] and granulysin expression by [E2]CD3[/E2](-) CD16(+) cells in healthy controls.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "perforin", "entity_1_idx": [[53, 61]], "entity_1_idx_in_text_with_entity_marker": [57, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD3", "entity_2_idx": [[91, 94]], "entity_2_idx_in_text_with_entity_marker": [104, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d26.s217_AIMed.d26.s217.p2", "text": "Flow cytometric analysis demonstrated high levels of perforin and granulysin expression by CD3(-) CD16(+) cells in healthy controls.", "text_with_entity_marker": "Flow cytometric analysis demonstrated high levels of [E1]perforin[/E1] and granulysin expression by CD3(-) [E2]CD16[/E2](+) cells in healthy controls.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "perforin", "entity_1_idx": [[53, 61]], "entity_1_idx_in_text_with_entity_marker": [57, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD16", "entity_2_idx": [[98, 102]], "entity_2_idx_in_text_with_entity_marker": [111, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d26.s217_AIMed.d26.s217.p3", "text": "Flow cytometric analysis demonstrated high levels of perforin and granulysin expression by CD3(-) CD16(+) cells in healthy controls.", "text_with_entity_marker": "Flow cytometric analysis demonstrated high levels of perforin and [E1]granulysin[/E1] expression by [E2]CD3[/E2](-) CD16(+) cells in healthy controls.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "granulysin", "entity_1_idx": [[66, 76]], "entity_1_idx_in_text_with_entity_marker": [70, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD3", "entity_2_idx": [[91, 94]], "entity_2_idx_in_text_with_entity_marker": [104, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d26.s217_AIMed.d26.s217.p4", "text": "Flow cytometric analysis demonstrated high levels of perforin and granulysin expression by CD3(-) CD16(+) cells in healthy controls.", "text_with_entity_marker": "Flow cytometric analysis demonstrated high levels of perforin and [E1]granulysin[/E1] expression by CD3(-) [E2]CD16[/E2](+) cells in healthy controls.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "granulysin", "entity_1_idx": [[66, 76]], "entity_1_idx_in_text_with_entity_marker": [70, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD16", "entity_2_idx": [[98, 102]], "entity_2_idx_in_text_with_entity_marker": [111, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d26.s217_AIMed.d26.s217.p5", "text": "Flow cytometric analysis demonstrated high levels of perforin and granulysin expression by CD3(-) CD16(+) cells in healthy controls.", "text_with_entity_marker": "Flow cytometric analysis demonstrated high levels of perforin and granulysin expression by [E1]CD3[/E1](-) [E2]CD16[/E2](+) cells in healthy controls.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD3", "entity_1_idx": [[91, 94]], "entity_1_idx_in_text_with_entity_marker": [95, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD16", "entity_2_idx": [[98, 102]], "entity_2_idx_in_text_with_entity_marker": [111, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d26.s218_AIMed.d26.s218.p0", "text": "In contrast, cancer patients exhibited significantly decreased levels of granulysin expression ( P<0.005), despite having equally high levels of perforin expression in comparison with healthy controls.", "text_with_entity_marker": "In contrast, cancer patients exhibited significantly decreased levels of [E1]granulysin[/E1] expression ( P<0.005), despite having equally high levels of [E2]perforin[/E2] expression in comparison with healthy controls.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "granulysin", "entity_1_idx": [[73, 83]], "entity_1_idx_in_text_with_entity_marker": [77, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "perforin", "entity_2_idx": [[145, 153]], "entity_2_idx_in_text_with_entity_marker": [158, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d26.s219_AIMed.d26.s219.p0", "text": "The tumor-free patients expressed granulysin at levels similar to healthy controls, while the progressive tumor-bearing patients expressed remarkably lower levels of granulysin compared to healthy controls ( P<0.0001).", "text_with_entity_marker": "The tumor-free patients expressed [E1]granulysin[/E1] at levels similar to healthy controls, while the progressive tumor-bearing patients expressed remarkably lower levels of [E2]granulysin[/E2] compared to healthy controls ( P<0.0001).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "granulysin", "entity_1_idx": [[34, 44]], "entity_1_idx_in_text_with_entity_marker": [38, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "granulysin", "entity_2_idx": [[166, 176]], "entity_2_idx_in_text_with_entity_marker": [179, 189], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d26.s223_AIMed.d26.s223.p0", "text": "In conclusion, impaired expression of granulysin by NK cells correlates with progression of cancer, and determination of granulysin expression might prove informative for assessing the immunological condition of cancer patients.", "text_with_entity_marker": "In conclusion, impaired expression of [E1]granulysin[/E1] by NK cells correlates with progression of cancer, and determination of [E2]granulysin[/E2] expression might prove informative for assessing the immunological condition of cancer patients.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "granulysin", "entity_1_idx": [[38, 48]], "entity_1_idx_in_text_with_entity_marker": [42, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "granulysin", "entity_2_idx": [[121, 131]], "entity_2_idx_in_text_with_entity_marker": [134, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p0", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "[E1]GAP-43[/E1] ([E2]neuromodulin[/E2], B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GAP-43", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "neuromodulin", "entity_2_idx": [[8, 20]], "entity_2_idx_in_text_with_entity_marker": [21, 33], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p1", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "[E1]GAP-43[/E1] (neuromodulin, [E2]B-50[/E2], F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GAP-43", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "B-50", "entity_2_idx": [[22, 26]], "entity_2_idx_in_text_with_entity_marker": [35, 39], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p2", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "[E1]GAP-43[/E1] (neuromodulin, B-50, [E2]F1[/E2]), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GAP-43", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "F1", "entity_2_idx": [[28, 30]], "entity_2_idx_in_text_with_entity_marker": [41, 43], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p3", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "[E1]GAP-43[/E1] (neuromodulin, B-50, F1), a [E2]protein kinase C[/E2] (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GAP-43", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "protein kinase C", "entity_2_idx": [[35, 51]], "entity_2_idx_in_text_with_entity_marker": [48, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p4", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "[E1]GAP-43[/E1] (neuromodulin, B-50, F1), a protein kinase C ([E2]PKC[/E2]) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GAP-43", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PKC", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p5", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "GAP-43 ([E1]neuromodulin[/E1], [E2]B-50[/E2], F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "neuromodulin", "entity_1_idx": [[8, 20]], "entity_1_idx_in_text_with_entity_marker": [12, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "B-50", "entity_2_idx": [[22, 26]], "entity_2_idx_in_text_with_entity_marker": [35, 39], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p6", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "GAP-43 ([E1]neuromodulin[/E1], B-50, [E2]F1[/E2]), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "neuromodulin", "entity_1_idx": [[8, 20]], "entity_1_idx_in_text_with_entity_marker": [12, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "F1", "entity_2_idx": [[28, 30]], "entity_2_idx_in_text_with_entity_marker": [41, 43], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p7", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "GAP-43 ([E1]neuromodulin[/E1], B-50, F1), a [E2]protein kinase C[/E2] (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "neuromodulin", "entity_1_idx": [[8, 20]], "entity_1_idx_in_text_with_entity_marker": [12, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "protein kinase C", "entity_2_idx": [[35, 51]], "entity_2_idx_in_text_with_entity_marker": [48, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p8", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "GAP-43 ([E1]neuromodulin[/E1], B-50, F1), a protein kinase C ([E2]PKC[/E2]) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "neuromodulin", "entity_1_idx": [[8, 20]], "entity_1_idx_in_text_with_entity_marker": [12, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PKC", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p9", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "GAP-43 (neuromodulin, [E1]B-50[/E1], [E2]F1[/E2]), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "B-50", "entity_1_idx": [[22, 26]], "entity_1_idx_in_text_with_entity_marker": [26, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "F1", "entity_2_idx": [[28, 30]], "entity_2_idx_in_text_with_entity_marker": [41, 43], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p10", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "GAP-43 (neuromodulin, [E1]B-50[/E1], F1), a [E2]protein kinase C[/E2] (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "B-50", "entity_1_idx": [[22, 26]], "entity_1_idx_in_text_with_entity_marker": [26, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "protein kinase C", "entity_2_idx": [[35, 51]], "entity_2_idx_in_text_with_entity_marker": [48, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p11", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "GAP-43 (neuromodulin, [E1]B-50[/E1], F1), a protein kinase C ([E2]PKC[/E2]) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "B-50", "entity_1_idx": [[22, 26]], "entity_1_idx_in_text_with_entity_marker": [26, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PKC", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p12", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "GAP-43 (neuromodulin, B-50, [E1]F1[/E1]), a [E2]protein kinase C[/E2] (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "F1", "entity_1_idx": [[28, 30]], "entity_1_idx_in_text_with_entity_marker": [32, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "protein kinase C", "entity_2_idx": [[35, 51]], "entity_2_idx_in_text_with_entity_marker": [48, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p13", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "GAP-43 (neuromodulin, B-50, [E1]F1[/E1]), a protein kinase C ([E2]PKC[/E2]) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "F1", "entity_1_idx": [[28, 30]], "entity_1_idx_in_text_with_entity_marker": [32, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PKC", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p14", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "GAP-43 (neuromodulin, B-50, F1), a [E1]protein kinase C[/E1] ([E2]PKC[/E2]) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "protein kinase C", "entity_1_idx": [[35, 51]], "entity_1_idx_in_text_with_entity_marker": [39, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PKC", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1533_AIMed.d180.s1533.p0", "text": "In the yeast-based cloning system, the only strong interaction that was detected between GAP-43 and the calcium effector protein, calmodulin (CaM).", "text_with_entity_marker": "In the yeast-based cloning system, the only strong interaction that was detected between [E1]GAP-43[/E1] and the [E2]calcium effector protein[/E2], calmodulin (CaM).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GAP-43", "entity_1_idx": [[89, 95]], "entity_1_idx_in_text_with_entity_marker": [93, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calcium effector protein", "entity_2_idx": [[104, 128]], "entity_2_idx_in_text_with_entity_marker": [117, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1533_AIMed.d180.s1533.p1", "text": "In the yeast-based cloning system, the only strong interaction that was detected between GAP-43 and the calcium effector protein, calmodulin (CaM).", "text_with_entity_marker": "In the yeast-based cloning system, the only strong interaction that was detected between [E1]GAP-43[/E1] and the calcium effector protein, [E2]calmodulin[/E2] (CaM).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GAP-43", "entity_1_idx": [[89, 95]], "entity_1_idx_in_text_with_entity_marker": [93, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calmodulin", "entity_2_idx": [[130, 140]], "entity_2_idx_in_text_with_entity_marker": [143, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1533_AIMed.d180.s1533.p2", "text": "In the yeast-based cloning system, the only strong interaction that was detected between GAP-43 and the calcium effector protein, calmodulin (CaM).", "text_with_entity_marker": "In the yeast-based cloning system, the only strong interaction that was detected between [E1]GAP-43[/E1] and the calcium effector protein, calmodulin ([E2]CaM[/E2]).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GAP-43", "entity_1_idx": [[89, 95]], "entity_1_idx_in_text_with_entity_marker": [93, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CaM", "entity_2_idx": [[142, 145]], "entity_2_idx_in_text_with_entity_marker": [155, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1533_AIMed.d180.s1533.p3", "text": "In the yeast-based cloning system, the only strong interaction that was detected between GAP-43 and the calcium effector protein, calmodulin (CaM).", "text_with_entity_marker": "In the yeast-based cloning system, the only strong interaction that was detected between GAP-43 and the [E1]calcium effector protein[/E1], [E2]calmodulin[/E2] (CaM).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "calcium effector protein", "entity_1_idx": [[104, 128]], "entity_1_idx_in_text_with_entity_marker": [108, 132], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calmodulin", "entity_2_idx": [[130, 140]], "entity_2_idx_in_text_with_entity_marker": [143, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1533_AIMed.d180.s1533.p4", "text": "In the yeast-based cloning system, the only strong interaction that was detected between GAP-43 and the calcium effector protein, calmodulin (CaM).", "text_with_entity_marker": "In the yeast-based cloning system, the only strong interaction that was detected between GAP-43 and the [E1]calcium effector protein[/E1], calmodulin ([E2]CaM[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "calcium effector protein", "entity_1_idx": [[104, 128]], "entity_1_idx_in_text_with_entity_marker": [108, 132], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CaM", "entity_2_idx": [[142, 145]], "entity_2_idx_in_text_with_entity_marker": [155, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1533_AIMed.d180.s1533.p5", "text": "In the yeast-based cloning system, the only strong interaction that was detected between GAP-43 and the calcium effector protein, calmodulin (CaM).", "text_with_entity_marker": "In the yeast-based cloning system, the only strong interaction that was detected between GAP-43 and the calcium effector protein, [E1]calmodulin[/E1] ([E2]CaM[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "calmodulin", "entity_1_idx": [[130, 140]], "entity_1_idx_in_text_with_entity_marker": [134, 144], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CaM", "entity_2_idx": [[142, 145]], "entity_2_idx_in_text_with_entity_marker": [155, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1534_AIMed.d180.s1534.p0", "text": "PKC phosphorylates GAP-43 on serine 41.", "text_with_entity_marker": "[E1]PKC[/E1] phosphorylates [E2]GAP-43[/E2] on serine 41.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PKC", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GAP-43", "entity_2_idx": [[19, 25]], "entity_2_idx_in_text_with_entity_marker": [32, 38], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1536_AIMed.d180.s1536.p0", "text": "Surprisingly, the N-terminal third of GAP-43 alone bound CaM more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.", "text_with_entity_marker": "Surprisingly, the N-terminal third of [E1]GAP-43[/E1] alone bound [E2]CaM[/E2] more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GAP-43", "entity_1_idx": [[38, 44]], "entity_1_idx_in_text_with_entity_marker": [42, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CaM", "entity_2_idx": [[57, 60]], "entity_2_idx_in_text_with_entity_marker": [70, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1536_AIMed.d180.s1536.p1", "text": "Surprisingly, the N-terminal third of GAP-43 alone bound CaM more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.", "text_with_entity_marker": "Surprisingly, the N-terminal third of [E1]GAP-43[/E1] alone bound CaM more strongly than did intact [E2]GAP-43[/E2], suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GAP-43", "entity_1_idx": [[38, 44]], "entity_1_idx_in_text_with_entity_marker": [42, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GAP-43", "entity_2_idx": [[91, 97]], "entity_2_idx_in_text_with_entity_marker": [104, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1536_AIMed.d180.s1536.p2", "text": "Surprisingly, the N-terminal third of GAP-43 alone bound CaM more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.", "text_with_entity_marker": "Surprisingly, the N-terminal third of [E1]GAP-43[/E1] alone bound CaM more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with [E2]CaM[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GAP-43", "entity_1_idx": [[38, 44]], "entity_1_idx_in_text_with_entity_marker": [42, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CaM", "entity_2_idx": [[191, 194]], "entity_2_idx_in_text_with_entity_marker": [204, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1536_AIMed.d180.s1536.p3", "text": "Surprisingly, the N-terminal third of GAP-43 alone bound CaM more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.", "text_with_entity_marker": "Surprisingly, the N-terminal third of GAP-43 alone bound [E1]CaM[/E1] more strongly than did intact [E2]GAP-43[/E2], suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CaM", "entity_1_idx": [[57, 60]], "entity_1_idx_in_text_with_entity_marker": [61, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GAP-43", "entity_2_idx": [[91, 97]], "entity_2_idx_in_text_with_entity_marker": [104, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1536_AIMed.d180.s1536.p4", "text": "Surprisingly, the N-terminal third of GAP-43 alone bound CaM more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.", "text_with_entity_marker": "Surprisingly, the N-terminal third of GAP-43 alone bound [E1]CaM[/E1] more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with [E2]CaM[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CaM", "entity_1_idx": [[57, 60]], "entity_1_idx_in_text_with_entity_marker": [61, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CaM", "entity_2_idx": [[191, 194]], "entity_2_idx_in_text_with_entity_marker": [204, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1536_AIMed.d180.s1536.p5", "text": "Surprisingly, the N-terminal third of GAP-43 alone bound CaM more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.", "text_with_entity_marker": "Surprisingly, the N-terminal third of GAP-43 alone bound CaM more strongly than did intact [E1]GAP-43[/E1], suggesting that the protein's C-terminus may play a role in modulating the interaction with [E2]CaM[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GAP-43", "entity_1_idx": [[91, 97]], "entity_1_idx_in_text_with_entity_marker": [95, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CaM", "entity_2_idx": [[191, 194]], "entity_2_idx_in_text_with_entity_marker": [204, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1537_AIMed.d180.s1537.p0", "text": "These results, along with other recent findings, suggest a novel role for the interaction between GAP-43 and CaM.", "text_with_entity_marker": "These results, along with other recent findings, suggest a novel role for the interaction between [E1]GAP-43[/E1] and [E2]CaM[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GAP-43", "entity_1_idx": [[98, 104]], "entity_1_idx_in_text_with_entity_marker": [102, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CaM", "entity_2_idx": [[109, 112]], "entity_2_idx_in_text_with_entity_marker": [122, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d7.s53_AIMed.d7.s53.p0", "text": "A comparative study of E-cadherin and stromelysin-3 expression in de novo and ex adenoma carcinoma of the colorectum.", "text_with_entity_marker": "A comparative study of [E1]E-cadherin[/E1] and [E2]stromelysin-3[/E2] expression in de novo and ex adenoma carcinoma of the colorectum.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E-cadherin", "entity_1_idx": [[23, 33]], "entity_1_idx_in_text_with_entity_marker": [27, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "stromelysin-3", "entity_2_idx": [[38, 51]], "entity_2_idx_in_text_with_entity_marker": [51, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d7.s56_AIMed.d7.s56.p0", "text": "The purpose of the present comparative immunohistochemical study was to compare rates of cell adhesion molecule (E-cadherin) and protease [stromelysin-3 (ST-3)] expression in groups of de novo (n=64) and ex adenoma (n=42) lesions in order to see whether their more aggressive behavior is associated with decreased cell adhesion and increased protease expression.", "text_with_entity_marker": "The purpose of the present comparative immunohistochemical study was to compare rates of cell adhesion molecule ([E1]E-cadherin[/E1]) and protease [[E2]stromelysin-3[/E2] (ST-3)] expression in groups of de novo (n=64) and ex adenoma (n=42) lesions in order to see whether their more aggressive behavior is associated with decreased cell adhesion and increased protease expression.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E-cadherin", "entity_1_idx": [[113, 123]], "entity_1_idx_in_text_with_entity_marker": [117, 127], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "stromelysin-3", "entity_2_idx": [[139, 152]], "entity_2_idx_in_text_with_entity_marker": [152, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d7.s56_AIMed.d7.s56.p1", "text": "The purpose of the present comparative immunohistochemical study was to compare rates of cell adhesion molecule (E-cadherin) and protease [stromelysin-3 (ST-3)] expression in groups of de novo (n=64) and ex adenoma (n=42) lesions in order to see whether their more aggressive behavior is associated with decreased cell adhesion and increased protease expression.", "text_with_entity_marker": "The purpose of the present comparative immunohistochemical study was to compare rates of cell adhesion molecule ([E1]E-cadherin[/E1]) and protease [stromelysin-3 ([E2]ST-3[/E2])] expression in groups of de novo (n=64) and ex adenoma (n=42) lesions in order to see whether their more aggressive behavior is associated with decreased cell adhesion and increased protease expression.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E-cadherin", "entity_1_idx": [[113, 123]], "entity_1_idx_in_text_with_entity_marker": [117, 127], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ST-3", "entity_2_idx": [[154, 158]], "entity_2_idx_in_text_with_entity_marker": [167, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d7.s56_AIMed.d7.s56.p2", "text": "The purpose of the present comparative immunohistochemical study was to compare rates of cell adhesion molecule (E-cadherin) and protease [stromelysin-3 (ST-3)] expression in groups of de novo (n=64) and ex adenoma (n=42) lesions in order to see whether their more aggressive behavior is associated with decreased cell adhesion and increased protease expression.", "text_with_entity_marker": "The purpose of the present comparative immunohistochemical study was to compare rates of cell adhesion molecule (E-cadherin) and protease [[E1]stromelysin-3[/E1] ([E2]ST-3[/E2])] expression in groups of de novo (n=64) and ex adenoma (n=42) lesions in order to see whether their more aggressive behavior is associated with decreased cell adhesion and increased protease expression.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "stromelysin-3", "entity_1_idx": [[139, 152]], "entity_1_idx_in_text_with_entity_marker": [143, 156], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ST-3", "entity_2_idx": [[154, 158]], "entity_2_idx_in_text_with_entity_marker": [167, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d7.s57_AIMed.d7.s57.p0", "text": "The rates of extensive ST-3 expression and decreased E-cadherin expression were significantly higher in the de novo group (P=0.014 and 0.005, respectively).", "text_with_entity_marker": "The rates of extensive [E1]ST-3[/E1] expression and decreased [E2]E-cadherin[/E2] expression were significantly higher in the de novo group (P=0.014 and 0.005, respectively).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ST-3", "entity_1_idx": [[23, 27]], "entity_1_idx_in_text_with_entity_marker": [27, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E-cadherin", "entity_2_idx": [[53, 63]], "entity_2_idx_in_text_with_entity_marker": [66, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d155.s1316_AIMed.d155.s1316.p0", "text": "The general transcription factor TFIID nucleates initiation complex formation through direct core promoter binding, commits promoters within chromatin to transcription, and mediates the action of transcriptional activators, a phenomenon that may correlate with enhanced TFIID recruitment or conformational changes in TFIID-promoter complexes.", "text_with_entity_marker": "The general transcription factor [E1]TFIID[/E1] nucleates initiation complex formation through direct core promoter binding, commits promoters within chromatin to transcription, and mediates the action of transcriptional activators, a phenomenon that may correlate with enhanced [E2]TFIID[/E2] recruitment or conformational changes in TFIID-promoter complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[33, 38]], "entity_1_idx_in_text_with_entity_marker": [37, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIID", "entity_2_idx": [[270, 275]], "entity_2_idx_in_text_with_entity_marker": [283, 288], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d155.s1316_AIMed.d155.s1316.p1", "text": "The general transcription factor TFIID nucleates initiation complex formation through direct core promoter binding, commits promoters within chromatin to transcription, and mediates the action of transcriptional activators, a phenomenon that may correlate with enhanced TFIID recruitment or conformational changes in TFIID-promoter complexes.", "text_with_entity_marker": "The general transcription factor [E1]TFIID[/E1] nucleates initiation complex formation through direct core promoter binding, commits promoters within chromatin to transcription, and mediates the action of transcriptional activators, a phenomenon that may correlate with enhanced TFIID recruitment or conformational changes in [E2]TFIID[/E2]-promoter complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[33, 38]], "entity_1_idx_in_text_with_entity_marker": [37, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIID", "entity_2_idx": [[317, 322]], "entity_2_idx_in_text_with_entity_marker": [330, 335], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d155.s1316_AIMed.d155.s1316.p2", "text": "The general transcription factor TFIID nucleates initiation complex formation through direct core promoter binding, commits promoters within chromatin to transcription, and mediates the action of transcriptional activators, a phenomenon that may correlate with enhanced TFIID recruitment or conformational changes in TFIID-promoter complexes.", "text_with_entity_marker": "The general transcription factor TFIID nucleates initiation complex formation through direct core promoter binding, commits promoters within chromatin to transcription, and mediates the action of transcriptional activators, a phenomenon that may correlate with enhanced [E1]TFIID[/E1] recruitment or conformational changes in [E2]TFIID[/E2]-promoter complexes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[270, 275]], "entity_1_idx_in_text_with_entity_marker": [274, 279], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIID", "entity_2_idx": [[317, 322]], "entity_2_idx_in_text_with_entity_marker": [330, 335], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d155.s1317_AIMed.d155.s1317.p0", "text": "Molecular studies of the multiprotein TFIID complex have identified a primary TATA binding subunit (TBP), TBP-associated factors (TAFs) that interact with and mediate the function of activators and intersubunit interactions but have yielded relatively little insight into the structural organization of the complex or the actual mechanism of transcriptional activation.", "text_with_entity_marker": "Molecular studies of the multiprotein [E1]TFIID[/E1] complex have identified a primary [E2]TATA binding subunit[/E2] (TBP), TBP-associated factors (TAFs) that interact with and mediate the function of activators and intersubunit interactions but have yielded relatively little insight into the structural organization of the complex or the actual mechanism of transcriptional activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TATA binding subunit", "entity_2_idx": [[78, 98]], "entity_2_idx_in_text_with_entity_marker": [91, 111], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d155.s1317_AIMed.d155.s1317.p1", "text": "Molecular studies of the multiprotein TFIID complex have identified a primary TATA binding subunit (TBP), TBP-associated factors (TAFs) that interact with and mediate the function of activators and intersubunit interactions but have yielded relatively little insight into the structural organization of the complex or the actual mechanism of transcriptional activation.", "text_with_entity_marker": "Molecular studies of the multiprotein [E1]TFIID[/E1] complex have identified a primary TATA binding subunit ([E2]TBP[/E2]), TBP-associated factors (TAFs) that interact with and mediate the function of activators and intersubunit interactions but have yielded relatively little insight into the structural organization of the complex or the actual mechanism of transcriptional activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[100, 103]], "entity_2_idx_in_text_with_entity_marker": [113, 116], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d155.s1317_AIMed.d155.s1317.p2", "text": "Molecular studies of the multiprotein TFIID complex have identified a primary TATA binding subunit (TBP), TBP-associated factors (TAFs) that interact with and mediate the function of activators and intersubunit interactions but have yielded relatively little insight into the structural organization of the complex or the actual mechanism of transcriptional activation.", "text_with_entity_marker": "Molecular studies of the multiprotein TFIID complex have identified a primary [E1]TATA binding subunit[/E1] ([E2]TBP[/E2]), TBP-associated factors (TAFs) that interact with and mediate the function of activators and intersubunit interactions but have yielded relatively little insight into the structural organization of the complex or the actual mechanism of transcriptional activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA binding subunit", "entity_1_idx": [[78, 98]], "entity_1_idx_in_text_with_entity_marker": [82, 102], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[100, 103]], "entity_2_idx_in_text_with_entity_marker": [113, 116], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d155.s1318_AIMed.d155.s1318.p0", "text": "Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15.", "text_with_entity_marker": "Here we present biochemical evidence for the structural relevance of histone homologies in the human [E1]TFIID[/E1] subunits [E2]hTAF80[/E2], hTAF31 and hTAF20/15.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[101, 106]], "entity_1_idx_in_text_with_entity_marker": [105, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hTAF80", "entity_2_idx": [[116, 122]], "entity_2_idx_in_text_with_entity_marker": [129, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d155.s1318_AIMed.d155.s1318.p1", "text": "Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15.", "text_with_entity_marker": "Here we present biochemical evidence for the structural relevance of histone homologies in the human [E1]TFIID[/E1] subunits hTAF80, [E2]hTAF31[/E2] and hTAF20/15.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[101, 106]], "entity_1_idx_in_text_with_entity_marker": [105, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hTAF31", "entity_2_idx": [[124, 130]], "entity_2_idx_in_text_with_entity_marker": [137, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d155.s1318_AIMed.d155.s1318.p2", "text": "Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15.", "text_with_entity_marker": "Here we present biochemical evidence for the structural relevance of histone homologies in the human [E1]TFIID[/E1] subunits hTAF80, hTAF31 and [E2]hTAF20/15[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[101, 106]], "entity_1_idx_in_text_with_entity_marker": [105, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hTAF20/15", "entity_2_idx": [[135, 144]], "entity_2_idx_in_text_with_entity_marker": [148, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d155.s1318_AIMed.d155.s1318.p3", "text": "Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15.", "text_with_entity_marker": "Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits [E1]hTAF80[/E1], [E2]hTAF31[/E2] and hTAF20/15.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hTAF80", "entity_1_idx": [[116, 122]], "entity_1_idx_in_text_with_entity_marker": [120, 126], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hTAF31", "entity_2_idx": [[124, 130]], "entity_2_idx_in_text_with_entity_marker": [137, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d155.s1318_AIMed.d155.s1318.p4", "text": "Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15.", "text_with_entity_marker": "Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits [E1]hTAF80[/E1], hTAF31 and [E2]hTAF20/15[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hTAF80", "entity_1_idx": [[116, 122]], "entity_1_idx_in_text_with_entity_marker": [120, 126], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hTAF20/15", "entity_2_idx": [[135, 144]], "entity_2_idx_in_text_with_entity_marker": [148, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d155.s1318_AIMed.d155.s1318.p5", "text": "Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15.", "text_with_entity_marker": "Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, [E1]hTAF31[/E1] and [E2]hTAF20/15[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hTAF31", "entity_1_idx": [[124, 130]], "entity_1_idx_in_text_with_entity_marker": [128, 134], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hTAF20/15", "entity_2_idx": [[135, 144]], "entity_2_idx_in_text_with_entity_marker": [148, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d155.s1319_AIMed.d155.s1319.p0", "text": "Together with analyses of native TFIID complexes and accompanying crystallographic studies, the results suggest that there is a histone octamer-like TAF complex within TFIID.", "text_with_entity_marker": "Together with analyses of native [E1]TFIID[/E1] complexes and accompanying crystallographic studies, the results suggest that there is a histone octamer-like TAF complex within [E2]TFIID[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[33, 38]], "entity_1_idx_in_text_with_entity_marker": [37, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIID", "entity_2_idx": [[168, 173]], "entity_2_idx_in_text_with_entity_marker": [181, 186], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d10.s81_AIMed.d10.s81.p0", "text": "BMP-4 and BMP-6 involvement in the osteogenic properties of the HeLa cell line.", "text_with_entity_marker": "[E1]BMP-4[/E1] and [E2]BMP-6[/E2] involvement in the osteogenic properties of the HeLa cell line.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMP-4", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP-6", "entity_2_idx": [[10, 15]], "entity_2_idx_in_text_with_entity_marker": [23, 28], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d10.s84_AIMed.d10.s84.p0", "text": "We postulate that the mechanism of bone induction is based on the secretion of bone morphogenetic proteins BMP-4 and BMP-6 by the grafted HeLa cells.", "text_with_entity_marker": "We postulate that the mechanism of bone induction is based on the secretion of bone morphogenetic proteins [E1]BMP-4[/E1] and [E2]BMP-6[/E2] by the grafted HeLa cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMP-4", "entity_1_idx": [[107, 112]], "entity_1_idx_in_text_with_entity_marker": [111, 116], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP-6", "entity_2_idx": [[117, 122]], "entity_2_idx_in_text_with_entity_marker": [130, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d58.s511_AIMed.d58.s511.p0", "text": "A cDNA clone encoding a novel, widely expressed protein (called growth factor receptor-bound protein 2 or GRB2) containing one src homology 2 (SH2) domain and two SH3 domains was isolated.", "text_with_entity_marker": "A cDNA clone encoding a novel, widely expressed protein (called [E1]growth factor receptor-bound protein 2[/E1] or [E2]GRB2[/E2]) containing one src homology 2 (SH2) domain and two SH3 domains was isolated.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "growth factor receptor-bound protein 2", "entity_1_idx": [[64, 102]], "entity_1_idx_in_text_with_entity_marker": [68, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[106, 110]], "entity_2_idx_in_text_with_entity_marker": [119, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d58.s516_AIMed.d58.s516.p0", "text": "While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.", "text_with_entity_marker": "While injection of [E1]GRB2[/E1] or [E2]H-ras[/E2] proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GRB2", "entity_1_idx": [[19, 23]], "entity_1_idx_in_text_with_entity_marker": [23, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "H-ras", "entity_2_idx": [[27, 32]], "entity_2_idx_in_text_with_entity_marker": [40, 45], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d58.s516_AIMed.d58.s516.p1", "text": "While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.", "text_with_entity_marker": "While injection of [E1]GRB2[/E1] or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of [E2]GRB2[/E2] together with H-ras protein stimulated DNA synthesis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GRB2", "entity_1_idx": [[19, 23]], "entity_1_idx_in_text_with_entity_marker": [23, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[128, 132]], "entity_2_idx_in_text_with_entity_marker": [141, 145], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d58.s516_AIMed.d58.s516.p2", "text": "While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.", "text_with_entity_marker": "While injection of [E1]GRB2[/E1] or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with [E2]H-ras[/E2] protein stimulated DNA synthesis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GRB2", "entity_1_idx": [[19, 23]], "entity_1_idx_in_text_with_entity_marker": [23, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "H-ras", "entity_2_idx": [[147, 152]], "entity_2_idx_in_text_with_entity_marker": [160, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d58.s516_AIMed.d58.s516.p3", "text": "While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.", "text_with_entity_marker": "While injection of GRB2 or [E1]H-ras[/E1] proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of [E2]GRB2[/E2] together with H-ras protein stimulated DNA synthesis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "H-ras", "entity_1_idx": [[27, 32]], "entity_1_idx_in_text_with_entity_marker": [31, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[128, 132]], "entity_2_idx_in_text_with_entity_marker": [141, 145], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d58.s516_AIMed.d58.s516.p4", "text": "While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.", "text_with_entity_marker": "While injection of GRB2 or [E1]H-ras[/E1] proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with [E2]H-ras[/E2] protein stimulated DNA synthesis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "H-ras", "entity_1_idx": [[27, 32]], "entity_1_idx_in_text_with_entity_marker": [31, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "H-ras", "entity_2_idx": [[147, 152]], "entity_2_idx_in_text_with_entity_marker": [160, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d58.s516_AIMed.d58.s516.p5", "text": "While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.", "text_with_entity_marker": "While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of [E1]GRB2[/E1] together with [E2]H-ras[/E2] protein stimulated DNA synthesis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GRB2", "entity_1_idx": [[128, 132]], "entity_1_idx_in_text_with_entity_marker": [132, 136], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "H-ras", "entity_2_idx": [[147, 152]], "entity_2_idx_in_text_with_entity_marker": [160, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d58.s517_AIMed.d58.s517.p0", "text": "These results suggest that GRB2/sem-5 plays a crucial role in a highly conserved mechanism for growth factor control of ras signaling.", "text_with_entity_marker": "These results suggest that [E1]GRB2[/E1]/[E2]sem-5[/E2] plays a crucial role in a highly conserved mechanism for growth factor control of ras signaling.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GRB2", "entity_1_idx": [[27, 31]], "entity_1_idx_in_text_with_entity_marker": [31, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sem-5", "entity_2_idx": [[32, 37]], "entity_2_idx_in_text_with_entity_marker": [45, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s593_AIMed.d70.s593.p0", "text": "Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif.", "text_with_entity_marker": "Interaction of the regulatory subunit ([E1]RII[/E1]) of [E2]cAMP-dependent protein kinase[/E2] with RII-anchoring proteins occurs through an amphipathic helix binding motif.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RII", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cAMP-dependent protein kinase", "entity_2_idx": [[47, 76]], "entity_2_idx_in_text_with_entity_marker": [60, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s593_AIMed.d70.s593.p1", "text": "Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif.", "text_with_entity_marker": "Interaction of the regulatory subunit ([E1]RII[/E1]) of cAMP-dependent protein kinase with [E2]RII[/E2]-anchoring proteins occurs through an amphipathic helix binding motif.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RII", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RII", "entity_2_idx": [[82, 85]], "entity_2_idx_in_text_with_entity_marker": [95, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s593_AIMed.d70.s593.p2", "text": "Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif.", "text_with_entity_marker": "Interaction of the regulatory subunit (RII) of [E1]cAMP-dependent protein kinase[/E1] with [E2]RII[/E2]-anchoring proteins occurs through an amphipathic helix binding motif.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cAMP-dependent protein kinase", "entity_1_idx": [[47, 76]], "entity_1_idx_in_text_with_entity_marker": [51, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RII", "entity_2_idx": [[82, 85]], "entity_2_idx_in_text_with_entity_marker": [95, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s594_AIMed.d70.s594.p0", "text": "The type II cAMP-dependent protein kinase is localized to specific subcellular environments through the binding of the regulatory subunit (RII) dimer to RII-anchoring proteins.", "text_with_entity_marker": "The [E1]type II cAMP-dependent protein kinase[/E1] is localized to specific subcellular environments through the binding of the regulatory subunit ([E2]RII[/E2]) dimer to RII-anchoring proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "type II cAMP-dependent protein kinase", "entity_1_idx": [[4, 41]], "entity_1_idx_in_text_with_entity_marker": [8, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RII", "entity_2_idx": [[139, 142]], "entity_2_idx_in_text_with_entity_marker": [152, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s594_AIMed.d70.s594.p1", "text": "The type II cAMP-dependent protein kinase is localized to specific subcellular environments through the binding of the regulatory subunit (RII) dimer to RII-anchoring proteins.", "text_with_entity_marker": "The [E1]type II cAMP-dependent protein kinase[/E1] is localized to specific subcellular environments through the binding of the regulatory subunit (RII) dimer to [E2]RII[/E2]-anchoring proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "type II cAMP-dependent protein kinase", "entity_1_idx": [[4, 41]], "entity_1_idx_in_text_with_entity_marker": [8, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RII", "entity_2_idx": [[153, 156]], "entity_2_idx_in_text_with_entity_marker": [166, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s594_AIMed.d70.s594.p2", "text": "The type II cAMP-dependent protein kinase is localized to specific subcellular environments through the binding of the regulatory subunit (RII) dimer to RII-anchoring proteins.", "text_with_entity_marker": "The type II cAMP-dependent protein kinase is localized to specific subcellular environments through the binding of the regulatory subunit ([E1]RII[/E1]) dimer to [E2]RII[/E2]-anchoring proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RII", "entity_1_idx": [[139, 142]], "entity_1_idx_in_text_with_entity_marker": [143, 146], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RII", "entity_2_idx": [[153, 156]], "entity_2_idx_in_text_with_entity_marker": [166, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s595_AIMed.d70.s595.p0", "text": "Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.", "text_with_entity_marker": "Computer-aided analysis of secondary structure, performed on four [E1]RII[/E1]-anchoring protein sequences (the [E2]microtubule-associated protein 2[/E2], P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RII", "entity_1_idx": [[66, 69]], "entity_1_idx_in_text_with_entity_marker": [70, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "microtubule-associated protein 2", "entity_2_idx": [[103, 135]], "entity_2_idx_in_text_with_entity_marker": [116, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s595_AIMed.d70.s595.p1", "text": "Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.", "text_with_entity_marker": "Computer-aided analysis of secondary structure, performed on four [E1]RII[/E1]-anchoring protein sequences (the microtubule-associated protein 2, [E2]P150[/E2], and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RII", "entity_1_idx": [[66, 69]], "entity_1_idx_in_text_with_entity_marker": [70, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "P150", "entity_2_idx": [[137, 141]], "entity_2_idx_in_text_with_entity_marker": [150, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s595_AIMed.d70.s595.p2", "text": "Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.", "text_with_entity_marker": "Computer-aided analysis of secondary structure, performed on four [E1]RII[/E1]-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins [E2]Ht 21[/E2] and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RII", "entity_1_idx": [[66, 69]], "entity_1_idx_in_text_with_entity_marker": [70, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ht 21", "entity_2_idx": [[168, 173]], "entity_2_idx_in_text_with_entity_marker": [181, 186], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s595_AIMed.d70.s595.p3", "text": "Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.", "text_with_entity_marker": "Computer-aided analysis of secondary structure, performed on four [E1]RII[/E1]-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and [E2]Ht 31[/E2]), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RII", "entity_1_idx": [[66, 69]], "entity_1_idx_in_text_with_entity_marker": [70, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ht 31", "entity_2_idx": [[178, 183]], "entity_2_idx_in_text_with_entity_marker": [191, 196], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s595_AIMed.d70.s595.p4", "text": "Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.", "text_with_entity_marker": "Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the [E1]microtubule-associated protein 2[/E1], [E2]P150[/E2], and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "microtubule-associated protein 2", "entity_1_idx": [[103, 135]], "entity_1_idx_in_text_with_entity_marker": [107, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "P150", "entity_2_idx": [[137, 141]], "entity_2_idx_in_text_with_entity_marker": [150, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s595_AIMed.d70.s595.p5", "text": "Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.", "text_with_entity_marker": "Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the [E1]microtubule-associated protein 2[/E1], P150, and two thyroid proteins [E2]Ht 21[/E2] and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "microtubule-associated protein 2", "entity_1_idx": [[103, 135]], "entity_1_idx_in_text_with_entity_marker": [107, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ht 21", "entity_2_idx": [[168, 173]], "entity_2_idx_in_text_with_entity_marker": [181, 186], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s595_AIMed.d70.s595.p6", "text": "Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.", "text_with_entity_marker": "Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the [E1]microtubule-associated protein 2[/E1], P150, and two thyroid proteins Ht 21 and [E2]Ht 31[/E2]), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "microtubule-associated protein 2", "entity_1_idx": [[103, 135]], "entity_1_idx_in_text_with_entity_marker": [107, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ht 31", "entity_2_idx": [[178, 183]], "entity_2_idx_in_text_with_entity_marker": [191, 196], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s595_AIMed.d70.s595.p7", "text": "Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.", "text_with_entity_marker": "Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, [E1]P150[/E1], and two thyroid proteins [E2]Ht 21[/E2] and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "P150", "entity_1_idx": [[137, 141]], "entity_1_idx_in_text_with_entity_marker": [141, 145], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ht 21", "entity_2_idx": [[168, 173]], "entity_2_idx_in_text_with_entity_marker": [181, 186], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s595_AIMed.d70.s595.p8", "text": "Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.", "text_with_entity_marker": "Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, [E1]P150[/E1], and two thyroid proteins Ht 21 and [E2]Ht 31[/E2]), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "P150", "entity_1_idx": [[137, 141]], "entity_1_idx_in_text_with_entity_marker": [141, 145], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ht 31", "entity_2_idx": [[178, 183]], "entity_2_idx_in_text_with_entity_marker": [191, 196], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s595_AIMed.d70.s595.p9", "text": "Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins Ht 21 and Ht 31), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.", "text_with_entity_marker": "Computer-aided analysis of secondary structure, performed on four RII-anchoring protein sequences (the microtubule-associated protein 2, P150, and two thyroid proteins [E1]Ht 21[/E1] and [E2]Ht 31[/E2]), has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Ht 21", "entity_1_idx": [[168, 173]], "entity_1_idx_in_text_with_entity_marker": [172, 177], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ht 31", "entity_2_idx": [[178, 183]], "entity_2_idx_in_text_with_entity_marker": [191, 196], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s597_AIMed.d70.s597.p0", "text": "A bacterially expressed 318-amino acid fragment, Ht 31 (418-736), containing the amphipathic helix region, was able to bind RII alpha.", "text_with_entity_marker": "A bacterially expressed 318-amino acid fragment, [E1]Ht 31[/E1] (418-736), containing the amphipathic helix region, was able to bind [E2]RII[/E2] alpha.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Ht 31", "entity_1_idx": [[49, 54]], "entity_1_idx_in_text_with_entity_marker": [53, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RII", "entity_2_idx": [[124, 127]], "entity_2_idx_in_text_with_entity_marker": [137, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s597_AIMed.d70.s597.p1", "text": "A bacterially expressed 318-amino acid fragment, Ht 31 (418-736), containing the amphipathic helix region, was able to bind RII alpha.", "text_with_entity_marker": "A bacterially expressed 318-amino acid fragment, [E1]Ht 31[/E1] (418-736), containing the amphipathic helix region, was able to bind [E2]RII alpha[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Ht 31", "entity_1_idx": [[49, 54]], "entity_1_idx_in_text_with_entity_marker": [53, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RII alpha", "entity_2_idx": [[124, 133]], "entity_2_idx_in_text_with_entity_marker": [137, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s597_AIMed.d70.s597.p2", "text": "A bacterially expressed 318-amino acid fragment, Ht 31 (418-736), containing the amphipathic helix region, was able to bind RII alpha.", "text_with_entity_marker": "A bacterially expressed 318-amino acid fragment, Ht 31 (418-736), containing the amphipathic helix region, was able to bind [E1-E2]RII[/E1] alpha[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RII", "entity_1_idx": [[124, 127]], "entity_1_idx_in_text_with_entity_marker": [131, 134], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RII[/E1] alpha", "entity_2_idx": [[124, 133]], "entity_2_idx_in_text_with_entity_marker": [131, 145], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s599_AIMed.d70.s599.p0", "text": "Specifically, substitution of proline for Ala-498 significantly diminished RII alpha binding, and similar mutation of Ile-502 or Ile-507 abolished interaction.", "text_with_entity_marker": "Specifically, substitution of proline for Ala-498 significantly diminished [E1-E2]RII[/E1] alpha[/E2] binding, and similar mutation of Ile-502 or Ile-507 abolished interaction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RII", "entity_1_idx": [[75, 78]], "entity_1_idx_in_text_with_entity_marker": [82, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RII[/E1] alpha", "entity_2_idx": [[75, 84]], "entity_2_idx_in_text_with_entity_marker": [82, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s600_AIMed.d70.s600.p0", "text": "Mutation of Ala-522 to proline, which is located outside the predicted amphipathic helix region, had no effect on RII alpha binding.", "text_with_entity_marker": "Mutation of Ala-522 to proline, which is located outside the predicted amphipathic helix region, had no effect on [E1-E2]RII[/E1] alpha[/E2] binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RII", "entity_1_idx": [[114, 117]], "entity_1_idx_in_text_with_entity_marker": [121, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RII[/E1] alpha", "entity_2_idx": [[114, 123]], "entity_2_idx_in_text_with_entity_marker": [121, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d70.s601_AIMed.d70.s601.p0", "text": "These data suggest that anchoring proteins interact with RII alpha via an amphipathic helix binding motif.", "text_with_entity_marker": "These data suggest that anchoring proteins interact with [E1-E2]RII[/E1] alpha[/E2] via an amphipathic helix binding motif.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RII", "entity_1_idx": [[57, 60]], "entity_1_idx_in_text_with_entity_marker": [64, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RII[/E1] alpha", "entity_2_idx": [[57, 66]], "entity_2_idx_in_text_with_entity_marker": [64, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d166.s1394_AIMed.d166.s1394.p0", "text": "Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.", "text_with_entity_marker": "Residues in human [E1]leukemia inhibitory factor[/E1] ([E2]hLIF[/E2]) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "leukemia inhibitory factor", "entity_1_idx": [[18, 44]], "entity_1_idx_in_text_with_entity_marker": [22, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hLIF", "entity_2_idx": [[46, 50]], "entity_2_idx_in_text_with_entity_marker": [59, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d166.s1394_AIMed.d166.s1394.p1", "text": "Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.", "text_with_entity_marker": "Residues in human [E1]leukemia inhibitory factor[/E1] (hLIF) crucial for binding to both the human [E2]LIF receptor[/E2] (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "leukemia inhibitory factor", "entity_1_idx": [[18, 44]], "entity_1_idx_in_text_with_entity_marker": [22, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIF receptor", "entity_2_idx": [[90, 102]], "entity_2_idx_in_text_with_entity_marker": [103, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d166.s1394_AIMed.d166.s1394.p2", "text": "Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.", "text_with_entity_marker": "Residues in human [E1]leukemia inhibitory factor[/E1] (hLIF) crucial for binding to both the human LIF receptor (R) and [E2]gp130[/E2] were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "leukemia inhibitory factor", "entity_1_idx": [[18, 44]], "entity_1_idx_in_text_with_entity_marker": [22, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[111, 116]], "entity_2_idx_in_text_with_entity_marker": [124, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d166.s1394_AIMed.d166.s1394.p3", "text": "Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.", "text_with_entity_marker": "Residues in human [E1]leukemia inhibitory factor[/E1] (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of [E2]hLIF[/E2] in assays for both receptor binding and bioactivity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "leukemia inhibitory factor", "entity_1_idx": [[18, 44]], "entity_1_idx_in_text_with_entity_marker": [22, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hLIF", "entity_2_idx": [[176, 180]], "entity_2_idx_in_text_with_entity_marker": [189, 193], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d166.s1394_AIMed.d166.s1394.p4", "text": "Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.", "text_with_entity_marker": "Residues in human leukemia inhibitory factor ([E1]hLIF[/E1]) crucial for binding to both the human [E2]LIF receptor[/E2] (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hLIF", "entity_1_idx": [[46, 50]], "entity_1_idx_in_text_with_entity_marker": [50, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIF receptor", "entity_2_idx": [[90, 102]], "entity_2_idx_in_text_with_entity_marker": [103, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d166.s1394_AIMed.d166.s1394.p5", "text": "Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.", "text_with_entity_marker": "Residues in human leukemia inhibitory factor ([E1]hLIF[/E1]) crucial for binding to both the human LIF receptor (R) and [E2]gp130[/E2] were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hLIF", "entity_1_idx": [[46, 50]], "entity_1_idx_in_text_with_entity_marker": [50, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[111, 116]], "entity_2_idx_in_text_with_entity_marker": [124, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d166.s1394_AIMed.d166.s1394.p6", "text": "Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.", "text_with_entity_marker": "Residues in human leukemia inhibitory factor ([E1]hLIF[/E1]) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of [E2]hLIF[/E2] in assays for both receptor binding and bioactivity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hLIF", "entity_1_idx": [[46, 50]], "entity_1_idx_in_text_with_entity_marker": [50, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hLIF", "entity_2_idx": [[176, 180]], "entity_2_idx_in_text_with_entity_marker": [189, 193], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d166.s1394_AIMed.d166.s1394.p7", "text": "Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.", "text_with_entity_marker": "Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human [E1]LIF receptor[/E1] (R) and [E2]gp130[/E2] were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIF receptor", "entity_1_idx": [[90, 102]], "entity_1_idx_in_text_with_entity_marker": [94, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[111, 116]], "entity_2_idx_in_text_with_entity_marker": [124, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d166.s1394_AIMed.d166.s1394.p8", "text": "Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.", "text_with_entity_marker": "Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human [E1]LIF receptor[/E1] (R) and gp130 were identified by analysis of alanine scanning mutants of [E2]hLIF[/E2] in assays for both receptor binding and bioactivity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LIF receptor", "entity_1_idx": [[90, 102]], "entity_1_idx_in_text_with_entity_marker": [94, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hLIF", "entity_2_idx": [[176, 180]], "entity_2_idx_in_text_with_entity_marker": [189, 193], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d166.s1394_AIMed.d166.s1394.p9", "text": "Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.", "text_with_entity_marker": "Residues in human leukemia inhibitory factor (hLIF) crucial for binding to both the human LIF receptor (R) and [E1]gp130[/E1] were identified by analysis of alanine scanning mutants of [E2]hLIF[/E2] in assays for both receptor binding and bioactivity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[111, 116]], "entity_1_idx_in_text_with_entity_marker": [115, 120], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hLIF", "entity_2_idx": [[176, 180]], "entity_2_idx_in_text_with_entity_marker": [189, 193], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d166.s1395_AIMed.d166.s1395.p0", "text": "The region of hLIF most important for binding to the hLIF-R is composed of residues from the amino terminus of the D-helix, carboxyl terminus of the B-helix, and C-D loop.", "text_with_entity_marker": "The region of [E1]hLIF[/E1] most important for binding to the [E2]hLIF-R[/E2] is composed of residues from the amino terminus of the D-helix, carboxyl terminus of the B-helix, and C-D loop.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hLIF", "entity_1_idx": [[14, 18]], "entity_1_idx_in_text_with_entity_marker": [18, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hLIF-R", "entity_2_idx": [[53, 59]], "entity_2_idx_in_text_with_entity_marker": [66, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d166.s1397_AIMed.d166.s1397.p0", "text": "The two residues of hLIF that contribute the majority of free energy for hLIF-R binding, Phe-156 and Lys-159 are surrounded by other residues which have only a moderate impact.", "text_with_entity_marker": "The two residues of [E1]hLIF[/E1] that contribute the majority of free energy for [E2]hLIF-R[/E2] binding, Phe-156 and Lys-159 are surrounded by other residues which have only a moderate impact.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hLIF", "entity_1_idx": [[20, 24]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hLIF-R", "entity_2_idx": [[73, 79]], "entity_2_idx_in_text_with_entity_marker": [86, 92], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d166.s1399_AIMed.d166.s1399.p0", "text": "A second region of hLIF that includes residues from the carboxyl terminus of the D-helix and A-B loop also had a weak influence on hLIF-R binding.", "text_with_entity_marker": "A second region of [E1]hLIF[/E1] that includes residues from the carboxyl terminus of the D-helix and A-B loop also had a weak influence on [E2]hLIF-R[/E2] binding.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hLIF", "entity_1_idx": [[19, 23]], "entity_1_idx_in_text_with_entity_marker": [23, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hLIF-R", "entity_2_idx": [[131, 137]], "entity_2_idx_in_text_with_entity_marker": [144, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d166.s1400_AIMed.d166.s1400.p0", "text": "Residues in hLIF from both the A- and C-helices are involved in binding the gp130 co-receptor.", "text_with_entity_marker": "Residues in [E1]hLIF[/E1] from both the A- and C-helices are involved in binding the [E2]gp130[/E2] co-receptor.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hLIF", "entity_1_idx": [[12, 16]], "entity_1_idx_in_text_with_entity_marker": [16, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[76, 81]], "entity_2_idx_in_text_with_entity_marker": [89, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d166.s1401_AIMed.d166.s1401.p0", "text": "Abolition of the gp130 binding site in hLIF created antagonists of LIF action.", "text_with_entity_marker": "Abolition of the [E1]gp130[/E1] binding site in [E2]hLIF[/E2] created antagonists of LIF action.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "gp130", "entity_1_idx": [[17, 22]], "entity_1_idx_in_text_with_entity_marker": [21, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hLIF", "entity_2_idx": [[39, 43]], "entity_2_idx_in_text_with_entity_marker": [52, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d166.s1401_AIMed.d166.s1401.p1", "text": "Abolition of the gp130 binding site in hLIF created antagonists of LIF action.", "text_with_entity_marker": "Abolition of the [E1]gp130[/E1] binding site in hLIF created antagonists of [E2]LIF[/E2] action.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[17, 22]], "entity_1_idx_in_text_with_entity_marker": [21, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIF", "entity_2_idx": [[67, 70]], "entity_2_idx_in_text_with_entity_marker": [80, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d166.s1401_AIMed.d166.s1401.p2", "text": "Abolition of the gp130 binding site in hLIF created antagonists of LIF action.", "text_with_entity_marker": "Abolition of the gp130 binding site in [E1]hLIF[/E1] created antagonists of [E2]LIF[/E2] action.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hLIF", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LIF", "entity_2_idx": [[67, 70]], "entity_2_idx_in_text_with_entity_marker": [80, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d0.s5_AIMed.d0.s5.p0", "text": "Cytokines measurements during IFN-alpha treatment showed a trend to decreasing levels of IL-4 at 4, 12, and 24 weeks.", "text_with_entity_marker": "Cytokines measurements during [E1]IFN-alpha[/E1] treatment showed a trend to decreasing levels of [E2]IL-4[/E2] at 4, 12, and 24 weeks.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-alpha", "entity_1_idx": [[30, 39]], "entity_1_idx_in_text_with_entity_marker": [34, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[89, 93]], "entity_2_idx_in_text_with_entity_marker": [102, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d0.s6_AIMed.d0.s6.p0", "text": "Levels of IFN-gamma were slightly increased following IFN-alpha treatment (P = 0.09).", "text_with_entity_marker": "Levels of [E1]IFN-gamma[/E1] were slightly increased following [E2]IFN-alpha[/E2] treatment (P = 0.09).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[10, 19]], "entity_1_idx_in_text_with_entity_marker": [14, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-alpha", "entity_2_idx": [[54, 63]], "entity_2_idx_in_text_with_entity_marker": [67, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d0.s7_AIMed.d0.s7.p0", "text": "In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "text_with_entity_marker": "In patients with a complete response to [E1]IFN-alpha[/E1], the levels of [E2]IFN-gamma[/E2] were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-alpha", "entity_1_idx": [[40, 49]], "entity_1_idx_in_text_with_entity_marker": [44, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[65, 74]], "entity_2_idx_in_text_with_entity_marker": [78, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d0.s7_AIMed.d0.s7.p1", "text": "In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "text_with_entity_marker": "In patients with a complete response to [E1]IFN-alpha[/E1], the levels of IFN-gamma were higher at 24 weeks following [E2]IFN-alpha[/E2] treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-alpha", "entity_1_idx": [[40, 49]], "entity_1_idx_in_text_with_entity_marker": [44, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-alpha", "entity_2_idx": [[109, 118]], "entity_2_idx_in_text_with_entity_marker": [122, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d0.s7_AIMed.d0.s7.p2", "text": "In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "text_with_entity_marker": "In patients with a complete response to [E1]IFN-alpha[/E1], the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of [E2]IL-4[/E2] decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-alpha", "entity_1_idx": [[40, 49]], "entity_1_idx_in_text_with_entity_marker": [44, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[186, 190]], "entity_2_idx_in_text_with_entity_marker": [199, 203], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d0.s7_AIMed.d0.s7.p3", "text": "In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "text_with_entity_marker": "In patients with a complete response to IFN-alpha, the levels of [E1]IFN-gamma[/E1] were higher at 24 weeks following [E2]IFN-alpha[/E2] treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[65, 74]], "entity_1_idx_in_text_with_entity_marker": [69, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-alpha", "entity_2_idx": [[109, 118]], "entity_2_idx_in_text_with_entity_marker": [122, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d0.s7_AIMed.d0.s7.p4", "text": "In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "text_with_entity_marker": "In patients with a complete response to IFN-alpha, the levels of [E1]IFN-gamma[/E1] were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of [E2]IL-4[/E2] decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-gamma", "entity_1_idx": [[65, 74]], "entity_1_idx_in_text_with_entity_marker": [69, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[186, 190]], "entity_2_idx_in_text_with_entity_marker": [199, 203], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d0.s7_AIMed.d0.s7.p5", "text": "In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "text_with_entity_marker": "In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following [E1]IFN-alpha[/E1] treatment than that of pre-treatment (P = 0.04), and the levels of [E2]IL-4[/E2] decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN-alpha", "entity_1_idx": [[109, 118]], "entity_1_idx_in_text_with_entity_marker": [113, 122], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[186, 190]], "entity_2_idx_in_text_with_entity_marker": [199, 203], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s352_AIMed.d41.s352.p0", "text": "Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor.", "text_with_entity_marker": "Crystal structure of the hereditary haemochromatosis protein [E1]HFE[/E1] complexed with [E2]transferrin[/E2] receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HFE", "entity_1_idx": [[61, 64]], "entity_1_idx_in_text_with_entity_marker": [65, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transferrin", "entity_2_idx": [[80, 91]], "entity_2_idx_in_text_with_entity_marker": [93, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s352_AIMed.d41.s352.p1", "text": "Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor.", "text_with_entity_marker": "Crystal structure of the hereditary haemochromatosis protein [E1]HFE[/E1] complexed with [E2]transferrin receptor[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HFE", "entity_1_idx": [[61, 64]], "entity_1_idx_in_text_with_entity_marker": [65, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transferrin receptor", "entity_2_idx": [[80, 100]], "entity_2_idx_in_text_with_entity_marker": [93, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s352_AIMed.d41.s352.p2", "text": "Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor.", "text_with_entity_marker": "Crystal structure of the hereditary haemochromatosis protein HFE complexed with [E1-E2]transferrin[/E1] receptor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transferrin", "entity_1_idx": [[80, 91]], "entity_1_idx_in_text_with_entity_marker": [87, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transferrin[/E1] receptor", "entity_2_idx": [[80, 100]], "entity_2_idx_in_text_with_entity_marker": [87, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s354_AIMed.d41.s354.p0", "text": "HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.", "text_with_entity_marker": "[E1]HFE[/E1] binds to the [E2]transferrin[/E2] receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HFE", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transferrin", "entity_2_idx": [[17, 28]], "entity_2_idx_in_text_with_entity_marker": [30, 41], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s354_AIMed.d41.s354.p1", "text": "HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.", "text_with_entity_marker": "[E1]HFE[/E1] binds to the [E2]transferrin receptor[/E2] (TfR), a receptor by which cells acquire iron-loaded transferrin.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HFE", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transferrin receptor", "entity_2_idx": [[17, 37]], "entity_2_idx_in_text_with_entity_marker": [30, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s354_AIMed.d41.s354.p2", "text": "HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.", "text_with_entity_marker": "[E1]HFE[/E1] binds to the transferrin receptor ([E2]TfR[/E2]), a receptor by which cells acquire iron-loaded transferrin.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HFE", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TfR", "entity_2_idx": [[39, 42]], "entity_2_idx_in_text_with_entity_marker": [52, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s354_AIMed.d41.s354.p3", "text": "HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.", "text_with_entity_marker": "[E1]HFE[/E1] binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded [E2]transferrin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HFE", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transferrin", "entity_2_idx": [[91, 102]], "entity_2_idx_in_text_with_entity_marker": [104, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s354_AIMed.d41.s354.p4", "text": "HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.", "text_with_entity_marker": "HFE binds to the [E1-E2]transferrin[/E1] receptor[/E2] (TfR), a receptor by which cells acquire iron-loaded transferrin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transferrin", "entity_1_idx": [[17, 28]], "entity_1_idx_in_text_with_entity_marker": [24, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transferrin[/E1] receptor", "entity_2_idx": [[17, 37]], "entity_2_idx_in_text_with_entity_marker": [24, 49], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s354_AIMed.d41.s354.p5", "text": "HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.", "text_with_entity_marker": "HFE binds to the [E1]transferrin[/E1] receptor ([E2]TfR[/E2]), a receptor by which cells acquire iron-loaded transferrin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transferrin", "entity_1_idx": [[17, 28]], "entity_1_idx_in_text_with_entity_marker": [21, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TfR", "entity_2_idx": [[39, 42]], "entity_2_idx_in_text_with_entity_marker": [52, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s354_AIMed.d41.s354.p6", "text": "HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.", "text_with_entity_marker": "HFE binds to the [E1]transferrin[/E1] receptor (TfR), a receptor by which cells acquire iron-loaded [E2]transferrin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transferrin", "entity_1_idx": [[17, 28]], "entity_1_idx_in_text_with_entity_marker": [21, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transferrin", "entity_2_idx": [[91, 102]], "entity_2_idx_in_text_with_entity_marker": [104, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s354_AIMed.d41.s354.p7", "text": "HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.", "text_with_entity_marker": "HFE binds to the [E1]transferrin receptor[/E1] ([E2]TfR[/E2]), a receptor by which cells acquire iron-loaded transferrin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transferrin receptor", "entity_1_idx": [[17, 37]], "entity_1_idx_in_text_with_entity_marker": [21, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TfR", "entity_2_idx": [[39, 42]], "entity_2_idx_in_text_with_entity_marker": [52, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s354_AIMed.d41.s354.p8", "text": "HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.", "text_with_entity_marker": "HFE binds to the [E1]transferrin receptor[/E1] (TfR), a receptor by which cells acquire iron-loaded [E2]transferrin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transferrin receptor", "entity_1_idx": [[17, 37]], "entity_1_idx_in_text_with_entity_marker": [21, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transferrin", "entity_2_idx": [[91, 102]], "entity_2_idx_in_text_with_entity_marker": [104, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s354_AIMed.d41.s354.p9", "text": "HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.", "text_with_entity_marker": "HFE binds to the transferrin receptor ([E1]TfR[/E1]), a receptor by which cells acquire iron-loaded [E2]transferrin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TfR", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transferrin", "entity_2_idx": [[91, 102]], "entity_2_idx_in_text_with_entity_marker": [104, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s355_AIMed.d41.s355.p0", "text": "The 2.8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer.", "text_with_entity_marker": "The 2.8 A crystal structure of a complex between the extracellular portions of [E1]HFE[/E1] and [E2]TfR[/E2] shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HFE", "entity_1_idx": [[79, 82]], "entity_1_idx_in_text_with_entity_marker": [83, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TfR", "entity_2_idx": [[87, 90]], "entity_2_idx_in_text_with_entity_marker": [100, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s355_AIMed.d41.s355.p1", "text": "The 2.8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer.", "text_with_entity_marker": "The 2.8 A crystal structure of a complex between the extracellular portions of [E1]HFE[/E1] and TfR shows two [E2]HFE[/E2] molecules which grasp each side of a twofold symmetric TfR dimer.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HFE", "entity_1_idx": [[79, 82]], "entity_1_idx_in_text_with_entity_marker": [83, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HFE", "entity_2_idx": [[101, 104]], "entity_2_idx_in_text_with_entity_marker": [114, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s355_AIMed.d41.s355.p2", "text": "The 2.8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer.", "text_with_entity_marker": "The 2.8 A crystal structure of a complex between the extracellular portions of [E1]HFE[/E1] and TfR shows two HFE molecules which grasp each side of a twofold symmetric [E2]TfR[/E2] dimer.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HFE", "entity_1_idx": [[79, 82]], "entity_1_idx_in_text_with_entity_marker": [83, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TfR", "entity_2_idx": [[160, 163]], "entity_2_idx_in_text_with_entity_marker": [173, 176], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s355_AIMed.d41.s355.p3", "text": "The 2.8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer.", "text_with_entity_marker": "The 2.8 A crystal structure of a complex between the extracellular portions of HFE and [E1]TfR[/E1] shows two [E2]HFE[/E2] molecules which grasp each side of a twofold symmetric TfR dimer.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TfR", "entity_1_idx": [[87, 90]], "entity_1_idx_in_text_with_entity_marker": [91, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HFE", "entity_2_idx": [[101, 104]], "entity_2_idx_in_text_with_entity_marker": [114, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s355_AIMed.d41.s355.p4", "text": "The 2.8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer.", "text_with_entity_marker": "The 2.8 A crystal structure of a complex between the extracellular portions of HFE and [E1]TfR[/E1] shows two HFE molecules which grasp each side of a twofold symmetric [E2]TfR[/E2] dimer.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TfR", "entity_1_idx": [[87, 90]], "entity_1_idx_in_text_with_entity_marker": [91, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TfR", "entity_2_idx": [[160, 163]], "entity_2_idx_in_text_with_entity_marker": [173, 176], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s355_AIMed.d41.s355.p5", "text": "The 2.8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer.", "text_with_entity_marker": "The 2.8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two [E1]HFE[/E1] molecules which grasp each side of a twofold symmetric [E2]TfR[/E2] dimer.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HFE", "entity_1_idx": [[101, 104]], "entity_1_idx_in_text_with_entity_marker": [105, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TfR", "entity_2_idx": [[160, 163]], "entity_2_idx_in_text_with_entity_marker": [173, 176], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s356_AIMed.d41.s356.p0", "text": "On a cell membrane containing both proteins, HFE would 'lie down' parallel to the membrane, such that the HFE helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the TfR dimerization domain.", "text_with_entity_marker": "On a cell membrane containing both proteins, [E1]HFE[/E1] would 'lie down' parallel to the membrane, such that the [E2]HFE[/E2] helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the TfR dimerization domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HFE", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HFE", "entity_2_idx": [[106, 109]], "entity_2_idx_in_text_with_entity_marker": [119, 122], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s356_AIMed.d41.s356.p1", "text": "On a cell membrane containing both proteins, HFE would 'lie down' parallel to the membrane, such that the HFE helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the TfR dimerization domain.", "text_with_entity_marker": "On a cell membrane containing both proteins, [E1]HFE[/E1] would 'lie down' parallel to the membrane, such that the HFE helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the [E2]TfR[/E2] dimerization domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HFE", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TfR", "entity_2_idx": [[227, 230]], "entity_2_idx_in_text_with_entity_marker": [240, 243], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s356_AIMed.d41.s356.p2", "text": "On a cell membrane containing both proteins, HFE would 'lie down' parallel to the membrane, such that the HFE helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the TfR dimerization domain.", "text_with_entity_marker": "On a cell membrane containing both proteins, HFE would 'lie down' parallel to the membrane, such that the [E1]HFE[/E1] helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the [E2]TfR[/E2] dimerization domain.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HFE", "entity_1_idx": [[106, 109]], "entity_1_idx_in_text_with_entity_marker": [110, 113], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TfR", "entity_2_idx": [[227, 230]], "entity_2_idx_in_text_with_entity_marker": [240, 243], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s357_AIMed.d41.s357.p0", "text": "The structures of TfR alone and complexed with HFE differ in their domain arrangement and dimer interfaces, providing a mechanism for communicating binding events between TfR chains.", "text_with_entity_marker": "The structures of [E1]TfR[/E1] alone and complexed with [E2]HFE[/E2] differ in their domain arrangement and dimer interfaces, providing a mechanism for communicating binding events between TfR chains.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TfR", "entity_1_idx": [[18, 21]], "entity_1_idx_in_text_with_entity_marker": [22, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HFE", "entity_2_idx": [[47, 50]], "entity_2_idx_in_text_with_entity_marker": [60, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s357_AIMed.d41.s357.p1", "text": "The structures of TfR alone and complexed with HFE differ in their domain arrangement and dimer interfaces, providing a mechanism for communicating binding events between TfR chains.", "text_with_entity_marker": "The structures of [E1]TfR[/E1] alone and complexed with HFE differ in their domain arrangement and dimer interfaces, providing a mechanism for communicating binding events between [E2]TfR[/E2] chains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TfR", "entity_1_idx": [[18, 21]], "entity_1_idx_in_text_with_entity_marker": [22, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TfR", "entity_2_idx": [[171, 174]], "entity_2_idx_in_text_with_entity_marker": [184, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s357_AIMed.d41.s357.p2", "text": "The structures of TfR alone and complexed with HFE differ in their domain arrangement and dimer interfaces, providing a mechanism for communicating binding events between TfR chains.", "text_with_entity_marker": "The structures of TfR alone and complexed with [E1]HFE[/E1] differ in their domain arrangement and dimer interfaces, providing a mechanism for communicating binding events between [E2]TfR[/E2] chains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HFE", "entity_1_idx": [[47, 50]], "entity_1_idx_in_text_with_entity_marker": [51, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TfR", "entity_2_idx": [[171, 174]], "entity_2_idx_in_text_with_entity_marker": [184, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s358_AIMed.d41.s358.p0", "text": "The HFE-TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis.", "text_with_entity_marker": "The [E1]HFE[/E1]-[E2]TfR[/E2] complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HFE", "entity_1_idx": [[4, 7]], "entity_1_idx_in_text_with_entity_marker": [8, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TfR", "entity_2_idx": [[8, 11]], "entity_2_idx_in_text_with_entity_marker": [21, 24], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s358_AIMed.d41.s358.p1", "text": "The HFE-TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis.", "text_with_entity_marker": "The [E1]HFE[/E1]-TfR complex suggests a binding site for transferrin on [E2]TfR[/E2] and sheds light upon the function of HFE in regulating iron homeostasis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HFE", "entity_1_idx": [[4, 7]], "entity_1_idx_in_text_with_entity_marker": [8, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TfR", "entity_2_idx": [[63, 66]], "entity_2_idx_in_text_with_entity_marker": [76, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s358_AIMed.d41.s358.p2", "text": "The HFE-TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis.", "text_with_entity_marker": "The [E1]HFE[/E1]-TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of [E2]HFE[/E2] in regulating iron homeostasis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HFE", "entity_1_idx": [[4, 7]], "entity_1_idx_in_text_with_entity_marker": [8, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HFE", "entity_2_idx": [[104, 107]], "entity_2_idx_in_text_with_entity_marker": [117, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s358_AIMed.d41.s358.p3", "text": "The HFE-TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis.", "text_with_entity_marker": "The HFE-[E1]TfR[/E1] complex suggests a binding site for transferrin on [E2]TfR[/E2] and sheds light upon the function of HFE in regulating iron homeostasis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TfR", "entity_1_idx": [[8, 11]], "entity_1_idx_in_text_with_entity_marker": [12, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TfR", "entity_2_idx": [[63, 66]], "entity_2_idx_in_text_with_entity_marker": [76, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s358_AIMed.d41.s358.p4", "text": "The HFE-TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis.", "text_with_entity_marker": "The HFE-[E1]TfR[/E1] complex suggests a binding site for transferrin on TfR and sheds light upon the function of [E2]HFE[/E2] in regulating iron homeostasis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TfR", "entity_1_idx": [[8, 11]], "entity_1_idx_in_text_with_entity_marker": [12, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HFE", "entity_2_idx": [[104, 107]], "entity_2_idx_in_text_with_entity_marker": [117, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s358_AIMed.d41.s358.p5", "text": "The HFE-TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis.", "text_with_entity_marker": "The HFE-TfR complex suggests a binding site for transferrin on [E1]TfR[/E1] and sheds light upon the function of [E2]HFE[/E2] in regulating iron homeostasis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TfR", "entity_1_idx": [[63, 66]], "entity_1_idx_in_text_with_entity_marker": [67, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HFE", "entity_2_idx": [[104, 107]], "entity_2_idx_in_text_with_entity_marker": [117, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1829_AIMed.d211.s1829.p0", "text": "Through their interaction with the ErbB family of receptors (ErbB2, ErbB3 and ErbB4), neuregulins help to regulate cell growth and differentiation in many tissues.", "text_with_entity_marker": "Through their interaction with the ErbB family of receptors ([E1]ErbB2[/E1], [E2]ErbB3[/E2] and ErbB4), neuregulins help to regulate cell growth and differentiation in many tissues.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB2", "entity_1_idx": [[61, 66]], "entity_1_idx_in_text_with_entity_marker": [65, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB3", "entity_2_idx": [[68, 73]], "entity_2_idx_in_text_with_entity_marker": [81, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1829_AIMed.d211.s1829.p1", "text": "Through their interaction with the ErbB family of receptors (ErbB2, ErbB3 and ErbB4), neuregulins help to regulate cell growth and differentiation in many tissues.", "text_with_entity_marker": "Through their interaction with the ErbB family of receptors ([E1]ErbB2[/E1], ErbB3 and [E2]ErbB4[/E2]), neuregulins help to regulate cell growth and differentiation in many tissues.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB2", "entity_1_idx": [[61, 66]], "entity_1_idx_in_text_with_entity_marker": [65, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB4", "entity_2_idx": [[78, 83]], "entity_2_idx_in_text_with_entity_marker": [91, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1829_AIMed.d211.s1829.p2", "text": "Through their interaction with the ErbB family of receptors (ErbB2, ErbB3 and ErbB4), neuregulins help to regulate cell growth and differentiation in many tissues.", "text_with_entity_marker": "Through their interaction with the ErbB family of receptors (ErbB2, [E1]ErbB3[/E1] and [E2]ErbB4[/E2]), neuregulins help to regulate cell growth and differentiation in many tissues.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB3", "entity_1_idx": [[68, 73]], "entity_1_idx_in_text_with_entity_marker": [72, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB4", "entity_2_idx": [[78, 83]], "entity_2_idx_in_text_with_entity_marker": [91, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1831_AIMed.d211.s1831.p0", "text": "The encoded product of the neuregulin-2 gene has a motif structure similar to that of neuregulins and an alternative splicing site in the epidermal growth factor(EGF)-like domain gives rise to two isoforms (alpha and beta).", "text_with_entity_marker": "The encoded product of the [E1]neuregulin-2[/E1] gene has a motif structure similar to that of neuregulins and an alternative splicing site in the [E2]epidermal growth factor[/E2](EGF)-like domain gives rise to two isoforms (alpha and beta).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "neuregulin-2", "entity_1_idx": [[27, 39]], "entity_1_idx_in_text_with_entity_marker": [31, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "epidermal growth factor", "entity_2_idx": [[138, 161]], "entity_2_idx_in_text_with_entity_marker": [151, 174], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1831_AIMed.d211.s1831.p1", "text": "The encoded product of the neuregulin-2 gene has a motif structure similar to that of neuregulins and an alternative splicing site in the epidermal growth factor(EGF)-like domain gives rise to two isoforms (alpha and beta).", "text_with_entity_marker": "The encoded product of the [E1]neuregulin-2[/E1] gene has a motif structure similar to that of neuregulins and an alternative splicing site in the epidermal growth factor([E2]EGF[/E2])-like domain gives rise to two isoforms (alpha and beta).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "neuregulin-2", "entity_1_idx": [[27, 39]], "entity_1_idx_in_text_with_entity_marker": [31, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EGF", "entity_2_idx": [[162, 165]], "entity_2_idx_in_text_with_entity_marker": [175, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1831_AIMed.d211.s1831.p2", "text": "The encoded product of the neuregulin-2 gene has a motif structure similar to that of neuregulins and an alternative splicing site in the epidermal growth factor(EGF)-like domain gives rise to two isoforms (alpha and beta).", "text_with_entity_marker": "The encoded product of the neuregulin-2 gene has a motif structure similar to that of neuregulins and an alternative splicing site in the [E1]epidermal growth factor[/E1]([E2]EGF[/E2])-like domain gives rise to two isoforms (alpha and beta).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "epidermal growth factor", "entity_1_idx": [[138, 161]], "entity_1_idx_in_text_with_entity_marker": [142, 165], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EGF", "entity_2_idx": [[162, 165]], "entity_2_idx_in_text_with_entity_marker": [175, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1833_AIMed.d211.s1833.p0", "text": "Recombinant neuregulin-2beta induces the tyrosine-phosphorylation of ErbB2, ErbB3 and ErbB4 in cell lines expressing all of these ErbB-family receptors.", "text_with_entity_marker": "Recombinant [E1]neuregulin-2beta[/E1] induces the tyrosine-phosphorylation of [E2]ErbB2[/E2], ErbB3 and ErbB4 in cell lines expressing all of these ErbB-family receptors.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "neuregulin-2beta", "entity_1_idx": [[12, 28]], "entity_1_idx_in_text_with_entity_marker": [16, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB2", "entity_2_idx": [[69, 74]], "entity_2_idx_in_text_with_entity_marker": [82, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1833_AIMed.d211.s1833.p1", "text": "Recombinant neuregulin-2beta induces the tyrosine-phosphorylation of ErbB2, ErbB3 and ErbB4 in cell lines expressing all of these ErbB-family receptors.", "text_with_entity_marker": "Recombinant [E1]neuregulin-2beta[/E1] induces the tyrosine-phosphorylation of ErbB2, [E2]ErbB3[/E2] and ErbB4 in cell lines expressing all of these ErbB-family receptors.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "neuregulin-2beta", "entity_1_idx": [[12, 28]], "entity_1_idx_in_text_with_entity_marker": [16, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB3", "entity_2_idx": [[76, 81]], "entity_2_idx_in_text_with_entity_marker": [89, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1833_AIMed.d211.s1833.p2", "text": "Recombinant neuregulin-2beta induces the tyrosine-phosphorylation of ErbB2, ErbB3 and ErbB4 in cell lines expressing all of these ErbB-family receptors.", "text_with_entity_marker": "Recombinant [E1]neuregulin-2beta[/E1] induces the tyrosine-phosphorylation of ErbB2, ErbB3 and [E2]ErbB4[/E2] in cell lines expressing all of these ErbB-family receptors.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "neuregulin-2beta", "entity_1_idx": [[12, 28]], "entity_1_idx_in_text_with_entity_marker": [16, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB4", "entity_2_idx": [[86, 91]], "entity_2_idx_in_text_with_entity_marker": [99, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1833_AIMed.d211.s1833.p3", "text": "Recombinant neuregulin-2beta induces the tyrosine-phosphorylation of ErbB2, ErbB3 and ErbB4 in cell lines expressing all of these ErbB-family receptors.", "text_with_entity_marker": "Recombinant neuregulin-2beta induces the tyrosine-phosphorylation of [E1]ErbB2[/E1], [E2]ErbB3[/E2] and ErbB4 in cell lines expressing all of these ErbB-family receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB2", "entity_1_idx": [[69, 74]], "entity_1_idx_in_text_with_entity_marker": [73, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB3", "entity_2_idx": [[76, 81]], "entity_2_idx_in_text_with_entity_marker": [89, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1833_AIMed.d211.s1833.p4", "text": "Recombinant neuregulin-2beta induces the tyrosine-phosphorylation of ErbB2, ErbB3 and ErbB4 in cell lines expressing all of these ErbB-family receptors.", "text_with_entity_marker": "Recombinant neuregulin-2beta induces the tyrosine-phosphorylation of [E1]ErbB2[/E1], ErbB3 and [E2]ErbB4[/E2] in cell lines expressing all of these ErbB-family receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB2", "entity_1_idx": [[69, 74]], "entity_1_idx_in_text_with_entity_marker": [73, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB4", "entity_2_idx": [[86, 91]], "entity_2_idx_in_text_with_entity_marker": [99, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1833_AIMed.d211.s1833.p5", "text": "Recombinant neuregulin-2beta induces the tyrosine-phosphorylation of ErbB2, ErbB3 and ErbB4 in cell lines expressing all of these ErbB-family receptors.", "text_with_entity_marker": "Recombinant neuregulin-2beta induces the tyrosine-phosphorylation of ErbB2, [E1]ErbB3[/E1] and [E2]ErbB4[/E2] in cell lines expressing all of these ErbB-family receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB3", "entity_1_idx": [[76, 81]], "entity_1_idx_in_text_with_entity_marker": [80, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB4", "entity_2_idx": [[86, 91]], "entity_2_idx_in_text_with_entity_marker": [99, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1834_AIMed.d211.s1834.p0", "text": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.", "text_with_entity_marker": "However, in cell lines with defined combinations of ErbBs, [E1]neuregulin-2beta[/E1] only activates those with [E2]ErbB3[/E2] and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "neuregulin-2beta", "entity_1_idx": [[59, 75]], "entity_1_idx_in_text_with_entity_marker": [63, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB3", "entity_2_idx": [[102, 107]], "entity_2_idx_in_text_with_entity_marker": [115, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1834_AIMed.d211.s1834.p1", "text": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.", "text_with_entity_marker": "However, in cell lines with defined combinations of ErbBs, [E1]neuregulin-2beta[/E1] only activates those with ErbB3 and/or [E2]ErbB4[/E2], suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "neuregulin-2beta", "entity_1_idx": [[59, 75]], "entity_1_idx_in_text_with_entity_marker": [63, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB4", "entity_2_idx": [[115, 120]], "entity_2_idx_in_text_with_entity_marker": [128, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1834_AIMed.d211.s1834.p2", "text": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.", "text_with_entity_marker": "However, in cell lines with defined combinations of ErbBs, [E1]neuregulin-2beta[/E1] only activates those with ErbB3 and/or ErbB4, suggesting that signalling by [E2]neuregulin-2[/E2] is mediated by ErbB3 and/or ErbB4 receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "neuregulin-2beta", "entity_1_idx": [[59, 75]], "entity_1_idx_in_text_with_entity_marker": [63, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "neuregulin-2", "entity_2_idx": [[152, 164]], "entity_2_idx_in_text_with_entity_marker": [165, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1834_AIMed.d211.s1834.p3", "text": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.", "text_with_entity_marker": "However, in cell lines with defined combinations of ErbBs, [E1]neuregulin-2beta[/E1] only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by [E2]ErbB3[/E2] and/or ErbB4 receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "neuregulin-2beta", "entity_1_idx": [[59, 75]], "entity_1_idx_in_text_with_entity_marker": [63, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB3", "entity_2_idx": [[180, 185]], "entity_2_idx_in_text_with_entity_marker": [193, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1834_AIMed.d211.s1834.p4", "text": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.", "text_with_entity_marker": "However, in cell lines with defined combinations of ErbBs, [E1]neuregulin-2beta[/E1] only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or [E2]ErbB4[/E2] receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "neuregulin-2beta", "entity_1_idx": [[59, 75]], "entity_1_idx_in_text_with_entity_marker": [63, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB4", "entity_2_idx": [[193, 198]], "entity_2_idx_in_text_with_entity_marker": [206, 211], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1834_AIMed.d211.s1834.p5", "text": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.", "text_with_entity_marker": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with [E1]ErbB3[/E1] and/or [E2]ErbB4[/E2], suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB3", "entity_1_idx": [[102, 107]], "entity_1_idx_in_text_with_entity_marker": [106, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB4", "entity_2_idx": [[115, 120]], "entity_2_idx_in_text_with_entity_marker": [128, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1834_AIMed.d211.s1834.p6", "text": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.", "text_with_entity_marker": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with [E1]ErbB3[/E1] and/or ErbB4, suggesting that signalling by [E2]neuregulin-2[/E2] is mediated by ErbB3 and/or ErbB4 receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB3", "entity_1_idx": [[102, 107]], "entity_1_idx_in_text_with_entity_marker": [106, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "neuregulin-2", "entity_2_idx": [[152, 164]], "entity_2_idx_in_text_with_entity_marker": [165, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1834_AIMed.d211.s1834.p7", "text": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.", "text_with_entity_marker": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with [E1]ErbB3[/E1] and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by [E2]ErbB3[/E2] and/or ErbB4 receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB3", "entity_1_idx": [[102, 107]], "entity_1_idx_in_text_with_entity_marker": [106, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB3", "entity_2_idx": [[180, 185]], "entity_2_idx_in_text_with_entity_marker": [193, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1834_AIMed.d211.s1834.p8", "text": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.", "text_with_entity_marker": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with [E1]ErbB3[/E1] and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or [E2]ErbB4[/E2] receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB3", "entity_1_idx": [[102, 107]], "entity_1_idx_in_text_with_entity_marker": [106, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB4", "entity_2_idx": [[193, 198]], "entity_2_idx_in_text_with_entity_marker": [206, 211], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1834_AIMed.d211.s1834.p9", "text": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.", "text_with_entity_marker": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or [E1]ErbB4[/E1], suggesting that signalling by [E2]neuregulin-2[/E2] is mediated by ErbB3 and/or ErbB4 receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB4", "entity_1_idx": [[115, 120]], "entity_1_idx_in_text_with_entity_marker": [119, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "neuregulin-2", "entity_2_idx": [[152, 164]], "entity_2_idx_in_text_with_entity_marker": [165, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1834_AIMed.d211.s1834.p10", "text": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.", "text_with_entity_marker": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or [E1]ErbB4[/E1], suggesting that signalling by neuregulin-2 is mediated by [E2]ErbB3[/E2] and/or ErbB4 receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB4", "entity_1_idx": [[115, 120]], "entity_1_idx_in_text_with_entity_marker": [119, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB3", "entity_2_idx": [[180, 185]], "entity_2_idx_in_text_with_entity_marker": [193, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1834_AIMed.d211.s1834.p11", "text": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.", "text_with_entity_marker": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or [E1]ErbB4[/E1], suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or [E2]ErbB4[/E2] receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB4", "entity_1_idx": [[115, 120]], "entity_1_idx_in_text_with_entity_marker": [119, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB4", "entity_2_idx": [[193, 198]], "entity_2_idx_in_text_with_entity_marker": [206, 211], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1834_AIMed.d211.s1834.p12", "text": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.", "text_with_entity_marker": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by [E1]neuregulin-2[/E1] is mediated by [E2]ErbB3[/E2] and/or ErbB4 receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "neuregulin-2", "entity_1_idx": [[152, 164]], "entity_1_idx_in_text_with_entity_marker": [156, 168], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB3", "entity_2_idx": [[180, 185]], "entity_2_idx_in_text_with_entity_marker": [193, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1834_AIMed.d211.s1834.p13", "text": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.", "text_with_entity_marker": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by [E1]neuregulin-2[/E1] is mediated by ErbB3 and/or [E2]ErbB4[/E2] receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "neuregulin-2", "entity_1_idx": [[152, 164]], "entity_1_idx_in_text_with_entity_marker": [156, 168], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB4", "entity_2_idx": [[193, 198]], "entity_2_idx_in_text_with_entity_marker": [206, 211], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d211.s1834_AIMed.d211.s1834.p14", "text": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.", "text_with_entity_marker": "However, in cell lines with defined combinations of ErbBs, neuregulin-2beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by [E1]ErbB3[/E1] and/or [E2]ErbB4[/E2] receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ErbB3", "entity_1_idx": [[180, 185]], "entity_1_idx_in_text_with_entity_marker": [184, 189], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB4", "entity_2_idx": [[193, 198]], "entity_2_idx_in_text_with_entity_marker": [206, 211], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d12.s96_AIMed.d12.s96.p0", "text": "Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples.", "text_with_entity_marker": "Soluble [E1-E2]interleukin 2[/E1] receptor[/E2] and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin 2", "entity_1_idx": [[8, 21]], "entity_1_idx_in_text_with_entity_marker": [15, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin 2[/E1] receptor", "entity_2_idx": [[8, 30]], "entity_2_idx_in_text_with_entity_marker": [15, 42], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d12.s96_AIMed.d12.s96.p1", "text": "Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples.", "text_with_entity_marker": "Soluble [E1]interleukin 2[/E1] receptor and [E2]interleukin 1alpha[/E2] in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin 2", "entity_1_idx": [[8, 21]], "entity_1_idx_in_text_with_entity_marker": [12, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin 1alpha", "entity_2_idx": [[35, 53]], "entity_2_idx_in_text_with_entity_marker": [48, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d12.s96_AIMed.d12.s96.p2", "text": "Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples.", "text_with_entity_marker": "Soluble [E1]interleukin 2 receptor[/E1] and [E2]interleukin 1alpha[/E2] in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin 2 receptor", "entity_1_idx": [[8, 30]], "entity_1_idx_in_text_with_entity_marker": [12, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin 1alpha", "entity_2_idx": [[35, 53]], "entity_2_idx_in_text_with_entity_marker": [48, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d12.s102_AIMed.d12.s102.p0", "text": "MAIN OUTCOME MEASURES: Measurement of soluble interleukin (IL) 2 receptor (sIL-2R) and IL-1alpha in serum samples and fluid of recent blisters.", "text_with_entity_marker": "MAIN OUTCOME MEASURES: Measurement of soluble [E1]interleukin (IL) 2 receptor[/E1] ([E2]sIL-2R[/E2]) and IL-1alpha in serum samples and fluid of recent blisters.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin (IL) 2 receptor", "entity_1_idx": [[46, 73]], "entity_1_idx_in_text_with_entity_marker": [50, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sIL-2R", "entity_2_idx": [[75, 81]], "entity_2_idx_in_text_with_entity_marker": [88, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d12.s102_AIMed.d12.s102.p1", "text": "MAIN OUTCOME MEASURES: Measurement of soluble interleukin (IL) 2 receptor (sIL-2R) and IL-1alpha in serum samples and fluid of recent blisters.", "text_with_entity_marker": "MAIN OUTCOME MEASURES: Measurement of soluble [E1]interleukin (IL) 2 receptor[/E1] (sIL-2R) and [E2]IL-1alpha[/E2] in serum samples and fluid of recent blisters.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin (IL) 2 receptor", "entity_1_idx": [[46, 73]], "entity_1_idx_in_text_with_entity_marker": [50, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1alpha", "entity_2_idx": [[87, 96]], "entity_2_idx_in_text_with_entity_marker": [100, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d12.s102_AIMed.d12.s102.p2", "text": "MAIN OUTCOME MEASURES: Measurement of soluble interleukin (IL) 2 receptor (sIL-2R) and IL-1alpha in serum samples and fluid of recent blisters.", "text_with_entity_marker": "MAIN OUTCOME MEASURES: Measurement of soluble interleukin (IL) 2 receptor ([E1]sIL-2R[/E1]) and [E2]IL-1alpha[/E2] in serum samples and fluid of recent blisters.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sIL-2R", "entity_1_idx": [[75, 81]], "entity_1_idx_in_text_with_entity_marker": [79, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1alpha", "entity_2_idx": [[87, 96]], "entity_2_idx_in_text_with_entity_marker": [100, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d12.s103_AIMed.d12.s103.p0", "text": "RESULTS: In the blister fluid of patients with TEN, we found significantly higher levels of sIL-2R than in patients with burns, whereas IL-1alpha levels were higher in the blister fluid of burned patients.", "text_with_entity_marker": "RESULTS: In the blister fluid of patients with TEN, we found significantly higher levels of [E1]sIL-2R[/E1] than in patients with burns, whereas [E2]IL-1alpha[/E2] levels were higher in the blister fluid of burned patients.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sIL-2R", "entity_1_idx": [[92, 98]], "entity_1_idx_in_text_with_entity_marker": [96, 102], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1alpha", "entity_2_idx": [[136, 145]], "entity_2_idx_in_text_with_entity_marker": [149, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d12.s104_AIMed.d12.s104.p0", "text": "No significant differences were found in serum samples of patients with TEN and burns, in either sIL-2R or IL-1alpha.", "text_with_entity_marker": "No significant differences were found in serum samples of patients with TEN and burns, in either [E1]sIL-2R[/E1] or [E2]IL-1alpha[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sIL-2R", "entity_1_idx": [[97, 103]], "entity_1_idx_in_text_with_entity_marker": [101, 107], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1alpha", "entity_2_idx": [[107, 116]], "entity_2_idx_in_text_with_entity_marker": [120, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d12.s105_AIMed.d12.s105.p0", "text": "In TEN we also found significantly higher levels of sIL-2R in the blister fluid compared with serum samples, pointing to a predominantly local production contrasting with the low concentration of sIL-2R in the blister fluid of burned patients.", "text_with_entity_marker": "In TEN we also found significantly higher levels of [E1]sIL-2R[/E1] in the blister fluid compared with serum samples, pointing to a predominantly local production contrasting with the low concentration of [E2]sIL-2R[/E2] in the blister fluid of burned patients.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sIL-2R", "entity_1_idx": [[52, 58]], "entity_1_idx_in_text_with_entity_marker": [56, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sIL-2R", "entity_2_idx": [[196, 202]], "entity_2_idx_in_text_with_entity_marker": [209, 215], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1695_AIMed.d199.s1695.p0", "text": "Stimulation of fibroblast growth factor receptor 3 (FGFR3) results in a variety of functional effects, including regulation of epithelial cell growth and differentiation.", "text_with_entity_marker": "Stimulation of [E1]fibroblast growth factor receptor 3[/E1] ([E2]FGFR3[/E2]) results in a variety of functional effects, including regulation of epithelial cell growth and differentiation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "fibroblast growth factor receptor 3", "entity_1_idx": [[15, 50]], "entity_1_idx_in_text_with_entity_marker": [19, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3", "entity_2_idx": [[52, 57]], "entity_2_idx_in_text_with_entity_marker": [65, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1696_AIMed.d199.s1696.p0", "text": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "text_with_entity_marker": "In order to characterize the signaling pathway through which [E1]FGFR3[/E1] regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, [E2]FGFR3[/E2] IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[61, 66]], "entity_1_idx_in_text_with_entity_marker": [65, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3", "entity_2_idx": [[190, 195]], "entity_2_idx_in_text_with_entity_marker": [203, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1696_AIMed.d199.s1696.p1", "text": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "text_with_entity_marker": "In order to characterize the signaling pathway through which [E1]FGFR3[/E1] regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, [E2]FGFR3 IIIb[/E2] and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[61, 66]], "entity_1_idx_in_text_with_entity_marker": [65, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3 IIIb", "entity_2_idx": [[190, 200]], "entity_2_idx_in_text_with_entity_marker": [203, 213], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1696_AIMed.d199.s1696.p2", "text": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "text_with_entity_marker": "In order to characterize the signaling pathway through which [E1]FGFR3[/E1] regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and [E2]FGFR3[/E2] IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[61, 66]], "entity_1_idx_in_text_with_entity_marker": [65, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3", "entity_2_idx": [[205, 210]], "entity_2_idx_in_text_with_entity_marker": [218, 223], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1696_AIMed.d199.s1696.p3", "text": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "text_with_entity_marker": "In order to characterize the signaling pathway through which [E1]FGFR3[/E1] regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and [E2]FGFR3 IIIc[/E2], that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[61, 66]], "entity_1_idx_in_text_with_entity_marker": [65, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3 IIIc", "entity_2_idx": [[205, 215]], "entity_2_idx_in_text_with_entity_marker": [218, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1696_AIMed.d199.s1696.p4", "text": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "text_with_entity_marker": "In order to characterize the signaling pathway through which [E1]FGFR3[/E1] regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the [E2]FGFR3[/E2] gene encoding the ligand binding domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[61, 66]], "entity_1_idx_in_text_with_entity_marker": [65, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3", "entity_2_idx": [[274, 279]], "entity_2_idx_in_text_with_entity_marker": [287, 292], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1696_AIMed.d199.s1696.p5", "text": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "text_with_entity_marker": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, [E1-E2]FGFR3[/E1] IIIb[/E2] and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[190, 195]], "entity_1_idx_in_text_with_entity_marker": [197, 202], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3[/E1] IIIb", "entity_2_idx": [[190, 200]], "entity_2_idx_in_text_with_entity_marker": [197, 212], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1696_AIMed.d199.s1696.p6", "text": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "text_with_entity_marker": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, [E1]FGFR3[/E1] IIIb and [E2]FGFR3[/E2] IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[190, 195]], "entity_1_idx_in_text_with_entity_marker": [194, 199], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3", "entity_2_idx": [[205, 210]], "entity_2_idx_in_text_with_entity_marker": [218, 223], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1696_AIMed.d199.s1696.p7", "text": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "text_with_entity_marker": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, [E1]FGFR3[/E1] IIIb and [E2]FGFR3 IIIc[/E2], that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[190, 195]], "entity_1_idx_in_text_with_entity_marker": [194, 199], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3 IIIc", "entity_2_idx": [[205, 215]], "entity_2_idx_in_text_with_entity_marker": [218, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1696_AIMed.d199.s1696.p8", "text": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "text_with_entity_marker": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, [E1]FGFR3[/E1] IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the [E2]FGFR3[/E2] gene encoding the ligand binding domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[190, 195]], "entity_1_idx_in_text_with_entity_marker": [194, 199], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3", "entity_2_idx": [[274, 279]], "entity_2_idx_in_text_with_entity_marker": [287, 292], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1696_AIMed.d199.s1696.p9", "text": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "text_with_entity_marker": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, [E1]FGFR3 IIIb[/E1] and [E2]FGFR3[/E2] IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3 IIIb", "entity_1_idx": [[190, 200]], "entity_1_idx_in_text_with_entity_marker": [194, 204], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3", "entity_2_idx": [[205, 210]], "entity_2_idx_in_text_with_entity_marker": [218, 223], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1696_AIMed.d199.s1696.p10", "text": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "text_with_entity_marker": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, [E1]FGFR3 IIIb[/E1] and [E2]FGFR3 IIIc[/E2], that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3 IIIb", "entity_1_idx": [[190, 200]], "entity_1_idx_in_text_with_entity_marker": [194, 204], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3 IIIc", "entity_2_idx": [[205, 215]], "entity_2_idx_in_text_with_entity_marker": [218, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1696_AIMed.d199.s1696.p11", "text": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "text_with_entity_marker": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, [E1]FGFR3 IIIb[/E1] and FGFR3 IIIc, that result from alternative splicing of exon III of the [E2]FGFR3[/E2] gene encoding the ligand binding domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3 IIIb", "entity_1_idx": [[190, 200]], "entity_1_idx_in_text_with_entity_marker": [194, 204], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3", "entity_2_idx": [[274, 279]], "entity_2_idx_in_text_with_entity_marker": [287, 292], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1696_AIMed.d199.s1696.p12", "text": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "text_with_entity_marker": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and [E1-E2]FGFR3[/E1] IIIc[/E2], that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[205, 210]], "entity_1_idx_in_text_with_entity_marker": [212, 217], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3[/E1] IIIc", "entity_2_idx": [[205, 215]], "entity_2_idx_in_text_with_entity_marker": [212, 227], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1696_AIMed.d199.s1696.p13", "text": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "text_with_entity_marker": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and [E1]FGFR3[/E1] IIIc, that result from alternative splicing of exon III of the [E2]FGFR3[/E2] gene encoding the ligand binding domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[205, 210]], "entity_1_idx_in_text_with_entity_marker": [209, 214], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3", "entity_2_idx": [[274, 279]], "entity_2_idx_in_text_with_entity_marker": [287, 292], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1696_AIMed.d199.s1696.p14", "text": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and FGFR3 IIIc, that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain.", "text_with_entity_marker": "In order to characterize the signaling pathway through which FGFR3 regulates cell growth, L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms, FGFR3 IIIb and [E1]FGFR3 IIIc[/E1], that result from alternative splicing of exon III of the [E2]FGFR3[/E2] gene encoding the ligand binding domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3 IIIc", "entity_1_idx": [[205, 215]], "entity_1_idx_in_text_with_entity_marker": [209, 219], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3", "entity_2_idx": [[274, 279]], "entity_2_idx_in_text_with_entity_marker": [287, 292], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1697_AIMed.d199.s1697.p0", "text": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.", "text_with_entity_marker": "Expression of [E1-E2]FGFR3[/E1] IIIc[/E2] in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[14, 19]], "entity_1_idx_in_text_with_entity_marker": [21, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3[/E1] IIIc", "entity_2_idx": [[14, 24]], "entity_2_idx_in_text_with_entity_marker": [21, 36], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1697_AIMed.d199.s1697.p1", "text": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.", "text_with_entity_marker": "Expression of [E1]FGFR3[/E1] IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including [E2]FGF-1[/E2], -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[14, 19]], "entity_1_idx_in_text_with_entity_marker": [18, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF-1", "entity_2_idx": [[130, 135]], "entity_2_idx_in_text_with_entity_marker": [143, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1697_AIMed.d199.s1697.p2", "text": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.", "text_with_entity_marker": "Expression of [E1]FGFR3[/E1] IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while [E2]FGFR3[/E2] IIIb-expressing cells responded only to FGF-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[14, 19]], "entity_1_idx_in_text_with_entity_marker": [18, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1697_AIMed.d199.s1697.p3", "text": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.", "text_with_entity_marker": "Expression of [E1]FGFR3[/E1] IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while [E2]FGFR3 IIIb[/E2]-expressing cells responded only to FGF-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[14, 19]], "entity_1_idx_in_text_with_entity_marker": [18, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3 IIIb", "entity_2_idx": [[159, 169]], "entity_2_idx_in_text_with_entity_marker": [172, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1697_AIMed.d199.s1697.p4", "text": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.", "text_with_entity_marker": "Expression of [E1]FGFR3[/E1] IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to [E2]FGF-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[14, 19]], "entity_1_idx_in_text_with_entity_marker": [18, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF-1", "entity_2_idx": [[205, 210]], "entity_2_idx_in_text_with_entity_marker": [218, 223], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1697_AIMed.d199.s1697.p5", "text": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.", "text_with_entity_marker": "Expression of [E1]FGFR3 IIIc[/E1] in stably transfected L6 cells conferred growth responses to several members of the FGF family including [E2]FGF-1[/E2], -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3 IIIc", "entity_1_idx": [[14, 24]], "entity_1_idx_in_text_with_entity_marker": [18, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF-1", "entity_2_idx": [[130, 135]], "entity_2_idx_in_text_with_entity_marker": [143, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1697_AIMed.d199.s1697.p6", "text": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.", "text_with_entity_marker": "Expression of [E1]FGFR3 IIIc[/E1] in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while [E2]FGFR3[/E2] IIIb-expressing cells responded only to FGF-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3 IIIc", "entity_1_idx": [[14, 24]], "entity_1_idx_in_text_with_entity_marker": [18, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1697_AIMed.d199.s1697.p7", "text": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.", "text_with_entity_marker": "Expression of [E1]FGFR3 IIIc[/E1] in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while [E2]FGFR3 IIIb[/E2]-expressing cells responded only to FGF-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3 IIIc", "entity_1_idx": [[14, 24]], "entity_1_idx_in_text_with_entity_marker": [18, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3 IIIb", "entity_2_idx": [[159, 169]], "entity_2_idx_in_text_with_entity_marker": [172, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1697_AIMed.d199.s1697.p8", "text": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.", "text_with_entity_marker": "Expression of [E1]FGFR3 IIIc[/E1] in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to [E2]FGF-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3 IIIc", "entity_1_idx": [[14, 24]], "entity_1_idx_in_text_with_entity_marker": [18, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF-1", "entity_2_idx": [[205, 210]], "entity_2_idx_in_text_with_entity_marker": [218, 223], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1697_AIMed.d199.s1697.p9", "text": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.", "text_with_entity_marker": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including [E1]FGF-1[/E1], -2, -4, and -6, while [E2]FGFR3[/E2] IIIb-expressing cells responded only to FGF-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF-1", "entity_1_idx": [[130, 135]], "entity_1_idx_in_text_with_entity_marker": [134, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1697_AIMed.d199.s1697.p10", "text": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.", "text_with_entity_marker": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including [E1]FGF-1[/E1], -2, -4, and -6, while [E2]FGFR3 IIIb[/E2]-expressing cells responded only to FGF-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF-1", "entity_1_idx": [[130, 135]], "entity_1_idx_in_text_with_entity_marker": [134, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3 IIIb", "entity_2_idx": [[159, 169]], "entity_2_idx_in_text_with_entity_marker": [172, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1697_AIMed.d199.s1697.p11", "text": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.", "text_with_entity_marker": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including [E1]FGF-1[/E1], -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to [E2]FGF-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF-1", "entity_1_idx": [[130, 135]], "entity_1_idx_in_text_with_entity_marker": [134, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF-1", "entity_2_idx": [[205, 210]], "entity_2_idx_in_text_with_entity_marker": [218, 223], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1697_AIMed.d199.s1697.p12", "text": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.", "text_with_entity_marker": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while [E1-E2]FGFR3[/E1] IIIb[/E2]-expressing cells responded only to FGF-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[159, 164]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3[/E1] IIIb", "entity_2_idx": [[159, 169]], "entity_2_idx_in_text_with_entity_marker": [166, 181], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1697_AIMed.d199.s1697.p13", "text": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.", "text_with_entity_marker": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while [E1]FGFR3[/E1] IIIb-expressing cells responded only to [E2]FGF-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[159, 164]], "entity_1_idx_in_text_with_entity_marker": [163, 168], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF-1", "entity_2_idx": [[205, 210]], "entity_2_idx_in_text_with_entity_marker": [218, 223], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1697_AIMed.d199.s1697.p14", "text": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while FGFR3 IIIb-expressing cells responded only to FGF-1.", "text_with_entity_marker": "Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF-1, -2, -4, and -6, while [E1]FGFR3 IIIb[/E1]-expressing cells responded only to [E2]FGF-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3 IIIb", "entity_1_idx": [[159, 169]], "entity_1_idx_in_text_with_entity_marker": [163, 173], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF-1", "entity_2_idx": [[205, 210]], "entity_2_idx_in_text_with_entity_marker": [218, 223], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1698_AIMed.d199.s1698.p0", "text": "Activation of FGFR3 upon ligand binding resulted in activation of mitogen-activated protein kinase pathway.", "text_with_entity_marker": "Activation of [E1]FGFR3[/E1] upon ligand binding resulted in activation of [E2]mitogen-activated protein kinase[/E2] pathway.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[14, 19]], "entity_1_idx_in_text_with_entity_marker": [18, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mitogen-activated protein kinase", "entity_2_idx": [[66, 98]], "entity_2_idx_in_text_with_entity_marker": [79, 111], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1699_AIMed.d199.s1699.p0", "text": "FGFR3 utilizes two different pools of adapter protein GRB2 to link to Ras.", "text_with_entity_marker": "[E1]FGFR3[/E1] utilizes two different pools of adapter protein [E2]GRB2[/E2] to link to Ras.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[54, 58]], "entity_2_idx_in_text_with_entity_marker": [67, 71], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1699_AIMed.d199.s1699.p1", "text": "FGFR3 utilizes two different pools of adapter protein GRB2 to link to Ras.", "text_with_entity_marker": "[E1]FGFR3[/E1] utilizes two different pools of adapter protein GRB2 to link to [E2]Ras[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ras", "entity_2_idx": [[70, 73]], "entity_2_idx_in_text_with_entity_marker": [83, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1699_AIMed.d199.s1699.p2", "text": "FGFR3 utilizes two different pools of adapter protein GRB2 to link to Ras.", "text_with_entity_marker": "FGFR3 utilizes two different pools of adapter protein [E1]GRB2[/E1] to link to [E2]Ras[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GRB2", "entity_1_idx": [[54, 58]], "entity_1_idx_in_text_with_entity_marker": [58, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ras", "entity_2_idx": [[70, 73]], "entity_2_idx_in_text_with_entity_marker": [83, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1700_AIMed.d199.s1700.p0", "text": "Activated FGFR3 predominantly interacts with GRB2.", "text_with_entity_marker": "Activated [E1]FGFR3[/E1] predominantly interacts with [E2]GRB2[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGFR3", "entity_1_idx": [[10, 15]], "entity_1_idx_in_text_with_entity_marker": [14, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[45, 49]], "entity_2_idx_in_text_with_entity_marker": [58, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1701_AIMed.d199.s1701.p0", "text": "Sos in complex with a previously identified 90-kDa protein and designated protein 80K-H.", "text_with_entity_marker": "[E1]Sos[/E1] in complex with a previously identified 90-kDa protein and designated protein [E2]80K-H[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sos", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "80K-H", "entity_2_idx": [[82, 87]], "entity_2_idx_in_text_with_entity_marker": [95, 100], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1705_AIMed.d199.s1705.p0", "text": "Tyrosine phophorylation of the 66-kDa protein was dependent on ligand activation of FGFR3, suggesting that the 66-kDa protein may play an important role in FGFR3-specific signaling.", "text_with_entity_marker": "Tyrosine phophorylation of the 66-kDa protein was dependent on ligand activation of [E1]FGFR3[/E1], suggesting that the 66-kDa protein may play an important role in [E2]FGFR3[/E2]-specific signaling.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[84, 89]], "entity_1_idx_in_text_with_entity_marker": [88, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR3", "entity_2_idx": [[156, 161]], "entity_2_idx_in_text_with_entity_marker": [169, 174], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1706_AIMed.d199.s1706.p0", "text": "In addition to this unique pathway, FGFR3 also links to GRB2.", "text_with_entity_marker": "In addition to this unique pathway, [E1]FGFR3[/E1] also links to [E2]GRB2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[36, 41]], "entity_1_idx_in_text_with_entity_marker": [40, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[56, 60]], "entity_2_idx_in_text_with_entity_marker": [69, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1707_AIMed.d199.s1707.p0", "text": "Sos complex via the adapter protein Shc.", "text_with_entity_marker": "[E1]Sos[/E1] complex via the adapter protein [E2]Shc[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sos", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Shc", "entity_2_idx": [[36, 39]], "entity_2_idx_in_text_with_entity_marker": [49, 52], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1708_AIMed.d199.s1708.p0", "text": "Furthermore, activated FGFR3 was not able to induce dissociation of GRB2.", "text_with_entity_marker": "Furthermore, activated [E1]FGFR3[/E1] was not able to induce dissociation of [E2]GRB2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[68, 72]], "entity_2_idx_in_text_with_entity_marker": [81, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1709_AIMed.d199.s1709.p0", "text": "Sos complex following Sos phosphorylation.", "text_with_entity_marker": "[E1]Sos[/E1] complex following [E2]Sos[/E2] phosphorylation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sos", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Sos", "entity_2_idx": [[22, 25]], "entity_2_idx_in_text_with_entity_marker": [35, 38], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1710_AIMed.d199.s1710.p0", "text": "In summary, FGFR3 signaling pathway utilizes two GRB2-containing complexes; Shc.", "text_with_entity_marker": "In summary, [E1]FGFR3[/E1] signaling pathway utilizes two [E2]GRB2[/E2]-containing complexes; Shc.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[12, 17]], "entity_1_idx_in_text_with_entity_marker": [16, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[49, 53]], "entity_2_idx_in_text_with_entity_marker": [62, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1710_AIMed.d199.s1710.p1", "text": "In summary, FGFR3 signaling pathway utilizes two GRB2-containing complexes; Shc.", "text_with_entity_marker": "In summary, [E1]FGFR3[/E1] signaling pathway utilizes two GRB2-containing complexes; [E2]Shc[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[12, 17]], "entity_1_idx_in_text_with_entity_marker": [16, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Shc", "entity_2_idx": [[76, 79]], "entity_2_idx_in_text_with_entity_marker": [89, 92], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1710_AIMed.d199.s1710.p2", "text": "In summary, FGFR3 signaling pathway utilizes two GRB2-containing complexes; Shc.", "text_with_entity_marker": "In summary, FGFR3 signaling pathway utilizes two [E1]GRB2[/E1]-containing complexes; [E2]Shc[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GRB2", "entity_1_idx": [[49, 53]], "entity_1_idx_in_text_with_entity_marker": [53, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Shc", "entity_2_idx": [[76, 79]], "entity_2_idx_in_text_with_entity_marker": [89, 92], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1712_AIMed.d199.s1712.p0", "text": "Sos and 80K-H.pp66.", "text_with_entity_marker": "[E1]Sos[/E1] and [E2]80K-H[/E2].pp66.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sos", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "80K-H", "entity_2_idx": [[8, 13]], "entity_2_idx_in_text_with_entity_marker": [21, 26], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1712_AIMed.d199.s1712.p1", "text": "Sos and 80K-H.pp66.", "text_with_entity_marker": "[E1]Sos[/E1] and 80K-H.[E2]pp66[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sos", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp66", "entity_2_idx": [[14, 18]], "entity_2_idx_in_text_with_entity_marker": [27, 31], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1712_AIMed.d199.s1712.p2", "text": "Sos and 80K-H.pp66.", "text_with_entity_marker": "Sos and [E1]80K-H[/E1].[E2]pp66[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "80K-H", "entity_1_idx": [[8, 13]], "entity_1_idx_in_text_with_entity_marker": [12, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp66", "entity_2_idx": [[14, 18]], "entity_2_idx_in_text_with_entity_marker": [27, 31], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1714_AIMed.d199.s1714.p0", "text": "Sos; these two complexes may alternatively link FGFG3 to mitogen-activated protein kinase.", "text_with_entity_marker": "[E1]Sos[/E1]; these two complexes may alternatively link [E2]FGFG3[/E2] to mitogen-activated protein kinase.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sos", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFG3", "entity_2_idx": [[48, 53]], "entity_2_idx_in_text_with_entity_marker": [61, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1714_AIMed.d199.s1714.p1", "text": "Sos; these two complexes may alternatively link FGFG3 to mitogen-activated protein kinase.", "text_with_entity_marker": "[E1]Sos[/E1]; these two complexes may alternatively link FGFG3 to [E2]mitogen-activated protein kinase[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Sos", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mitogen-activated protein kinase", "entity_2_idx": [[57, 89]], "entity_2_idx_in_text_with_entity_marker": [70, 102], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1714_AIMed.d199.s1714.p2", "text": "Sos; these two complexes may alternatively link FGFG3 to mitogen-activated protein kinase.", "text_with_entity_marker": "Sos; these two complexes may alternatively link [E1]FGFG3[/E1] to [E2]mitogen-activated protein kinase[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFG3", "entity_1_idx": [[48, 53]], "entity_1_idx_in_text_with_entity_marker": [52, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mitogen-activated protein kinase", "entity_2_idx": [[57, 89]], "entity_2_idx_in_text_with_entity_marker": [70, 102], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1715_AIMed.d199.s1715.p0", "text": "Finally, activated FGFR3 was also found to result in phosphorylation of phospholipase C-gamma but reduced phosphorylation of c-Src.", "text_with_entity_marker": "Finally, activated [E1]FGFR3[/E1] was also found to result in phosphorylation of [E2]phospholipase C-gamma[/E2] but reduced phosphorylation of c-Src.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[19, 24]], "entity_1_idx_in_text_with_entity_marker": [23, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "phospholipase C-gamma", "entity_2_idx": [[72, 93]], "entity_2_idx_in_text_with_entity_marker": [85, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1715_AIMed.d199.s1715.p1", "text": "Finally, activated FGFR3 was also found to result in phosphorylation of phospholipase C-gamma but reduced phosphorylation of c-Src.", "text_with_entity_marker": "Finally, activated [E1]FGFR3[/E1] was also found to result in phosphorylation of phospholipase C-gamma but reduced phosphorylation of [E2]c-Src[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR3", "entity_1_idx": [[19, 24]], "entity_1_idx_in_text_with_entity_marker": [23, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Src", "entity_2_idx": [[125, 130]], "entity_2_idx_in_text_with_entity_marker": [138, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d199.s1715_AIMed.d199.s1715.p2", "text": "Finally, activated FGFR3 was also found to result in phosphorylation of phospholipase C-gamma but reduced phosphorylation of c-Src.", "text_with_entity_marker": "Finally, activated FGFR3 was also found to result in phosphorylation of [E1]phospholipase C-gamma[/E1] but reduced phosphorylation of [E2]c-Src[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "phospholipase C-gamma", "entity_1_idx": [[72, 93]], "entity_1_idx_in_text_with_entity_marker": [76, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Src", "entity_2_idx": [[125, 130]], "entity_2_idx_in_text_with_entity_marker": [138, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p0", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, [E1]tyrosine hydroxylase[/E1] ([E2]TH[/E2]), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tyrosine hydroxylase", "entity_1_idx": [[51, 71]], "entity_1_idx_in_text_with_entity_marker": [55, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TH", "entity_2_idx": [[73, 75]], "entity_2_idx_in_text_with_entity_marker": [86, 88], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p1", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, [E1]tyrosine hydroxylase[/E1] (TH), [E2]aromatic L-amino acid decarboxylase[/E2] (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tyrosine hydroxylase", "entity_1_idx": [[51, 71]], "entity_1_idx_in_text_with_entity_marker": [55, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "aromatic L-amino acid decarboxylase", "entity_2_idx": [[78, 113]], "entity_2_idx_in_text_with_entity_marker": [91, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p2", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, [E1]tyrosine hydroxylase[/E1] (TH), aromatic L-amino acid decarboxylase ([E2]AADC[/E2]), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tyrosine hydroxylase", "entity_1_idx": [[51, 71]], "entity_1_idx_in_text_with_entity_marker": [55, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AADC", "entity_2_idx": [[115, 119]], "entity_2_idx_in_text_with_entity_marker": [128, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p3", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, [E1]tyrosine hydroxylase[/E1] (TH), aromatic L-amino acid decarboxylase (AADC), and [E2]GTP cyclohydrolase I[/E2] (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tyrosine hydroxylase", "entity_1_idx": [[51, 71]], "entity_1_idx_in_text_with_entity_marker": [55, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GTP cyclohydrolase I", "entity_2_idx": [[126, 146]], "entity_2_idx_in_text_with_entity_marker": [139, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p4", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, [E1]tyrosine hydroxylase[/E1] (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I ([E2]GCH[/E2], an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tyrosine hydroxylase", "entity_1_idx": [[51, 71]], "entity_1_idx_in_text_with_entity_marker": [55, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[148, 151]], "entity_2_idx_in_text_with_entity_marker": [161, 164], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p5", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase ([E1]TH[/E1]), [E2]aromatic L-amino acid decarboxylase[/E2] (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TH", "entity_1_idx": [[73, 75]], "entity_1_idx_in_text_with_entity_marker": [77, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "aromatic L-amino acid decarboxylase", "entity_2_idx": [[78, 113]], "entity_2_idx_in_text_with_entity_marker": [91, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p6", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase ([E1]TH[/E1]), aromatic L-amino acid decarboxylase ([E2]AADC[/E2]), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TH", "entity_1_idx": [[73, 75]], "entity_1_idx_in_text_with_entity_marker": [77, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AADC", "entity_2_idx": [[115, 119]], "entity_2_idx_in_text_with_entity_marker": [128, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p7", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase ([E1]TH[/E1]), aromatic L-amino acid decarboxylase (AADC), and [E2]GTP cyclohydrolase I[/E2] (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TH", "entity_1_idx": [[73, 75]], "entity_1_idx_in_text_with_entity_marker": [77, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GTP cyclohydrolase I", "entity_2_idx": [[126, 146]], "entity_2_idx_in_text_with_entity_marker": [139, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p8", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase ([E1]TH[/E1]), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I ([E2]GCH[/E2], an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TH", "entity_1_idx": [[73, 75]], "entity_1_idx_in_text_with_entity_marker": [77, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[148, 151]], "entity_2_idx_in_text_with_entity_marker": [161, 164], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p9", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), [E1]aromatic L-amino acid decarboxylase[/E1] ([E2]AADC[/E2]), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "aromatic L-amino acid decarboxylase", "entity_1_idx": [[78, 113]], "entity_1_idx_in_text_with_entity_marker": [82, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AADC", "entity_2_idx": [[115, 119]], "entity_2_idx_in_text_with_entity_marker": [128, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p10", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), [E1]aromatic L-amino acid decarboxylase[/E1] (AADC), and [E2]GTP cyclohydrolase I[/E2] (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "aromatic L-amino acid decarboxylase", "entity_1_idx": [[78, 113]], "entity_1_idx_in_text_with_entity_marker": [82, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GTP cyclohydrolase I", "entity_2_idx": [[126, 146]], "entity_2_idx_in_text_with_entity_marker": [139, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p11", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), [E1]aromatic L-amino acid decarboxylase[/E1] (AADC), and GTP cyclohydrolase I ([E2]GCH[/E2], an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "aromatic L-amino acid decarboxylase", "entity_1_idx": [[78, 113]], "entity_1_idx_in_text_with_entity_marker": [82, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[148, 151]], "entity_2_idx_in_text_with_entity_marker": [161, 164], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p12", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase ([E1]AADC[/E1]), and [E2]GTP cyclohydrolase I[/E2] (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "AADC", "entity_1_idx": [[115, 119]], "entity_1_idx_in_text_with_entity_marker": [119, 123], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GTP cyclohydrolase I", "entity_2_idx": [[126, 146]], "entity_2_idx_in_text_with_entity_marker": [139, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p13", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase ([E1]AADC[/E1]), and GTP cyclohydrolase I ([E2]GCH[/E2], an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "AADC", "entity_1_idx": [[115, 119]], "entity_1_idx_in_text_with_entity_marker": [119, 123], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[148, 151]], "entity_2_idx_in_text_with_entity_marker": [161, 164], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p14", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and [E1]GTP cyclohydrolase I[/E1] ([E2]GCH[/E2], an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GTP cyclohydrolase I", "entity_1_idx": [[126, 146]], "entity_1_idx_in_text_with_entity_marker": [130, 150], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[148, 151]], "entity_2_idx_in_text_with_entity_marker": [161, 164], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s137_AIMed.d16.s137.p0", "text": "Expressions of TH, AADC and GCH were detected by Western blot analysis.", "text_with_entity_marker": "Expressions of [E1]TH[/E1], [E2]AADC[/E2] and GCH were detected by Western blot analysis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TH", "entity_1_idx": [[15, 17]], "entity_1_idx_in_text_with_entity_marker": [19, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AADC", "entity_2_idx": [[19, 23]], "entity_2_idx_in_text_with_entity_marker": [32, 36], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s137_AIMed.d16.s137.p1", "text": "Expressions of TH, AADC and GCH were detected by Western blot analysis.", "text_with_entity_marker": "Expressions of [E1]TH[/E1], AADC and [E2]GCH[/E2] were detected by Western blot analysis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TH", "entity_1_idx": [[15, 17]], "entity_1_idx_in_text_with_entity_marker": [19, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[28, 31]], "entity_2_idx_in_text_with_entity_marker": [41, 44], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s137_AIMed.d16.s137.p2", "text": "Expressions of TH, AADC and GCH were detected by Western blot analysis.", "text_with_entity_marker": "Expressions of TH, [E1]AADC[/E1] and [E2]GCH[/E2] were detected by Western blot analysis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "AADC", "entity_1_idx": [[19, 23]], "entity_1_idx_in_text_with_entity_marker": [23, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[28, 31]], "entity_2_idx_in_text_with_entity_marker": [41, 44], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p0", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: [E1]TH[/E1], [E2]AADC[/E2] and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TH", "entity_1_idx": [[9, 11]], "entity_1_idx_in_text_with_entity_marker": [13, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AADC", "entity_2_idx": [[13, 17]], "entity_2_idx_in_text_with_entity_marker": [26, 30], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p1", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: [E1]TH[/E1], AADC and [E2]GCH[/E2] were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TH", "entity_1_idx": [[9, 11]], "entity_1_idx_in_text_with_entity_marker": [13, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[22, 25]], "entity_2_idx_in_text_with_entity_marker": [35, 38], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p2", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: [E1]TH[/E1], AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-[E2]TH[/E2], AAV-AADC and AAV-GCH.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TH", "entity_1_idx": [[9, 11]], "entity_1_idx_in_text_with_entity_marker": [13, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TH", "entity_2_idx": [[112, 114]], "entity_2_idx_in_text_with_entity_marker": [125, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p3", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: [E1]TH[/E1], AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-[E2]AADC[/E2] and AAV-GCH.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TH", "entity_1_idx": [[9, 11]], "entity_1_idx_in_text_with_entity_marker": [13, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AADC", "entity_2_idx": [[120, 124]], "entity_2_idx_in_text_with_entity_marker": [133, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p4", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: [E1]TH[/E1], AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-[E2]GCH[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TH", "entity_1_idx": [[9, 11]], "entity_1_idx_in_text_with_entity_marker": [13, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[133, 136]], "entity_2_idx_in_text_with_entity_marker": [146, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p5", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: TH, [E1]AADC[/E1] and [E2]GCH[/E2] were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "AADC", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[22, 25]], "entity_2_idx_in_text_with_entity_marker": [35, 38], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p6", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: TH, [E1]AADC[/E1] and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-[E2]TH[/E2], AAV-AADC and AAV-GCH.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "AADC", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TH", "entity_2_idx": [[112, 114]], "entity_2_idx_in_text_with_entity_marker": [125, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p7", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: TH, [E1]AADC[/E1] and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-[E2]AADC[/E2] and AAV-GCH.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "AADC", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AADC", "entity_2_idx": [[120, 124]], "entity_2_idx_in_text_with_entity_marker": [133, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p8", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: TH, [E1]AADC[/E1] and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-[E2]GCH[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "AADC", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[133, 136]], "entity_2_idx_in_text_with_entity_marker": [146, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p9", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: TH, AADC and [E1]GCH[/E1] were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-[E2]TH[/E2], AAV-AADC and AAV-GCH.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GCH", "entity_1_idx": [[22, 25]], "entity_1_idx_in_text_with_entity_marker": [26, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TH", "entity_2_idx": [[112, 114]], "entity_2_idx_in_text_with_entity_marker": [125, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p10", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: TH, AADC and [E1]GCH[/E1] were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-[E2]AADC[/E2] and AAV-GCH.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GCH", "entity_1_idx": [[22, 25]], "entity_1_idx_in_text_with_entity_marker": [26, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AADC", "entity_2_idx": [[120, 124]], "entity_2_idx_in_text_with_entity_marker": [133, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p11", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: TH, AADC and [E1]GCH[/E1] were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-[E2]GCH[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GCH", "entity_1_idx": [[22, 25]], "entity_1_idx_in_text_with_entity_marker": [26, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[133, 136]], "entity_2_idx_in_text_with_entity_marker": [146, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p12", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-[E1]TH[/E1], AAV-[E2]AADC[/E2] and AAV-GCH.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TH", "entity_1_idx": [[112, 114]], "entity_1_idx_in_text_with_entity_marker": [116, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AADC", "entity_2_idx": [[120, 124]], "entity_2_idx_in_text_with_entity_marker": [133, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p13", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-[E1]TH[/E1], AAV-AADC and AAV-[E2]GCH[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TH", "entity_1_idx": [[112, 114]], "entity_1_idx_in_text_with_entity_marker": [116, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[133, 136]], "entity_2_idx_in_text_with_entity_marker": [146, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p14", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-[E1]AADC[/E1] and AAV-[E2]GCH[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "AADC", "entity_1_idx": [[120, 124]], "entity_1_idx_in_text_with_entity_marker": [124, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[133, 136]], "entity_2_idx_in_text_with_entity_marker": [146, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s141_AIMed.d16.s141.p0", "text": "CONCLUSION: The triple transduction of TH, AADC and GCH genes with separate AAV vectors is effective, which might be important to gene therapy for Parkinson's disease.", "text_with_entity_marker": "CONCLUSION: The triple transduction of [E1]TH[/E1], [E2]AADC[/E2] and GCH genes with separate AAV vectors is effective, which might be important to gene therapy for Parkinson's disease.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TH", "entity_1_idx": [[39, 41]], "entity_1_idx_in_text_with_entity_marker": [43, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AADC", "entity_2_idx": [[43, 47]], "entity_2_idx_in_text_with_entity_marker": [56, 60], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s141_AIMed.d16.s141.p1", "text": "CONCLUSION: The triple transduction of TH, AADC and GCH genes with separate AAV vectors is effective, which might be important to gene therapy for Parkinson's disease.", "text_with_entity_marker": "CONCLUSION: The triple transduction of [E1]TH[/E1], AADC and [E2]GCH[/E2] genes with separate AAV vectors is effective, which might be important to gene therapy for Parkinson's disease.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TH", "entity_1_idx": [[39, 41]], "entity_1_idx_in_text_with_entity_marker": [43, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[52, 55]], "entity_2_idx_in_text_with_entity_marker": [65, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s141_AIMed.d16.s141.p2", "text": "CONCLUSION: The triple transduction of TH, AADC and GCH genes with separate AAV vectors is effective, which might be important to gene therapy for Parkinson's disease.", "text_with_entity_marker": "CONCLUSION: The triple transduction of TH, [E1]AADC[/E1] and [E2]GCH[/E2] genes with separate AAV vectors is effective, which might be important to gene therapy for Parkinson's disease.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "AADC", "entity_1_idx": [[43, 47]], "entity_1_idx_in_text_with_entity_marker": [47, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[52, 55]], "entity_2_idx_in_text_with_entity_marker": [65, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d27.s226_AIMed.d27.s226.p0", "text": "Activin A, a member of the TGFbeta superfamily, has various effects on diverse biological systems, including cell growth inhibition in many cell types.", "text_with_entity_marker": "[E1]Activin A[/E1], a member of the [E2]TGFbeta[/E2] superfamily, has various effects on diverse biological systems, including cell growth inhibition in many cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Activin A", "entity_1_idx": [[0, 9]], "entity_1_idx_in_text_with_entity_marker": [4, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TGFbeta", "entity_2_idx": [[27, 34]], "entity_2_idx_in_text_with_entity_marker": [40, 47], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d27.s229_AIMed.d27.s229.p0", "text": "Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as p16 and p21 and regulators of apoptosis such as p53 and members of the bcl-2 family.", "text_with_entity_marker": "Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as [E1]p16[/E1] and [E2]p21[/E2] and regulators of apoptosis such as p53 and members of the bcl-2 family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p16", "entity_1_idx": [[89, 92]], "entity_1_idx_in_text_with_entity_marker": [93, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21", "entity_2_idx": [[97, 100]], "entity_2_idx_in_text_with_entity_marker": [110, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d27.s229_AIMed.d27.s229.p1", "text": "Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as p16 and p21 and regulators of apoptosis such as p53 and members of the bcl-2 family.", "text_with_entity_marker": "Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as [E1]p16[/E1] and p21 and regulators of apoptosis such as [E2]p53[/E2] and members of the bcl-2 family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p16", "entity_1_idx": [[89, 92]], "entity_1_idx_in_text_with_entity_marker": [93, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[137, 140]], "entity_2_idx_in_text_with_entity_marker": [150, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d27.s229_AIMed.d27.s229.p2", "text": "Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as p16 and p21 and regulators of apoptosis such as p53 and members of the bcl-2 family.", "text_with_entity_marker": "Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as [E1]p16[/E1] and p21 and regulators of apoptosis such as p53 and members of the [E2]bcl-2[/E2] family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p16", "entity_1_idx": [[89, 92]], "entity_1_idx_in_text_with_entity_marker": [93, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "bcl-2", "entity_2_idx": [[160, 165]], "entity_2_idx_in_text_with_entity_marker": [173, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d27.s229_AIMed.d27.s229.p3", "text": "Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as p16 and p21 and regulators of apoptosis such as p53 and members of the bcl-2 family.", "text_with_entity_marker": "Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as p16 and [E1]p21[/E1] and regulators of apoptosis such as [E2]p53[/E2] and members of the bcl-2 family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21", "entity_1_idx": [[97, 100]], "entity_1_idx_in_text_with_entity_marker": [101, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[137, 140]], "entity_2_idx_in_text_with_entity_marker": [150, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d27.s229_AIMed.d27.s229.p4", "text": "Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as p16 and p21 and regulators of apoptosis such as p53 and members of the bcl-2 family.", "text_with_entity_marker": "Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as p16 and [E1]p21[/E1] and regulators of apoptosis such as p53 and members of the [E2]bcl-2[/E2] family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21", "entity_1_idx": [[97, 100]], "entity_1_idx_in_text_with_entity_marker": [101, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "bcl-2", "entity_2_idx": [[160, 165]], "entity_2_idx_in_text_with_entity_marker": [173, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d27.s229_AIMed.d27.s229.p5", "text": "Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as p16 and p21 and regulators of apoptosis such as p53 and members of the bcl-2 family.", "text_with_entity_marker": "Based on the experiences of all the authors, we emphasized cell cycle inhibitors such as p16 and p21 and regulators of apoptosis such as [E1]p53[/E1] and members of the [E2]bcl-2[/E2] family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[137, 140]], "entity_1_idx_in_text_with_entity_marker": [141, 144], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "bcl-2", "entity_2_idx": [[160, 165]], "entity_2_idx_in_text_with_entity_marker": [173, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d145.s1229_AIMed.d145.s1229.p0", "text": "The novel fold of the TNF receptor structure is likely to be representative of the nerve growth factor (NGF)/TNF receptor family as a whole.", "text_with_entity_marker": "The novel fold of the TNF receptor structure is likely to be representative of the [E1]nerve growth factor[/E1] ([E2]NGF[/E2])/TNF receptor family as a whole.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "nerve growth factor", "entity_1_idx": [[83, 102]], "entity_1_idx_in_text_with_entity_marker": [87, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF", "entity_2_idx": [[104, 107]], "entity_2_idx_in_text_with_entity_marker": [117, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1552_AIMed.d183.s1552.p0", "text": "The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner.", "text_with_entity_marker": "The cytokine-activated tyrosine kinase [E1]JAK2[/E1] activates [E2]Raf-1[/E2] in a p21ras-dependent manner.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "JAK2", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[54, 59]], "entity_2_idx_in_text_with_entity_marker": [67, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1552_AIMed.d183.s1552.p1", "text": "The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner.", "text_with_entity_marker": "The cytokine-activated tyrosine kinase [E1]JAK2[/E1] activates Raf-1 in a [E2]p21ras[/E2]-dependent manner.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "JAK2", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21ras", "entity_2_idx": [[65, 71]], "entity_2_idx_in_text_with_entity_marker": [78, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1552_AIMed.d183.s1552.p2", "text": "The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner.", "text_with_entity_marker": "The cytokine-activated tyrosine kinase JAK2 activates [E1]Raf-1[/E1] in a [E2]p21ras[/E2]-dependent manner.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Raf-1", "entity_1_idx": [[54, 59]], "entity_1_idx_in_text_with_entity_marker": [58, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21ras", "entity_2_idx": [[65, 71]], "entity_2_idx_in_text_with_entity_marker": [78, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1553_AIMed.d183.s1553.p0", "text": "JAK2, a member of the Janus kinase superfamily was found to interact functionally with Raf-1, a central component of the ras/mitogen-activated protein kinase signal transduction pathway.", "text_with_entity_marker": "[E1]JAK2[/E1], a member of the Janus kinase superfamily was found to interact functionally with [E2]Raf-1[/E2], a central component of the ras/mitogen-activated protein kinase signal transduction pathway.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "JAK2", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[87, 92]], "entity_2_idx_in_text_with_entity_marker": [100, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1553_AIMed.d183.s1553.p1", "text": "JAK2, a member of the Janus kinase superfamily was found to interact functionally with Raf-1, a central component of the ras/mitogen-activated protein kinase signal transduction pathway.", "text_with_entity_marker": "[E1]JAK2[/E1], a member of the Janus kinase superfamily was found to interact functionally with Raf-1, a central component of the [E2]ras[/E2]/mitogen-activated protein kinase signal transduction pathway.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "JAK2", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ras", "entity_2_idx": [[121, 124]], "entity_2_idx_in_text_with_entity_marker": [134, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1553_AIMed.d183.s1553.p2", "text": "JAK2, a member of the Janus kinase superfamily was found to interact functionally with Raf-1, a central component of the ras/mitogen-activated protein kinase signal transduction pathway.", "text_with_entity_marker": "[E1]JAK2[/E1], a member of the Janus kinase superfamily was found to interact functionally with Raf-1, a central component of the ras/[E2]mitogen-activated protein kinase[/E2] signal transduction pathway.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "JAK2", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mitogen-activated protein kinase", "entity_2_idx": [[125, 157]], "entity_2_idx_in_text_with_entity_marker": [138, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1553_AIMed.d183.s1553.p3", "text": "JAK2, a member of the Janus kinase superfamily was found to interact functionally with Raf-1, a central component of the ras/mitogen-activated protein kinase signal transduction pathway.", "text_with_entity_marker": "JAK2, a member of the Janus kinase superfamily was found to interact functionally with [E1]Raf-1[/E1], a central component of the [E2]ras[/E2]/mitogen-activated protein kinase signal transduction pathway.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Raf-1", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [91, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ras", "entity_2_idx": [[121, 124]], "entity_2_idx_in_text_with_entity_marker": [134, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1553_AIMed.d183.s1553.p4", "text": "JAK2, a member of the Janus kinase superfamily was found to interact functionally with Raf-1, a central component of the ras/mitogen-activated protein kinase signal transduction pathway.", "text_with_entity_marker": "JAK2, a member of the Janus kinase superfamily was found to interact functionally with [E1]Raf-1[/E1], a central component of the ras/[E2]mitogen-activated protein kinase[/E2] signal transduction pathway.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Raf-1", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [91, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mitogen-activated protein kinase", "entity_2_idx": [[125, 157]], "entity_2_idx_in_text_with_entity_marker": [138, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1553_AIMed.d183.s1553.p5", "text": "JAK2, a member of the Janus kinase superfamily was found to interact functionally with Raf-1, a central component of the ras/mitogen-activated protein kinase signal transduction pathway.", "text_with_entity_marker": "JAK2, a member of the Janus kinase superfamily was found to interact functionally with Raf-1, a central component of the [E1]ras[/E1]/[E2]mitogen-activated protein kinase[/E2] signal transduction pathway.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ras", "entity_1_idx": [[121, 124]], "entity_1_idx_in_text_with_entity_marker": [125, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mitogen-activated protein kinase", "entity_2_idx": [[125, 157]], "entity_2_idx_in_text_with_entity_marker": [138, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1554_AIMed.d183.s1554.p0", "text": "Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.", "text_with_entity_marker": "[E1]Interferon-gamma[/E1] and several other cytokines that are known to activate [E2]JAK2[/E2] kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Interferon-gamma", "entity_1_idx": [[0, 16]], "entity_1_idx_in_text_with_entity_marker": [4, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "JAK2", "entity_2_idx": [[72, 76]], "entity_2_idx_in_text_with_entity_marker": [85, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1554_AIMed.d183.s1554.p1", "text": "Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.", "text_with_entity_marker": "[E1]Interferon-gamma[/E1] and several other cytokines that are known to activate [E2]JAK2 kinase[/E2] were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Interferon-gamma", "entity_1_idx": [[0, 16]], "entity_1_idx_in_text_with_entity_marker": [4, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "JAK2 kinase", "entity_2_idx": [[72, 83]], "entity_2_idx_in_text_with_entity_marker": [85, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1554_AIMed.d183.s1554.p2", "text": "Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.", "text_with_entity_marker": "[E1]Interferon-gamma[/E1] and several other cytokines that are known to activate JAK2 kinase were also found to stimulate [E2]Raf-1[/E2] kinase activity toward MEK-1 in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Interferon-gamma", "entity_1_idx": [[0, 16]], "entity_1_idx_in_text_with_entity_marker": [4, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[113, 118]], "entity_2_idx_in_text_with_entity_marker": [126, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1554_AIMed.d183.s1554.p3", "text": "Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.", "text_with_entity_marker": "[E1]Interferon-gamma[/E1] and several other cytokines that are known to activate JAK2 kinase were also found to stimulate [E2]Raf-1 kinase[/E2] activity toward MEK-1 in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Interferon-gamma", "entity_1_idx": [[0, 16]], "entity_1_idx_in_text_with_entity_marker": [4, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1 kinase", "entity_2_idx": [[113, 125]], "entity_2_idx_in_text_with_entity_marker": [126, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1554_AIMed.d183.s1554.p4", "text": "Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.", "text_with_entity_marker": "[E1]Interferon-gamma[/E1] and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward [E2]MEK-1[/E2] in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Interferon-gamma", "entity_1_idx": [[0, 16]], "entity_1_idx_in_text_with_entity_marker": [4, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MEK-1", "entity_2_idx": [[142, 147]], "entity_2_idx_in_text_with_entity_marker": [155, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1554_AIMed.d183.s1554.p5", "text": "Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.", "text_with_entity_marker": "Interferon-gamma and several other cytokines that are known to activate [E1-E2]JAK2[/E1] kinase[/E2] were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "JAK2", "entity_1_idx": [[72, 76]], "entity_1_idx_in_text_with_entity_marker": [79, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "JAK2[/E1] kinase", "entity_2_idx": [[72, 83]], "entity_2_idx_in_text_with_entity_marker": [79, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1554_AIMed.d183.s1554.p6", "text": "Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.", "text_with_entity_marker": "Interferon-gamma and several other cytokines that are known to activate [E1]JAK2[/E1] kinase were also found to stimulate [E2]Raf-1[/E2] kinase activity toward MEK-1 in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "JAK2", "entity_1_idx": [[72, 76]], "entity_1_idx_in_text_with_entity_marker": [76, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[113, 118]], "entity_2_idx_in_text_with_entity_marker": [126, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1554_AIMed.d183.s1554.p7", "text": "Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.", "text_with_entity_marker": "Interferon-gamma and several other cytokines that are known to activate [E1]JAK2[/E1] kinase were also found to stimulate [E2]Raf-1 kinase[/E2] activity toward MEK-1 in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "JAK2", "entity_1_idx": [[72, 76]], "entity_1_idx_in_text_with_entity_marker": [76, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1 kinase", "entity_2_idx": [[113, 125]], "entity_2_idx_in_text_with_entity_marker": [126, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1554_AIMed.d183.s1554.p8", "text": "Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.", "text_with_entity_marker": "Interferon-gamma and several other cytokines that are known to activate [E1]JAK2[/E1] kinase were also found to stimulate Raf-1 kinase activity toward [E2]MEK-1[/E2] in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "JAK2", "entity_1_idx": [[72, 76]], "entity_1_idx_in_text_with_entity_marker": [76, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MEK-1", "entity_2_idx": [[142, 147]], "entity_2_idx_in_text_with_entity_marker": [155, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1554_AIMed.d183.s1554.p9", "text": "Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.", "text_with_entity_marker": "Interferon-gamma and several other cytokines that are known to activate [E1]JAK2 kinase[/E1] were also found to stimulate [E2]Raf-1[/E2] kinase activity toward MEK-1 in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "JAK2 kinase", "entity_1_idx": [[72, 83]], "entity_1_idx_in_text_with_entity_marker": [76, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[113, 118]], "entity_2_idx_in_text_with_entity_marker": [126, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1554_AIMed.d183.s1554.p10", "text": "Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.", "text_with_entity_marker": "Interferon-gamma and several other cytokines that are known to activate [E1]JAK2 kinase[/E1] were also found to stimulate [E2]Raf-1 kinase[/E2] activity toward MEK-1 in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "JAK2 kinase", "entity_1_idx": [[72, 83]], "entity_1_idx_in_text_with_entity_marker": [76, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1 kinase", "entity_2_idx": [[113, 125]], "entity_2_idx_in_text_with_entity_marker": [126, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1554_AIMed.d183.s1554.p11", "text": "Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.", "text_with_entity_marker": "Interferon-gamma and several other cytokines that are known to activate [E1]JAK2 kinase[/E1] were also found to stimulate Raf-1 kinase activity toward [E2]MEK-1[/E2] in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "JAK2 kinase", "entity_1_idx": [[72, 83]], "entity_1_idx_in_text_with_entity_marker": [76, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MEK-1", "entity_2_idx": [[142, 147]], "entity_2_idx_in_text_with_entity_marker": [155, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1554_AIMed.d183.s1554.p12", "text": "Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.", "text_with_entity_marker": "Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate [E1-E2]Raf-1[/E1] kinase[/E2] activity toward MEK-1 in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Raf-1", "entity_1_idx": [[113, 118]], "entity_1_idx_in_text_with_entity_marker": [120, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1[/E1] kinase", "entity_2_idx": [[113, 125]], "entity_2_idx_in_text_with_entity_marker": [120, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1554_AIMed.d183.s1554.p13", "text": "Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.", "text_with_entity_marker": "Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate [E1]Raf-1[/E1] kinase activity toward [E2]MEK-1[/E2] in mammalian cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Raf-1", "entity_1_idx": [[113, 118]], "entity_1_idx_in_text_with_entity_marker": [117, 122], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MEK-1", "entity_2_idx": [[142, 147]], "entity_2_idx_in_text_with_entity_marker": [155, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1554_AIMed.d183.s1554.p14", "text": "Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf-1 kinase activity toward MEK-1 in mammalian cells.", "text_with_entity_marker": "Interferon-gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate [E1]Raf-1 kinase[/E1] activity toward [E2]MEK-1[/E2] in mammalian cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Raf-1 kinase", "entity_1_idx": [[113, 125]], "entity_1_idx_in_text_with_entity_marker": [117, 129], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MEK-1", "entity_2_idx": [[142, 147]], "entity_2_idx_in_text_with_entity_marker": [155, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1555_AIMed.d183.s1555.p0", "text": "In the baculovirus coexpression system, Raf-1 was activated by JAK2 in the presence of p21ras.", "text_with_entity_marker": "In the baculovirus coexpression system, [E1]Raf-1[/E1] was activated by [E2]JAK2[/E2] in the presence of p21ras.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Raf-1", "entity_1_idx": [[40, 45]], "entity_1_idx_in_text_with_entity_marker": [44, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "JAK2", "entity_2_idx": [[63, 67]], "entity_2_idx_in_text_with_entity_marker": [76, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1555_AIMed.d183.s1555.p1", "text": "In the baculovirus coexpression system, Raf-1 was activated by JAK2 in the presence of p21ras.", "text_with_entity_marker": "In the baculovirus coexpression system, [E1]Raf-1[/E1] was activated by JAK2 in the presence of [E2]p21ras[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Raf-1", "entity_1_idx": [[40, 45]], "entity_1_idx_in_text_with_entity_marker": [44, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21ras", "entity_2_idx": [[87, 93]], "entity_2_idx_in_text_with_entity_marker": [100, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1555_AIMed.d183.s1555.p2", "text": "In the baculovirus coexpression system, Raf-1 was activated by JAK2 in the presence of p21ras.", "text_with_entity_marker": "In the baculovirus coexpression system, Raf-1 was activated by [E1]JAK2[/E1] in the presence of [E2]p21ras[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "JAK2", "entity_1_idx": [[63, 67]], "entity_1_idx_in_text_with_entity_marker": [67, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21ras", "entity_2_idx": [[87, 93]], "entity_2_idx_in_text_with_entity_marker": [100, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1556_AIMed.d183.s1556.p0", "text": "Under these conditions, a ternary complex of p21ras, JAK2, and Raf-1 was observed.", "text_with_entity_marker": "Under these conditions, a ternary complex of [E1]p21ras[/E1], [E2]JAK2[/E2], and Raf-1 was observed.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p21ras", "entity_1_idx": [[45, 51]], "entity_1_idx_in_text_with_entity_marker": [49, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "JAK2", "entity_2_idx": [[53, 57]], "entity_2_idx_in_text_with_entity_marker": [66, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1556_AIMed.d183.s1556.p1", "text": "Under these conditions, a ternary complex of p21ras, JAK2, and Raf-1 was observed.", "text_with_entity_marker": "Under these conditions, a ternary complex of [E1]p21ras[/E1], JAK2, and [E2]Raf-1[/E2] was observed.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21ras", "entity_1_idx": [[45, 51]], "entity_1_idx_in_text_with_entity_marker": [49, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[63, 68]], "entity_2_idx_in_text_with_entity_marker": [76, 81], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1556_AIMed.d183.s1556.p2", "text": "Under these conditions, a ternary complex of p21ras, JAK2, and Raf-1 was observed.", "text_with_entity_marker": "Under these conditions, a ternary complex of p21ras, [E1]JAK2[/E1], and [E2]Raf-1[/E2] was observed.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "JAK2", "entity_1_idx": [[53, 57]], "entity_1_idx_in_text_with_entity_marker": [57, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[63, 68]], "entity_2_idx_in_text_with_entity_marker": [76, 81], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1557_AIMed.d183.s1557.p0", "text": "In contrast, in the absence of p21ras, coexpression of JAK2 and Raf-1 resulted in an overall decrease in the Raf-1 kinase activity.", "text_with_entity_marker": "In contrast, in the absence of [E1]p21ras[/E1], coexpression of [E2]JAK2[/E2] and Raf-1 resulted in an overall decrease in the Raf-1 kinase activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21ras", "entity_1_idx": [[31, 37]], "entity_1_idx_in_text_with_entity_marker": [35, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "JAK2", "entity_2_idx": [[55, 59]], "entity_2_idx_in_text_with_entity_marker": [68, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1557_AIMed.d183.s1557.p1", "text": "In contrast, in the absence of p21ras, coexpression of JAK2 and Raf-1 resulted in an overall decrease in the Raf-1 kinase activity.", "text_with_entity_marker": "In contrast, in the absence of [E1]p21ras[/E1], coexpression of JAK2 and [E2]Raf-1[/E2] resulted in an overall decrease in the Raf-1 kinase activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21ras", "entity_1_idx": [[31, 37]], "entity_1_idx_in_text_with_entity_marker": [35, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[64, 69]], "entity_2_idx_in_text_with_entity_marker": [77, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1557_AIMed.d183.s1557.p2", "text": "In contrast, in the absence of p21ras, coexpression of JAK2 and Raf-1 resulted in an overall decrease in the Raf-1 kinase activity.", "text_with_entity_marker": "In contrast, in the absence of [E1]p21ras[/E1], coexpression of JAK2 and Raf-1 resulted in an overall decrease in the [E2]Raf-1[/E2] kinase activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21ras", "entity_1_idx": [[31, 37]], "entity_1_idx_in_text_with_entity_marker": [35, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[109, 114]], "entity_2_idx_in_text_with_entity_marker": [122, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1557_AIMed.d183.s1557.p3", "text": "In contrast, in the absence of p21ras, coexpression of JAK2 and Raf-1 resulted in an overall decrease in the Raf-1 kinase activity.", "text_with_entity_marker": "In contrast, in the absence of p21ras, coexpression of [E1]JAK2[/E1] and [E2]Raf-1[/E2] resulted in an overall decrease in the Raf-1 kinase activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "JAK2", "entity_1_idx": [[55, 59]], "entity_1_idx_in_text_with_entity_marker": [59, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[64, 69]], "entity_2_idx_in_text_with_entity_marker": [77, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1557_AIMed.d183.s1557.p4", "text": "In contrast, in the absence of p21ras, coexpression of JAK2 and Raf-1 resulted in an overall decrease in the Raf-1 kinase activity.", "text_with_entity_marker": "In contrast, in the absence of p21ras, coexpression of [E1]JAK2[/E1] and Raf-1 resulted in an overall decrease in the [E2]Raf-1[/E2] kinase activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "JAK2", "entity_1_idx": [[55, 59]], "entity_1_idx_in_text_with_entity_marker": [59, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[109, 114]], "entity_2_idx_in_text_with_entity_marker": [122, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1557_AIMed.d183.s1557.p5", "text": "In contrast, in the absence of p21ras, coexpression of JAK2 and Raf-1 resulted in an overall decrease in the Raf-1 kinase activity.", "text_with_entity_marker": "In contrast, in the absence of p21ras, coexpression of JAK2 and [E1]Raf-1[/E1] resulted in an overall decrease in the [E2]Raf-1[/E2] kinase activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Raf-1", "entity_1_idx": [[64, 69]], "entity_1_idx_in_text_with_entity_marker": [68, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[109, 114]], "entity_2_idx_in_text_with_entity_marker": [122, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1558_AIMed.d183.s1558.p0", "text": "In addition, JAK2 phosphorylated Raf-1 at sites different from those phosphorylated by pp60v-src.", "text_with_entity_marker": "In addition, [E1]JAK2[/E1] phosphorylated [E2]Raf-1[/E2] at sites different from those phosphorylated by pp60v-src.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "JAK2", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[33, 38]], "entity_2_idx_in_text_with_entity_marker": [46, 51], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1558_AIMed.d183.s1558.p1", "text": "In addition, JAK2 phosphorylated Raf-1 at sites different from those phosphorylated by pp60v-src.", "text_with_entity_marker": "In addition, [E1]JAK2[/E1] phosphorylated Raf-1 at sites different from those phosphorylated by [E2]pp60v-src[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "JAK2", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp60v-src", "entity_2_idx": [[87, 96]], "entity_2_idx_in_text_with_entity_marker": [100, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1558_AIMed.d183.s1558.p2", "text": "In addition, JAK2 phosphorylated Raf-1 at sites different from those phosphorylated by pp60v-src.", "text_with_entity_marker": "In addition, JAK2 phosphorylated [E1]Raf-1[/E1] at sites different from those phosphorylated by [E2]pp60v-src[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Raf-1", "entity_1_idx": [[33, 38]], "entity_1_idx_in_text_with_entity_marker": [37, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp60v-src", "entity_2_idx": [[87, 96]], "entity_2_idx_in_text_with_entity_marker": [100, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1559_AIMed.d183.s1559.p0", "text": "In mammalian cells treated with either erythropoietin or interferon-gamma, a small fraction of Raf-1 coimmunoprecipitated with JAK2 in lysates of cells in which JAK2 was activated as judged by its state of tyrosine phosphorylation.", "text_with_entity_marker": "In mammalian cells treated with either erythropoietin or interferon-gamma, a small fraction of [E1]Raf-1[/E1] coimmunoprecipitated with [E2]JAK2[/E2] in lysates of cells in which JAK2 was activated as judged by its state of tyrosine phosphorylation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Raf-1", "entity_1_idx": [[95, 100]], "entity_1_idx_in_text_with_entity_marker": [99, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "JAK2", "entity_2_idx": [[127, 131]], "entity_2_idx_in_text_with_entity_marker": [140, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1559_AIMed.d183.s1559.p1", "text": "In mammalian cells treated with either erythropoietin or interferon-gamma, a small fraction of Raf-1 coimmunoprecipitated with JAK2 in lysates of cells in which JAK2 was activated as judged by its state of tyrosine phosphorylation.", "text_with_entity_marker": "In mammalian cells treated with either erythropoietin or interferon-gamma, a small fraction of [E1]Raf-1[/E1] coimmunoprecipitated with JAK2 in lysates of cells in which [E2]JAK2[/E2] was activated as judged by its state of tyrosine phosphorylation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Raf-1", "entity_1_idx": [[95, 100]], "entity_1_idx_in_text_with_entity_marker": [99, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "JAK2", "entity_2_idx": [[161, 165]], "entity_2_idx_in_text_with_entity_marker": [174, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1559_AIMed.d183.s1559.p2", "text": "In mammalian cells treated with either erythropoietin or interferon-gamma, a small fraction of Raf-1 coimmunoprecipitated with JAK2 in lysates of cells in which JAK2 was activated as judged by its state of tyrosine phosphorylation.", "text_with_entity_marker": "In mammalian cells treated with either erythropoietin or interferon-gamma, a small fraction of Raf-1 coimmunoprecipitated with [E1]JAK2[/E1] in lysates of cells in which [E2]JAK2[/E2] was activated as judged by its state of tyrosine phosphorylation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "JAK2", "entity_1_idx": [[127, 131]], "entity_1_idx_in_text_with_entity_marker": [131, 135], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "JAK2", "entity_2_idx": [[161, 165]], "entity_2_idx_in_text_with_entity_marker": [174, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1560_AIMed.d183.s1560.p0", "text": "Taken together, these data suggest that JAK2 and p21ras cooperate to activate Raf-1.", "text_with_entity_marker": "Taken together, these data suggest that [E1]JAK2[/E1] and [E2]p21ras[/E2] cooperate to activate Raf-1.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "JAK2", "entity_1_idx": [[40, 44]], "entity_1_idx_in_text_with_entity_marker": [44, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21ras", "entity_2_idx": [[49, 55]], "entity_2_idx_in_text_with_entity_marker": [62, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1560_AIMed.d183.s1560.p1", "text": "Taken together, these data suggest that JAK2 and p21ras cooperate to activate Raf-1.", "text_with_entity_marker": "Taken together, these data suggest that [E1]JAK2[/E1] and p21ras cooperate to activate [E2]Raf-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "JAK2", "entity_1_idx": [[40, 44]], "entity_1_idx_in_text_with_entity_marker": [44, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[78, 83]], "entity_2_idx_in_text_with_entity_marker": [91, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d183.s1560_AIMed.d183.s1560.p2", "text": "Taken together, these data suggest that JAK2 and p21ras cooperate to activate Raf-1.", "text_with_entity_marker": "Taken together, these data suggest that JAK2 and [E1]p21ras[/E1] cooperate to activate [E2]Raf-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21ras", "entity_1_idx": [[49, 55]], "entity_1_idx_in_text_with_entity_marker": [53, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[78, 83]], "entity_2_idx_in_text_with_entity_marker": [91, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1298_AIMed.d153.s1298.p0", "text": "Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response.", "text_with_entity_marker": "Characterization of [E1]adenosine deaminase[/E1] binding to human [E2]CD26[/E2] on T cells and its biologic role in immune response.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "adenosine deaminase", "entity_1_idx": [[20, 39]], "entity_1_idx_in_text_with_entity_marker": [24, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD26", "entity_2_idx": [[57, 61]], "entity_2_idx_in_text_with_entity_marker": [70, 74], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1299_AIMed.d153.s1299.p0", "text": "CD26, a T cell activation Ag, also known as dipeptidyl peptidase IV,is directly associated with adenosine deaminase (ADA) on the surface of T cells and T cell lines.", "text_with_entity_marker": "[E1]CD26[/E1], a T cell activation Ag, also known as [E2]dipeptidyl peptidase IV[/E2],is directly associated with adenosine deaminase (ADA) on the surface of T cells and T cell lines.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD26", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dipeptidyl peptidase IV", "entity_2_idx": [[44, 67]], "entity_2_idx_in_text_with_entity_marker": [57, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1299_AIMed.d153.s1299.p1", "text": "CD26, a T cell activation Ag, also known as dipeptidyl peptidase IV,is directly associated with adenosine deaminase (ADA) on the surface of T cells and T cell lines.", "text_with_entity_marker": "[E1]CD26[/E1], a T cell activation Ag, also known as dipeptidyl peptidase IV,is directly associated with [E2]adenosine deaminase[/E2] (ADA) on the surface of T cells and T cell lines.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD26", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "adenosine deaminase", "entity_2_idx": [[96, 115]], "entity_2_idx_in_text_with_entity_marker": [109, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1299_AIMed.d153.s1299.p2", "text": "CD26, a T cell activation Ag, also known as dipeptidyl peptidase IV,is directly associated with adenosine deaminase (ADA) on the surface of T cells and T cell lines.", "text_with_entity_marker": "[E1]CD26[/E1], a T cell activation Ag, also known as dipeptidyl peptidase IV,is directly associated with adenosine deaminase ([E2]ADA[/E2]) on the surface of T cells and T cell lines.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD26", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ADA", "entity_2_idx": [[117, 120]], "entity_2_idx_in_text_with_entity_marker": [130, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1299_AIMed.d153.s1299.p3", "text": "CD26, a T cell activation Ag, also known as dipeptidyl peptidase IV,is directly associated with adenosine deaminase (ADA) on the surface of T cells and T cell lines.", "text_with_entity_marker": "CD26, a T cell activation Ag, also known as [E1]dipeptidyl peptidase IV[/E1],is directly associated with [E2]adenosine deaminase[/E2] (ADA) on the surface of T cells and T cell lines.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "dipeptidyl peptidase IV", "entity_1_idx": [[44, 67]], "entity_1_idx_in_text_with_entity_marker": [48, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "adenosine deaminase", "entity_2_idx": [[96, 115]], "entity_2_idx_in_text_with_entity_marker": [109, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1299_AIMed.d153.s1299.p4", "text": "CD26, a T cell activation Ag, also known as dipeptidyl peptidase IV,is directly associated with adenosine deaminase (ADA) on the surface of T cells and T cell lines.", "text_with_entity_marker": "CD26, a T cell activation Ag, also known as [E1]dipeptidyl peptidase IV[/E1],is directly associated with adenosine deaminase ([E2]ADA[/E2]) on the surface of T cells and T cell lines.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "dipeptidyl peptidase IV", "entity_1_idx": [[44, 67]], "entity_1_idx_in_text_with_entity_marker": [48, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ADA", "entity_2_idx": [[117, 120]], "entity_2_idx_in_text_with_entity_marker": [130, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1299_AIMed.d153.s1299.p5", "text": "CD26, a T cell activation Ag, also known as dipeptidyl peptidase IV,is directly associated with adenosine deaminase (ADA) on the surface of T cells and T cell lines.", "text_with_entity_marker": "CD26, a T cell activation Ag, also known as dipeptidyl peptidase IV,is directly associated with [E1]adenosine deaminase[/E1] ([E2]ADA[/E2]) on the surface of T cells and T cell lines.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "adenosine deaminase", "entity_1_idx": [[96, 115]], "entity_1_idx_in_text_with_entity_marker": [100, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ADA", "entity_2_idx": [[117, 120]], "entity_2_idx_in_text_with_entity_marker": [130, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1300_AIMed.d153.s1300.p0", "text": "In the present study, we examined both the binding of ADA and CD26 and the functional consequences of this interaction.", "text_with_entity_marker": "In the present study, we examined both the binding of [E1]ADA[/E1] and [E2]CD26[/E2] and the functional consequences of this interaction.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ADA", "entity_1_idx": [[54, 57]], "entity_1_idx_in_text_with_entity_marker": [58, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD26", "entity_2_idx": [[62, 66]], "entity_2_idx_in_text_with_entity_marker": [75, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1301_AIMed.d153.s1301.p0", "text": "We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "text_with_entity_marker": "We found that [E1]ADA[/E1] was associated with [E2]CD26[/E2] on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ADA", "entity_1_idx": [[14, 17]], "entity_1_idx_in_text_with_entity_marker": [18, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD26", "entity_2_idx": [[38, 42]], "entity_2_idx_in_text_with_entity_marker": [51, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1301_AIMed.d153.s1301.p1", "text": "We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "text_with_entity_marker": "We found that [E1]ADA[/E1] was associated with CD26 on T cell lines lacking either [E2]ADA[/E2] or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ADA", "entity_1_idx": [[14, 17]], "entity_1_idx_in_text_with_entity_marker": [18, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ADA", "entity_2_idx": [[74, 77]], "entity_2_idx_in_text_with_entity_marker": [87, 90], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1301_AIMed.d153.s1301.p2", "text": "We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "text_with_entity_marker": "We found that [E1]ADA[/E1] was associated with CD26 on T cell lines lacking either ADA or [E2]dipeptidyl peptidase IV[/E2] enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ADA", "entity_1_idx": [[14, 17]], "entity_1_idx_in_text_with_entity_marker": [18, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dipeptidyl peptidase IV", "entity_2_idx": [[81, 104]], "entity_2_idx_in_text_with_entity_marker": [94, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1301_AIMed.d153.s1301.p3", "text": "We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "text_with_entity_marker": "We found that [E1]ADA[/E1] was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between [E2]dipeptidyl peptidase IV[/E2] and ADA did not require enzymatic activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ADA", "entity_1_idx": [[14, 17]], "entity_1_idx_in_text_with_entity_marker": [18, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dipeptidyl peptidase IV", "entity_2_idx": [[165, 188]], "entity_2_idx_in_text_with_entity_marker": [178, 201], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1301_AIMed.d153.s1301.p4", "text": "We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "text_with_entity_marker": "We found that [E1]ADA[/E1] was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and [E2]ADA[/E2] did not require enzymatic activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ADA", "entity_1_idx": [[14, 17]], "entity_1_idx_in_text_with_entity_marker": [18, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ADA", "entity_2_idx": [[193, 196]], "entity_2_idx_in_text_with_entity_marker": [206, 209], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1301_AIMed.d153.s1301.p5", "text": "We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "text_with_entity_marker": "We found that ADA was associated with [E1]CD26[/E1] on T cell lines lacking either [E2]ADA[/E2] or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD26", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ADA", "entity_2_idx": [[74, 77]], "entity_2_idx_in_text_with_entity_marker": [87, 90], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1301_AIMed.d153.s1301.p6", "text": "We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "text_with_entity_marker": "We found that ADA was associated with [E1]CD26[/E1] on T cell lines lacking either ADA or [E2]dipeptidyl peptidase IV[/E2] enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD26", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dipeptidyl peptidase IV", "entity_2_idx": [[81, 104]], "entity_2_idx_in_text_with_entity_marker": [94, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1301_AIMed.d153.s1301.p7", "text": "We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "text_with_entity_marker": "We found that ADA was associated with [E1]CD26[/E1] on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between [E2]dipeptidyl peptidase IV[/E2] and ADA did not require enzymatic activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD26", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dipeptidyl peptidase IV", "entity_2_idx": [[165, 188]], "entity_2_idx_in_text_with_entity_marker": [178, 201], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1301_AIMed.d153.s1301.p8", "text": "We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "text_with_entity_marker": "We found that ADA was associated with [E1]CD26[/E1] on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and [E2]ADA[/E2] did not require enzymatic activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD26", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ADA", "entity_2_idx": [[193, 196]], "entity_2_idx_in_text_with_entity_marker": [206, 209], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1301_AIMed.d153.s1301.p9", "text": "We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "text_with_entity_marker": "We found that ADA was associated with CD26 on T cell lines lacking either [E1]ADA[/E1] or [E2]dipeptidyl peptidase IV[/E2] enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ADA", "entity_1_idx": [[74, 77]], "entity_1_idx_in_text_with_entity_marker": [78, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dipeptidyl peptidase IV", "entity_2_idx": [[81, 104]], "entity_2_idx_in_text_with_entity_marker": [94, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1301_AIMed.d153.s1301.p10", "text": "We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "text_with_entity_marker": "We found that ADA was associated with CD26 on T cell lines lacking either [E1]ADA[/E1] or dipeptidyl peptidase IV enzymatic activity, indicating that the association between [E2]dipeptidyl peptidase IV[/E2] and ADA did not require enzymatic activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ADA", "entity_1_idx": [[74, 77]], "entity_1_idx_in_text_with_entity_marker": [78, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dipeptidyl peptidase IV", "entity_2_idx": [[165, 188]], "entity_2_idx_in_text_with_entity_marker": [178, 201], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1301_AIMed.d153.s1301.p11", "text": "We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "text_with_entity_marker": "We found that ADA was associated with CD26 on T cell lines lacking either [E1]ADA[/E1] or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and [E2]ADA[/E2] did not require enzymatic activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ADA", "entity_1_idx": [[74, 77]], "entity_1_idx_in_text_with_entity_marker": [78, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ADA", "entity_2_idx": [[193, 196]], "entity_2_idx_in_text_with_entity_marker": [206, 209], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1301_AIMed.d153.s1301.p12", "text": "We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "text_with_entity_marker": "We found that ADA was associated with CD26 on T cell lines lacking either ADA or [E1]dipeptidyl peptidase IV[/E1] enzymatic activity, indicating that the association between [E2]dipeptidyl peptidase IV[/E2] and ADA did not require enzymatic activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dipeptidyl peptidase IV", "entity_1_idx": [[81, 104]], "entity_1_idx_in_text_with_entity_marker": [85, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dipeptidyl peptidase IV", "entity_2_idx": [[165, 188]], "entity_2_idx_in_text_with_entity_marker": [178, 201], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1301_AIMed.d153.s1301.p13", "text": "We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "text_with_entity_marker": "We found that ADA was associated with CD26 on T cell lines lacking either ADA or [E1]dipeptidyl peptidase IV[/E1] enzymatic activity, indicating that the association between dipeptidyl peptidase IV and [E2]ADA[/E2] did not require enzymatic activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dipeptidyl peptidase IV", "entity_1_idx": [[81, 104]], "entity_1_idx_in_text_with_entity_marker": [85, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ADA", "entity_2_idx": [[193, 196]], "entity_2_idx_in_text_with_entity_marker": [206, 209], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1301_AIMed.d153.s1301.p14", "text": "We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity.", "text_with_entity_marker": "We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity, indicating that the association between [E1]dipeptidyl peptidase IV[/E1] and [E2]ADA[/E2] did not require enzymatic activity.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "dipeptidyl peptidase IV", "entity_1_idx": [[165, 188]], "entity_1_idx_in_text_with_entity_marker": [169, 192], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ADA", "entity_2_idx": [[193, 196]], "entity_2_idx_in_text_with_entity_marker": [206, 209], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1302_AIMed.d153.s1302.p0", "text": "Moreover, using immunoelectron microscopy, we demonstrated that CD26 and ADA co-localized on the cell surface, but not inside cells, suggesting that CD26 did not transport ADA to the surface.", "text_with_entity_marker": "Moreover, using immunoelectron microscopy, we demonstrated that [E1]CD26[/E1] and [E2]ADA[/E2] co-localized on the cell surface, but not inside cells, suggesting that CD26 did not transport ADA to the surface.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD26", "entity_1_idx": [[64, 68]], "entity_1_idx_in_text_with_entity_marker": [68, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ADA", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1302_AIMed.d153.s1302.p1", "text": "Moreover, using immunoelectron microscopy, we demonstrated that CD26 and ADA co-localized on the cell surface, but not inside cells, suggesting that CD26 did not transport ADA to the surface.", "text_with_entity_marker": "Moreover, using immunoelectron microscopy, we demonstrated that [E1]CD26[/E1] and ADA co-localized on the cell surface, but not inside cells, suggesting that [E2]CD26[/E2] did not transport ADA to the surface.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD26", "entity_1_idx": [[64, 68]], "entity_1_idx_in_text_with_entity_marker": [68, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD26", "entity_2_idx": [[149, 153]], "entity_2_idx_in_text_with_entity_marker": [162, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1302_AIMed.d153.s1302.p2", "text": "Moreover, using immunoelectron microscopy, we demonstrated that CD26 and ADA co-localized on the cell surface, but not inside cells, suggesting that CD26 did not transport ADA to the surface.", "text_with_entity_marker": "Moreover, using immunoelectron microscopy, we demonstrated that [E1]CD26[/E1] and ADA co-localized on the cell surface, but not inside cells, suggesting that CD26 did not transport [E2]ADA[/E2] to the surface.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD26", "entity_1_idx": [[64, 68]], "entity_1_idx_in_text_with_entity_marker": [68, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ADA", "entity_2_idx": [[172, 175]], "entity_2_idx_in_text_with_entity_marker": [185, 188], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1302_AIMed.d153.s1302.p3", "text": "Moreover, using immunoelectron microscopy, we demonstrated that CD26 and ADA co-localized on the cell surface, but not inside cells, suggesting that CD26 did not transport ADA to the surface.", "text_with_entity_marker": "Moreover, using immunoelectron microscopy, we demonstrated that CD26 and [E1]ADA[/E1] co-localized on the cell surface, but not inside cells, suggesting that [E2]CD26[/E2] did not transport ADA to the surface.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ADA", "entity_1_idx": [[73, 76]], "entity_1_idx_in_text_with_entity_marker": [77, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD26", "entity_2_idx": [[149, 153]], "entity_2_idx_in_text_with_entity_marker": [162, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1302_AIMed.d153.s1302.p4", "text": "Moreover, using immunoelectron microscopy, we demonstrated that CD26 and ADA co-localized on the cell surface, but not inside cells, suggesting that CD26 did not transport ADA to the surface.", "text_with_entity_marker": "Moreover, using immunoelectron microscopy, we demonstrated that CD26 and [E1]ADA[/E1] co-localized on the cell surface, but not inside cells, suggesting that CD26 did not transport [E2]ADA[/E2] to the surface.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ADA", "entity_1_idx": [[73, 76]], "entity_1_idx_in_text_with_entity_marker": [77, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ADA", "entity_2_idx": [[172, 175]], "entity_2_idx_in_text_with_entity_marker": [185, 188], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1302_AIMed.d153.s1302.p5", "text": "Moreover, using immunoelectron microscopy, we demonstrated that CD26 and ADA co-localized on the cell surface, but not inside cells, suggesting that CD26 did not transport ADA to the surface.", "text_with_entity_marker": "Moreover, using immunoelectron microscopy, we demonstrated that CD26 and ADA co-localized on the cell surface, but not inside cells, suggesting that [E1]CD26[/E1] did not transport [E2]ADA[/E2] to the surface.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD26", "entity_1_idx": [[149, 153]], "entity_1_idx_in_text_with_entity_marker": [153, 157], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ADA", "entity_2_idx": [[172, 175]], "entity_2_idx_in_text_with_entity_marker": [185, 188], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1303_AIMed.d153.s1303.p0", "text": "In keeping with this observation, we showed that human CD26-transfected murine pre-B cell lines lacking human ADA acquired ADA from an extracellular source.", "text_with_entity_marker": "In keeping with this observation, we showed that human [E1]CD26[/E1]-transfected murine pre-B cell lines lacking human [E2]ADA[/E2] acquired ADA from an extracellular source.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD26", "entity_1_idx": [[55, 59]], "entity_1_idx_in_text_with_entity_marker": [59, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ADA", "entity_2_idx": [[110, 113]], "entity_2_idx_in_text_with_entity_marker": [123, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1303_AIMed.d153.s1303.p1", "text": "In keeping with this observation, we showed that human CD26-transfected murine pre-B cell lines lacking human ADA acquired ADA from an extracellular source.", "text_with_entity_marker": "In keeping with this observation, we showed that human [E1]CD26[/E1]-transfected murine pre-B cell lines lacking human ADA acquired [E2]ADA[/E2] from an extracellular source.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD26", "entity_1_idx": [[55, 59]], "entity_1_idx_in_text_with_entity_marker": [59, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ADA", "entity_2_idx": [[123, 126]], "entity_2_idx_in_text_with_entity_marker": [136, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1303_AIMed.d153.s1303.p2", "text": "In keeping with this observation, we showed that human CD26-transfected murine pre-B cell lines lacking human ADA acquired ADA from an extracellular source.", "text_with_entity_marker": "In keeping with this observation, we showed that human CD26-transfected murine pre-B cell lines lacking human [E1]ADA[/E1] acquired [E2]ADA[/E2] from an extracellular source.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ADA", "entity_1_idx": [[110, 113]], "entity_1_idx_in_text_with_entity_marker": [114, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ADA", "entity_2_idx": [[123, 126]], "entity_2_idx_in_text_with_entity_marker": [136, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1304_AIMed.d153.s1304.p0", "text": "More importantly, adenosine in the absence of cell surface ADA inhibited T cell proliferation and IL-2 production induced by various stimuli.", "text_with_entity_marker": "More importantly, adenosine in the absence of cell surface [E1]ADA[/E1] inhibited T cell proliferation and [E2]IL-2[/E2] production induced by various stimuli.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ADA", "entity_1_idx": [[59, 62]], "entity_1_idx_in_text_with_entity_marker": [63, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[98, 102]], "entity_2_idx_in_text_with_entity_marker": [111, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1305_AIMed.d153.s1305.p0", "text": "On the other hand, cells expressing ADA and CD26 on the surface were much more resistant to the inhibitory effect of adenosine.", "text_with_entity_marker": "On the other hand, cells expressing [E1]ADA[/E1] and [E2]CD26[/E2] on the surface were much more resistant to the inhibitory effect of adenosine.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ADA", "entity_1_idx": [[36, 39]], "entity_1_idx_in_text_with_entity_marker": [40, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD26", "entity_2_idx": [[44, 48]], "entity_2_idx_in_text_with_entity_marker": [57, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1306_AIMed.d153.s1306.p0", "text": "These data suggest that ADA on the cell surface is involved in an important immunoregulatory mechanism by which released ADA binds to cell surface CD26, and this complex is capable of reducing the local concentration of adenosine.", "text_with_entity_marker": "These data suggest that [E1]ADA[/E1] on the cell surface is involved in an important immunoregulatory mechanism by which released [E2]ADA[/E2] binds to cell surface CD26, and this complex is capable of reducing the local concentration of adenosine.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ADA", "entity_1_idx": [[24, 27]], "entity_1_idx_in_text_with_entity_marker": [28, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ADA", "entity_2_idx": [[121, 124]], "entity_2_idx_in_text_with_entity_marker": [134, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1306_AIMed.d153.s1306.p1", "text": "These data suggest that ADA on the cell surface is involved in an important immunoregulatory mechanism by which released ADA binds to cell surface CD26, and this complex is capable of reducing the local concentration of adenosine.", "text_with_entity_marker": "These data suggest that [E1]ADA[/E1] on the cell surface is involved in an important immunoregulatory mechanism by which released ADA binds to cell surface [E2]CD26[/E2], and this complex is capable of reducing the local concentration of adenosine.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ADA", "entity_1_idx": [[24, 27]], "entity_1_idx_in_text_with_entity_marker": [28, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD26", "entity_2_idx": [[147, 151]], "entity_2_idx_in_text_with_entity_marker": [160, 164], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d153.s1306_AIMed.d153.s1306.p2", "text": "These data suggest that ADA on the cell surface is involved in an important immunoregulatory mechanism by which released ADA binds to cell surface CD26, and this complex is capable of reducing the local concentration of adenosine.", "text_with_entity_marker": "These data suggest that ADA on the cell surface is involved in an important immunoregulatory mechanism by which released [E1]ADA[/E1] binds to cell surface [E2]CD26[/E2], and this complex is capable of reducing the local concentration of adenosine.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ADA", "entity_1_idx": [[121, 124]], "entity_1_idx_in_text_with_entity_marker": [125, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD26", "entity_2_idx": [[147, 151]], "entity_2_idx_in_text_with_entity_marker": [160, 164], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p0", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "[E1]FGF-7[/E1] recognizes one FGFR isoform known as the [E2]FGFR2 IIIb[/E2] isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGF-7", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2 IIIb", "entity_2_idx": [[47, 57]], "entity_2_idx_in_text_with_entity_marker": [60, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p1", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "[E1]FGF-7[/E1] recognizes one FGFR isoform known as the FGFR2 IIIb isoform or [E2]keratinocyte growth factor[/E2] receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF-7", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "keratinocyte growth factor", "entity_2_idx": [[69, 95]], "entity_2_idx_in_text_with_entity_marker": [82, 108], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p2", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "[E1]FGF-7[/E1] recognizes one FGFR isoform known as the FGFR2 IIIb isoform or [E2]keratinocyte growth factor receptor[/E2] (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGF-7", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "keratinocyte growth factor receptor", "entity_2_idx": [[69, 104]], "entity_2_idx_in_text_with_entity_marker": [82, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p3", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "[E1]FGF-7[/E1] recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ([E2]KGFR[/E2]), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGF-7", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KGFR", "entity_2_idx": [[106, 110]], "entity_2_idx_in_text_with_entity_marker": [119, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p4", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "[E1]FGF-7[/E1] recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas [E2]FGF-2[/E2] binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF-7", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF-2", "entity_2_idx": [[121, 126]], "entity_2_idx_in_text_with_entity_marker": [134, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p5", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "[E1]FGF-7[/E1] recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to [E2]FGFR1[/E2], FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF-7", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR1", "entity_2_idx": [[141, 146]], "entity_2_idx_in_text_with_entity_marker": [154, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p6", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "[E1]FGF-7[/E1] recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, [E2]FGFR2[/E2], and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF-7", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2", "entity_2_idx": [[148, 153]], "entity_2_idx_in_text_with_entity_marker": [161, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p7", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "[E1]FGF-7[/E1] recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and [E2]FGFR4[/E2] but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF-7", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR4", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p8", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "[E1]FGF-7[/E1] recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with [E2]KGFR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF-7", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KGFR", "entity_2_idx": [[191, 195]], "entity_2_idx_in_text_with_entity_marker": [204, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p9", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the [E1]FGFR2 IIIb[/E1] isoform or [E2]keratinocyte growth factor[/E2] receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2 IIIb", "entity_1_idx": [[47, 57]], "entity_1_idx_in_text_with_entity_marker": [51, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "keratinocyte growth factor", "entity_2_idx": [[69, 95]], "entity_2_idx_in_text_with_entity_marker": [82, 108], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p10", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the [E1]FGFR2 IIIb[/E1] isoform or [E2]keratinocyte growth factor receptor[/E2] (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2 IIIb", "entity_1_idx": [[47, 57]], "entity_1_idx_in_text_with_entity_marker": [51, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "keratinocyte growth factor receptor", "entity_2_idx": [[69, 104]], "entity_2_idx_in_text_with_entity_marker": [82, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p11", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the [E1]FGFR2 IIIb[/E1] isoform or keratinocyte growth factor receptor ([E2]KGFR[/E2]), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2 IIIb", "entity_1_idx": [[47, 57]], "entity_1_idx_in_text_with_entity_marker": [51, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KGFR", "entity_2_idx": [[106, 110]], "entity_2_idx_in_text_with_entity_marker": [119, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p12", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the [E1]FGFR2 IIIb[/E1] isoform or keratinocyte growth factor receptor (KGFR), whereas [E2]FGF-2[/E2] binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2 IIIb", "entity_1_idx": [[47, 57]], "entity_1_idx_in_text_with_entity_marker": [51, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF-2", "entity_2_idx": [[121, 126]], "entity_2_idx_in_text_with_entity_marker": [134, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p13", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the [E1]FGFR2 IIIb[/E1] isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to [E2]FGFR1[/E2], FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2 IIIb", "entity_1_idx": [[47, 57]], "entity_1_idx_in_text_with_entity_marker": [51, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR1", "entity_2_idx": [[141, 146]], "entity_2_idx_in_text_with_entity_marker": [154, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p14", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the [E1]FGFR2 IIIb[/E1] isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, [E2]FGFR2[/E2], and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2 IIIb", "entity_1_idx": [[47, 57]], "entity_1_idx_in_text_with_entity_marker": [51, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2", "entity_2_idx": [[148, 153]], "entity_2_idx_in_text_with_entity_marker": [161, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p15", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the [E1]FGFR2 IIIb[/E1] isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and [E2]FGFR4[/E2] but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2 IIIb", "entity_1_idx": [[47, 57]], "entity_1_idx_in_text_with_entity_marker": [51, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR4", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p16", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the [E1]FGFR2 IIIb[/E1] isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with [E2]KGFR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2 IIIb", "entity_1_idx": [[47, 57]], "entity_1_idx_in_text_with_entity_marker": [51, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KGFR", "entity_2_idx": [[191, 195]], "entity_2_idx_in_text_with_entity_marker": [204, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p17", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or [E1-E2]keratinocyte growth factor[/E1] receptor[/E2] (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "keratinocyte growth factor", "entity_1_idx": [[69, 95]], "entity_1_idx_in_text_with_entity_marker": [76, 102], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "keratinocyte growth factor[/E1] receptor", "entity_2_idx": [[69, 104]], "entity_2_idx_in_text_with_entity_marker": [76, 116], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p18", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or [E1]keratinocyte growth factor[/E1] receptor ([E2]KGFR[/E2]), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "keratinocyte growth factor", "entity_1_idx": [[69, 95]], "entity_1_idx_in_text_with_entity_marker": [73, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KGFR", "entity_2_idx": [[106, 110]], "entity_2_idx_in_text_with_entity_marker": [119, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p19", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or [E1]keratinocyte growth factor[/E1] receptor (KGFR), whereas [E2]FGF-2[/E2] binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "keratinocyte growth factor", "entity_1_idx": [[69, 95]], "entity_1_idx_in_text_with_entity_marker": [73, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF-2", "entity_2_idx": [[121, 126]], "entity_2_idx_in_text_with_entity_marker": [134, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p20", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or [E1]keratinocyte growth factor[/E1] receptor (KGFR), whereas FGF-2 binds well to [E2]FGFR1[/E2], FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "keratinocyte growth factor", "entity_1_idx": [[69, 95]], "entity_1_idx_in_text_with_entity_marker": [73, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR1", "entity_2_idx": [[141, 146]], "entity_2_idx_in_text_with_entity_marker": [154, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p21", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or [E1]keratinocyte growth factor[/E1] receptor (KGFR), whereas FGF-2 binds well to FGFR1, [E2]FGFR2[/E2], and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "keratinocyte growth factor", "entity_1_idx": [[69, 95]], "entity_1_idx_in_text_with_entity_marker": [73, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2", "entity_2_idx": [[148, 153]], "entity_2_idx_in_text_with_entity_marker": [161, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p22", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or [E1]keratinocyte growth factor[/E1] receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and [E2]FGFR4[/E2] but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "keratinocyte growth factor", "entity_1_idx": [[69, 95]], "entity_1_idx_in_text_with_entity_marker": [73, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR4", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p23", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or [E1]keratinocyte growth factor[/E1] receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with [E2]KGFR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "keratinocyte growth factor", "entity_1_idx": [[69, 95]], "entity_1_idx_in_text_with_entity_marker": [73, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KGFR", "entity_2_idx": [[191, 195]], "entity_2_idx_in_text_with_entity_marker": [204, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p24", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or [E1]keratinocyte growth factor receptor[/E1] ([E2]KGFR[/E2]), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "keratinocyte growth factor receptor", "entity_1_idx": [[69, 104]], "entity_1_idx_in_text_with_entity_marker": [73, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KGFR", "entity_2_idx": [[106, 110]], "entity_2_idx_in_text_with_entity_marker": [119, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p25", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or [E1]keratinocyte growth factor receptor[/E1] (KGFR), whereas [E2]FGF-2[/E2] binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "keratinocyte growth factor receptor", "entity_1_idx": [[69, 104]], "entity_1_idx_in_text_with_entity_marker": [73, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF-2", "entity_2_idx": [[121, 126]], "entity_2_idx_in_text_with_entity_marker": [134, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p26", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or [E1]keratinocyte growth factor receptor[/E1] (KGFR), whereas FGF-2 binds well to [E2]FGFR1[/E2], FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "keratinocyte growth factor receptor", "entity_1_idx": [[69, 104]], "entity_1_idx_in_text_with_entity_marker": [73, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR1", "entity_2_idx": [[141, 146]], "entity_2_idx_in_text_with_entity_marker": [154, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p27", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or [E1]keratinocyte growth factor receptor[/E1] (KGFR), whereas FGF-2 binds well to FGFR1, [E2]FGFR2[/E2], and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "keratinocyte growth factor receptor", "entity_1_idx": [[69, 104]], "entity_1_idx_in_text_with_entity_marker": [73, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2", "entity_2_idx": [[148, 153]], "entity_2_idx_in_text_with_entity_marker": [161, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p28", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or [E1]keratinocyte growth factor receptor[/E1] (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and [E2]FGFR4[/E2] but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "keratinocyte growth factor receptor", "entity_1_idx": [[69, 104]], "entity_1_idx_in_text_with_entity_marker": [73, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR4", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p29", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or [E1]keratinocyte growth factor receptor[/E1] (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with [E2]KGFR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "keratinocyte growth factor receptor", "entity_1_idx": [[69, 104]], "entity_1_idx_in_text_with_entity_marker": [73, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KGFR", "entity_2_idx": [[191, 195]], "entity_2_idx_in_text_with_entity_marker": [204, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p30", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ([E1]KGFR[/E1]), whereas [E2]FGF-2[/E2] binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KGFR", "entity_1_idx": [[106, 110]], "entity_1_idx_in_text_with_entity_marker": [110, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF-2", "entity_2_idx": [[121, 126]], "entity_2_idx_in_text_with_entity_marker": [134, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p31", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ([E1]KGFR[/E1]), whereas FGF-2 binds well to [E2]FGFR1[/E2], FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KGFR", "entity_1_idx": [[106, 110]], "entity_1_idx_in_text_with_entity_marker": [110, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR1", "entity_2_idx": [[141, 146]], "entity_2_idx_in_text_with_entity_marker": [154, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p32", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ([E1]KGFR[/E1]), whereas FGF-2 binds well to FGFR1, [E2]FGFR2[/E2], and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KGFR", "entity_1_idx": [[106, 110]], "entity_1_idx_in_text_with_entity_marker": [110, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2", "entity_2_idx": [[148, 153]], "entity_2_idx_in_text_with_entity_marker": [161, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p33", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ([E1]KGFR[/E1]), whereas FGF-2 binds well to FGFR1, FGFR2, and [E2]FGFR4[/E2] but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KGFR", "entity_1_idx": [[106, 110]], "entity_1_idx_in_text_with_entity_marker": [110, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR4", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p34", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ([E1]KGFR[/E1]), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with [E2]KGFR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KGFR", "entity_1_idx": [[106, 110]], "entity_1_idx_in_text_with_entity_marker": [110, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KGFR", "entity_2_idx": [[191, 195]], "entity_2_idx_in_text_with_entity_marker": [204, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p35", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas [E1]FGF-2[/E1] binds well to [E2]FGFR1[/E2], FGFR2, and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGF-2", "entity_1_idx": [[121, 126]], "entity_1_idx_in_text_with_entity_marker": [125, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR1", "entity_2_idx": [[141, 146]], "entity_2_idx_in_text_with_entity_marker": [154, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p36", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas [E1]FGF-2[/E1] binds well to FGFR1, [E2]FGFR2[/E2], and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGF-2", "entity_1_idx": [[121, 126]], "entity_1_idx_in_text_with_entity_marker": [125, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2", "entity_2_idx": [[148, 153]], "entity_2_idx_in_text_with_entity_marker": [161, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p37", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas [E1]FGF-2[/E1] binds well to FGFR1, FGFR2, and [E2]FGFR4[/E2] but interacts poorly with KGFR.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGF-2", "entity_1_idx": [[121, 126]], "entity_1_idx_in_text_with_entity_marker": [125, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR4", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p38", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas [E1]FGF-2[/E1] binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with [E2]KGFR[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGF-2", "entity_1_idx": [[121, 126]], "entity_1_idx_in_text_with_entity_marker": [125, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KGFR", "entity_2_idx": [[191, 195]], "entity_2_idx_in_text_with_entity_marker": [204, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p39", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to [E1]FGFR1[/E1], [E2]FGFR2[/E2], and FGFR4 but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR1", "entity_1_idx": [[141, 146]], "entity_1_idx_in_text_with_entity_marker": [145, 150], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2", "entity_2_idx": [[148, 153]], "entity_2_idx_in_text_with_entity_marker": [161, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p40", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to [E1]FGFR1[/E1], FGFR2, and [E2]FGFR4[/E2] but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR1", "entity_1_idx": [[141, 146]], "entity_1_idx_in_text_with_entity_marker": [145, 150], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR4", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p41", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to [E1]FGFR1[/E1], FGFR2, and FGFR4 but interacts poorly with [E2]KGFR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR1", "entity_1_idx": [[141, 146]], "entity_1_idx_in_text_with_entity_marker": [145, 150], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KGFR", "entity_2_idx": [[191, 195]], "entity_2_idx_in_text_with_entity_marker": [204, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p42", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, [E1]FGFR2[/E1], and [E2]FGFR4[/E2] but interacts poorly with KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2", "entity_1_idx": [[148, 153]], "entity_1_idx_in_text_with_entity_marker": [152, 157], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR4", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p43", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, [E1]FGFR2[/E1], and FGFR4 but interacts poorly with [E2]KGFR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR2", "entity_1_idx": [[148, 153]], "entity_1_idx_in_text_with_entity_marker": [152, 157], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KGFR", "entity_2_idx": [[191, 195]], "entity_2_idx_in_text_with_entity_marker": [204, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s431_AIMed.d49.s431.p44", "text": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and FGFR4 but interacts poorly with KGFR.", "text_with_entity_marker": "FGF-7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor (KGFR), whereas FGF-2 binds well to FGFR1, FGFR2, and [E1]FGFR4[/E1] but interacts poorly with [E2]KGFR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR4", "entity_1_idx": [[159, 164]], "entity_1_idx_in_text_with_entity_marker": [163, 168], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KGFR", "entity_2_idx": [[191, 195]], "entity_2_idx_in_text_with_entity_marker": [204, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s433_AIMed.d49.s433.p0", "text": "FGF-7 contains this primary site as well as a region that restricts interaction with FGFR1.", "text_with_entity_marker": "[E1]FGF-7[/E1] contains this primary site as well as a region that restricts interaction with [E2]FGFR1[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGF-7", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR1", "entity_2_idx": [[85, 90]], "entity_2_idx_in_text_with_entity_marker": [98, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s434_AIMed.d49.s434.p0", "text": "The sequences that confer on FGF-7 its specific binding to KGFR have not been identified.", "text_with_entity_marker": "The sequences that confer on [E1]FGF-7[/E1] its specific binding to [E2]KGFR[/E2] have not been identified.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGF-7", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KGFR", "entity_2_idx": [[59, 63]], "entity_2_idx_in_text_with_entity_marker": [72, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s435_AIMed.d49.s435.p0", "text": "By utilizing domain swapping and site-directed mutagenesis we have found that the loop connecting the beta4-beta5 strands of FGF-7 contributes to high affinity receptor binding and is critical for KGFR recognition.", "text_with_entity_marker": "By utilizing domain swapping and site-directed mutagenesis we have found that the loop connecting the beta4-beta5 strands of [E1]FGF-7[/E1] contributes to high affinity receptor binding and is critical for [E2]KGFR[/E2] recognition.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGF-7", "entity_1_idx": [[125, 130]], "entity_1_idx_in_text_with_entity_marker": [129, 134], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KGFR", "entity_2_idx": [[197, 201]], "entity_2_idx_in_text_with_entity_marker": [210, 214], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s436_AIMed.d49.s436.p0", "text": "Replacement of this loop with the homologous loop from FGF-2 dramatically reduced both the affinity of FGF-7 for KGFR and its biological potency but did not result in the ability to bind FGFR1.", "text_with_entity_marker": "Replacement of this loop with the homologous loop from [E1]FGF-2[/E1] dramatically reduced both the affinity of [E2]FGF-7[/E2] for KGFR and its biological potency but did not result in the ability to bind FGFR1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF-2", "entity_1_idx": [[55, 60]], "entity_1_idx_in_text_with_entity_marker": [59, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF-7", "entity_2_idx": [[103, 108]], "entity_2_idx_in_text_with_entity_marker": [116, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s436_AIMed.d49.s436.p1", "text": "Replacement of this loop with the homologous loop from FGF-2 dramatically reduced both the affinity of FGF-7 for KGFR and its biological potency but did not result in the ability to bind FGFR1.", "text_with_entity_marker": "Replacement of this loop with the homologous loop from [E1]FGF-2[/E1] dramatically reduced both the affinity of FGF-7 for [E2]KGFR[/E2] and its biological potency but did not result in the ability to bind FGFR1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF-2", "entity_1_idx": [[55, 60]], "entity_1_idx_in_text_with_entity_marker": [59, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KGFR", "entity_2_idx": [[113, 117]], "entity_2_idx_in_text_with_entity_marker": [126, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s436_AIMed.d49.s436.p2", "text": "Replacement of this loop with the homologous loop from FGF-2 dramatically reduced both the affinity of FGF-7 for KGFR and its biological potency but did not result in the ability to bind FGFR1.", "text_with_entity_marker": "Replacement of this loop with the homologous loop from [E1]FGF-2[/E1] dramatically reduced both the affinity of FGF-7 for KGFR and its biological potency but did not result in the ability to bind [E2]FGFR1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF-2", "entity_1_idx": [[55, 60]], "entity_1_idx_in_text_with_entity_marker": [59, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR1", "entity_2_idx": [[187, 192]], "entity_2_idx_in_text_with_entity_marker": [200, 205], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s436_AIMed.d49.s436.p3", "text": "Replacement of this loop with the homologous loop from FGF-2 dramatically reduced both the affinity of FGF-7 for KGFR and its biological potency but did not result in the ability to bind FGFR1.", "text_with_entity_marker": "Replacement of this loop with the homologous loop from FGF-2 dramatically reduced both the affinity of [E1]FGF-7[/E1] for [E2]KGFR[/E2] and its biological potency but did not result in the ability to bind FGFR1.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGF-7", "entity_1_idx": [[103, 108]], "entity_1_idx_in_text_with_entity_marker": [107, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KGFR", "entity_2_idx": [[113, 117]], "entity_2_idx_in_text_with_entity_marker": [126, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s436_AIMed.d49.s436.p4", "text": "Replacement of this loop with the homologous loop from FGF-2 dramatically reduced both the affinity of FGF-7 for KGFR and its biological potency but did not result in the ability to bind FGFR1.", "text_with_entity_marker": "Replacement of this loop with the homologous loop from FGF-2 dramatically reduced both the affinity of [E1]FGF-7[/E1] for KGFR and its biological potency but did not result in the ability to bind [E2]FGFR1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF-7", "entity_1_idx": [[103, 108]], "entity_1_idx_in_text_with_entity_marker": [107, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR1", "entity_2_idx": [[187, 192]], "entity_2_idx_in_text_with_entity_marker": [200, 205], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s436_AIMed.d49.s436.p5", "text": "Replacement of this loop with the homologous loop from FGF-2 dramatically reduced both the affinity of FGF-7 for KGFR and its biological potency but did not result in the ability to bind FGFR1.", "text_with_entity_marker": "Replacement of this loop with the homologous loop from FGF-2 dramatically reduced both the affinity of FGF-7 for [E1]KGFR[/E1] and its biological potency but did not result in the ability to bind [E2]FGFR1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KGFR", "entity_1_idx": [[113, 117]], "entity_1_idx_in_text_with_entity_marker": [117, 121], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR1", "entity_2_idx": [[187, 192]], "entity_2_idx_in_text_with_entity_marker": [200, 205], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s438_AIMed.d49.s438.p0", "text": "The reciprocal loop replacement mutant (FGF2-L4/7) retained FGF-2 like affinity for FGFR1 and for KGFR.", "text_with_entity_marker": "The reciprocal loop replacement mutant ([E1]FGF2[/E1]-L4/7) retained [E2]FGF-2[/E2] like affinity for FGFR1 and for KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF2", "entity_1_idx": [[40, 44]], "entity_1_idx_in_text_with_entity_marker": [44, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF-2", "entity_2_idx": [[60, 65]], "entity_2_idx_in_text_with_entity_marker": [73, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s438_AIMed.d49.s438.p1", "text": "The reciprocal loop replacement mutant (FGF2-L4/7) retained FGF-2 like affinity for FGFR1 and for KGFR.", "text_with_entity_marker": "The reciprocal loop replacement mutant ([E1]FGF2[/E1]-L4/7) retained FGF-2 like affinity for [E2]FGFR1[/E2] and for KGFR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF2", "entity_1_idx": [[40, 44]], "entity_1_idx_in_text_with_entity_marker": [44, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR1", "entity_2_idx": [[84, 89]], "entity_2_idx_in_text_with_entity_marker": [97, 102], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s438_AIMed.d49.s438.p2", "text": "The reciprocal loop replacement mutant (FGF2-L4/7) retained FGF-2 like affinity for FGFR1 and for KGFR.", "text_with_entity_marker": "The reciprocal loop replacement mutant ([E1]FGF2[/E1]-L4/7) retained FGF-2 like affinity for FGFR1 and for [E2]KGFR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF2", "entity_1_idx": [[40, 44]], "entity_1_idx_in_text_with_entity_marker": [44, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KGFR", "entity_2_idx": [[98, 102]], "entity_2_idx_in_text_with_entity_marker": [111, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s438_AIMed.d49.s438.p3", "text": "The reciprocal loop replacement mutant (FGF2-L4/7) retained FGF-2 like affinity for FGFR1 and for KGFR.", "text_with_entity_marker": "The reciprocal loop replacement mutant (FGF2-L4/7) retained [E1]FGF-2[/E1] like affinity for [E2]FGFR1[/E2] and for KGFR.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGF-2", "entity_1_idx": [[60, 65]], "entity_1_idx_in_text_with_entity_marker": [64, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR1", "entity_2_idx": [[84, 89]], "entity_2_idx_in_text_with_entity_marker": [97, 102], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s438_AIMed.d49.s438.p4", "text": "The reciprocal loop replacement mutant (FGF2-L4/7) retained FGF-2 like affinity for FGFR1 and for KGFR.", "text_with_entity_marker": "The reciprocal loop replacement mutant (FGF2-L4/7) retained [E1]FGF-2[/E1] like affinity for FGFR1 and for [E2]KGFR[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGF-2", "entity_1_idx": [[60, 65]], "entity_1_idx_in_text_with_entity_marker": [64, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KGFR", "entity_2_idx": [[98, 102]], "entity_2_idx_in_text_with_entity_marker": [111, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d49.s438_AIMed.d49.s438.p5", "text": "The reciprocal loop replacement mutant (FGF2-L4/7) retained FGF-2 like affinity for FGFR1 and for KGFR.", "text_with_entity_marker": "The reciprocal loop replacement mutant (FGF2-L4/7) retained FGF-2 like affinity for [E1]FGFR1[/E1] and for [E2]KGFR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGFR1", "entity_1_idx": [[84, 89]], "entity_1_idx_in_text_with_entity_marker": [88, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KGFR", "entity_2_idx": [[98, 102]], "entity_2_idx_in_text_with_entity_marker": [111, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
